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RESUMO 
 
 
Chlamydia trachomatis é uma bactéria patogénica, intracelular obrigatória, que em células 
eucarióticas reside num vacúolo membranar. Durante o seu ciclo de desenvolvimento, esta bactéria 
usa um sistema de secreção do tipo III, que permite o transporte de proteínas efetoras para o citoplasma 
da célula hospedeira. Estas proteínas efetoras modificam vários processos e organelos das células 
hospedeiras, permitindo que as bactérias sobrevivam no ambiente intracelular. 
Para identificar novas proteínas efetoras de Chlamydia, foram infetadas células de mamífero 
com estirpes de C. trachomatis que expressavam proteínas candidatas com um duplo péptido de 
hemaglutinina na extremidade C-terminal.  Análises por microscopia de imunofluorescência revelaram 
que a proteína CT105/CteG era transportada para a célula hospedeira infetada. Observou-se que 
CT105/CteG associava-se inicialmente ao complexo de Golgi e que com a progressão da infeção, 
acumulava-se na membrana plasmática. Mostrou-se que esta mudança da localização de CT105/CteG 
é independente da integridade de filamentos de actina e microtúbulos. Além disso, quando diferentes 
regiões de CT105/CteG (656 resíduos de aminoácidos) foram expressas ectopicamente em células de 
mamífero, os primeiros 100 resíduos de CT105/CteG foram identificados como contendo uma região 
que direcionava a proteína para o Golgi. Apesar de uma estirpe de C. trachomatis com ct105/cteG 
inativado não ter apresentado um defeito no crescimento intracelular da bactéria, a expressão de 
CT105/CteG em Saccharomyces cerevisiae causou um defeito no transporte de proteínas para o 
vacúolo. Isto sugere que a função de CT105/CteG seja alterar o transporte vesicular em células 
eucarióticas. Por fim, a análise de várias estirpes de C. trachomatis sugeriu que o ct105/cteG é apenas 
transcrito em estirpes causadoras de linfogranuloma venéreo, indicando uma função de CT105/CteG 
neste contexto.  
Em conclusão, neste trabalho foi identificada e caracterizada a primeira proteína efetora de C. 
trachomatis que se associa com o complexo de Golgi, ajudando a uma melhor compreensão das 
interações bactéria-hospedeiro. 
 
 
 
 
 
 
 
 
 
 
Termos chave: Interações bactéria-hospedeiro; Chlamydia trachomatis; Sistema de secreção do tipo 
III; Golgi; tráfego vesicular
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ABSTRACT 
 
 
Chlamydia trachomatis is an obligate intracellular bacterial pathogen that resides in eukaryotic 
host cells within a membrane-bounded vacuole, termed inclusion. Throughout its characteristic biphasic 
developmental cycle, the bacterium uses a type III secretion system, which allows the direct delivery of 
effector proteins into the host cell cytoplasm. These effector proteins are thought to modify a variety of 
host cell processes enabling the bacteria to survive and multiply within the intracellular environment.  
To identify novel type III secretion effectors of Chlamydia, mammalian host cells were infected by 
C. trachomatis strains independently expressing previously identified candidate effectors with a double 
hemagglutinin tag at their C-termini. Immunofluorescence microscopy analysis revealed that 
CT105/CteG (Chlamydia trachomatis effector associated with the Golgi) was delivered into infected host 
cells, where initially (~ 16 to 20 h post-infection) associated with the Golgi complex and as the 
developmental cycle progressed (~30 to 40 h post-infection) accumulated at the plasma membrane. 
The change of subcellular localization of CT105/CteG in the host cell during infection was shown to be 
independent of intact actin filaments and microtubules. Furthermore, when ectopically expressing 
different regions of CT105/CteG (656 amino acid residues) in mammalian cells, the first 100 residues of 
the protein were identified as containing a Golgi-targeting region. Although a C. trachomatis ct105/cteG 
mutant did not display a defect in intracellular growth, CT105/CteG induced a vacuolar protein sorting 
defect when expressed in Saccharomyces cerevisiae. This suggested that CteG could function in 
modifying eukaryotic vesicular transport.  Lastly, ct105/cteG was mostly transcribed in C. trachomatis 
strains causing lymphogranuloma venereum, indicating that CT105/CteG might contribute to the 
characteristic tropism of these strains. 
 In conclusion, we have identified and characterized CT105/CteG, the first chlamydial effector 
found to associate with the Golgi complex, thus expanding the portfolio of known chlamydial effectors 
and increasing the understanding of host-pathogen interactions.  
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1.1 DISCOVERY OF THE CHLAMYDIA PATHOGEN 
 
In 1907, Ludwig Halberstadter and Stanislaus von Prowazek were examining Giemsa-stained 
smears of conjunctival scrapings from subjects with trachoma when they identified intracytoplasmatic 
inclusions arranged around the nucleus like a cloak. This was the first description of the etiological agent 
of trachoma which was named Chlamydozoa, derived from the Greek word “khlamús”, meaning cloak 
(Halberstaedter and von Prowazek, 1907). Later, similar inclusions were identified in scrapings from 
adults with urethritis and cervicitis, from newborns with nongonococcal conjunctivitis (Lindner, 1910), 
and in samples obtained from patients with lymphogranuloma venereum (LGV) (Durand et al., 1913).  
In 1935, the agent was classified as a virus because it was able to pass through bacterial filters and 
unable to grow  on agar or liquid media (Miyagawa et al., 1935). This was accepted until 1966, when 
alongside with the emergence of electron microscopy, Chlamydia was reclassified as bacterium, due to 
the presence of DNA, RNA, a cell wall similar to Gram-negative bacteria, and the ability to undergo 
binary fission (Moulder, 1966). 
 
1.2 TAXONOMY OF CHLAMYDIA 
 
1.2.1 The Chlamydiae 
 
Until the 1990’s, the phylum Chlamydiae was thought to have only one genus, the Chlamydia. 
However, the improvement and the increase accessibility to DNA sequencing set the grounds to the 
discovery of additional Chlamydiae. Over the last 25 years, the diversity of the Chlamydiae increased 
from one to nine families: Chlamydiaceae, Parachlamydia, Waddliaceae, Simkaminiaceae, 
Rhabdochlamydiaceae, Criblamydiaceae, Piscichlamydiaceae, Clavichlamydiaceae and 
Parilichlamydiaceae (Figure 1.1) (Horn, 2008). Despite covering a great host range and an ubiquitous 
distribution in the environment, all Chlamydiae share the obligate intracellular lifestyle within eukaryotic 
cells, a unique biphasic developmental cycle and more than 80% 16S ribosomal RNA (rRNA) and/or 
23S rRNA sequence identity (Everett, 2000). The non-Chlamydiaceae are also referred as Chlamydia-
like bacteria or environmental Chlamydia and exist as symbionts of free-living amoeba and of other 
eukaryotic hosts (Horn, 2008). 
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Figure 1.1 Phylogenetic 16S rRNA tree showing relationships among members of the phylum 
Chlamydiae. Representatives of all recognized families. Bar, 10% estimated evolutionary distance. Reprinted 
from Horn 2008. 
 
1.2.2 The Chlamydiaceae 
 
Based on the analysis of rRNA gene sequences, it was proposed the division of Chlamydiacea into 
two genera, Chlamydia and Chlamydiophyla (Everett et al., 1999). However, this division raised 
controversy, as the thresholds used were not consistent with those from other bacteria taxa, all genomes 
were highly similar and there were no distinct phenotypic features between the recently created genera.  
Therefore, most of the researchers in the field continued to use the one genera nomenclature and a 
reunification for the genera was proposed (Sachse et al., 2015). Although there are still doubts on the 
nomenclature, a single Chlamydia genus comprising all the known Chlamydiaceae species is the more 
accepted classification. The Chlamydiaceae family comprises 11 different species that infect a variety 
of hosts (Figure 1.2): 
 Chlamydia trachomatis is an exclusive human pathogen causing ocular and genital infections. It 
is the most studied and characterized Chlamydia species (see Section 1.3); 
 Chlamydia pneumoniae is another human pathogen and the major cause of community acquired 
pneumonia (Brown, 2012). It has been linked to several chronic diseases in humans such as 
atherosclerosis, osteoporosis, multiple sclerosis, and Alzheimer disease, although scarce data 
supports these associations. Besides infecting humans, C. pneumoniae infects amphibians, 
reptiles and other mammals (Roulis et al., 2013); 
 Chlamydia psittacci is the cause of avian respiratory disease and has a high impact on poultry 
farming and bird breeding. Transmission from birds to humans has been reported, when humans 
are in contact with infected birds. C. psitacci has been also isolated from other mammalian hosts, 
such as dogs, cats, pigs, cattle, sheep and horses (Longbottom and Coulter, 2003); 
 Chlamydia avium and Chlamydia gallinaceae infect pigeons and poultry, respectively. These were 
previously included in the C. psitacci species. (Sachse et al., 2014). 
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 Chlamydia pecorum is a pathogen of livestock (cattle, sheep, goats and pigs) (Walker et al., 2015) 
and wild animals such as the koalas. In fact, C. pecorum is a major cause of the decline of the 
koalas in Australia (Polkinghorne et al., 2013); 
 Chlamydia abortus causes abortion in sheep and goat due to infection of the placenta and 
therefore has a significant economic impact, particularly in Europe.  Although rare, transmission 
to humans has been reported and pregnant women exposed to infected animals are at risk of 
abortion (Longbottom and Coulter, 2003); 
 Chlamydia felis is a frequent cause of infection in cats causing conjunctivitis and pneumonitis (Cai 
et al., 2002). Infection of humans is rare and does not cause severe illness however transmission 
can occur to humans in close contact with cats (Hartley et al., 2001); 
 Chlamydia caviae is a pathogen of guinea pigs causing conjunctivitis and genital infections. These 
have been used as a model of  sexual transmission of Chlamydia (Rank et al., 2003) and to the 
study of genital tract infection and disease pathology (Rank and Sanders, 1992); 
 Chlamydia muridarum infects mice causing pneumonitis and is widely used as a model to study 
genital chlamydial infections (Barron et al., 1981).  
 Chlamydia suis is a common pathogen of pigs. It is the only chlamydial species known to have 
naturally acquired genes that confer antibiotic resistance, as it contains tetracycline resistant 
genes (tetC islands) (Dugan et al., 2004). 
 
Figure 1.2 Phylogenetic reconstruction of the Chlamydia genus. Chlamydiaceae species and the 
respective natural hosts are shown in the figure and arrows depicted the cases of zoonotic transmission. C. suis, 
C. avium and C. gallinacea are not represented due to lack of sequence data. Tree topology is based on the 
accumulation of single-nucleotide polymorphisms (SNPs) on 600 orthologous genes shared among the species. 
Reprinted from Nunes et a.l, 2014. 
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1.3 THE HUMAN PATHOGEN CHLAMYDIA TRACHOMATIS 
 
1.3.1 C. trachomatis strains 
 
C. trachomatis is an exclusive obligate intracellular human pathogen and the most studied Chlamydia 
species. C. trachomatis are conventionally divided into 15 major serovars (A to L), depending on the 
immunoreactivity of the C. trachomatis major outer membrane protein (MOMP), or the genotyping and 
sequencing of ompA (the gene encoding MOMP). Serovars A to C mainly infect ocular epithelial cells, 
serovars D to K mainly infect urogenital epithelial cells, and lymphogranuloma venereum (LGV) strains 
(serovars L1 to L3) are also sexually transmitted but are more invasive and can infect macrophages and 
monocytes and spread into lymph nodes (Schachter, 1999). 
All sequenced genomes of C. trachomatis are similar in size (1.04-1.05 Mb), exhibit more than 99% 
nucleotide sequence identity and have a high degree of synteny (Stephens et al., 2009; Harris et al., 
2012; Seth-Smith et al., 2013). Nevertheless, a small region in the genome (10 to 50 kb corresponding 
to 45-49 genes) named plasticity zone (PZ) has a high degree of genetic divergence between the 
different serovars and is likely involved in the different tissue tropisms (Read et al., 2000). For example, 
the tryptophan operon (trpRBA) and the gene encoding cytotoxin CT166 are localized in this region. The 
tryptophan operon is present in all C. trachomatis strains, but only in the genital strains the tryptophan 
synthase (encoded by trpBA) is active and able to synthesize tryptophan from indole, a compound found 
in the genital tract and thought to be produced by the resident microbiota. During infection, the host 
immune system produces interferon gamma (IFN-γ), which limits the availability of tryptophan. However, 
genital strains are able to produce their own tryptophan and can survive in the genital tract environment 
(A Shaw et al., 2000; Fehlner-Gardiner et al., 2002; Caldwell et al., 2003). Cytotoxin CT166 is a protein 
involved in the disassembly of actin filaments during bacterial internalization, which has been called the 
“cytopathic effect” (Thalmann et al., 2010). Although present (complete or truncated) in ocular and 
genital strains, the gene encoding CT166 is deleted in LGV strains (Carlson et al., 2004).  Besides the 
PZ region, other genes across the genome might contribute to the variability among different C. 
trachomatis serovars, such as the highly variable polymorphic outer membrane proteins (Pmps) (Gomes 
et al., 2006) and different secreted virulence proteins (Lutter et al., 2010; Almeida et al., 2012). 
 
1.3.2 Medical importance and public health 
 
C. trachomatis infections are a public health concern worldwide. Ocular strains are the major 
causative agent of preventable infectious blindness (trachoma), whereas urogenital strains are the most 
common cause of bacterial sexually transmitted infections. 
Ocular infections caused by C. trachomatis serovars A to C produce a conjunctival inflammation that 
can lead to the scarring of the eyelid. Repeated infections can result in severe eye scarring and 
ultimately cause irreversible blindness. Transmission occurs through the contact with eye or nose 
discharges of infected people (Taylor et al., 2014). C. trachomatis ocular infections are endemic in the 
poorest and rural areas of Africa, Central and South America, Asia, Australia and Middle East, mainly 
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due the lack of hygiene standards. C. trachomatis is responsible for visual impairment or blindness of 
about 1.9 million people, causing approximately 1.4% of all blindness (Taylor et al., 2014; Trachoma 
Fact Sheet, World Health Organization (WHO), 2018) 
C. trachomatis serovars D to K infect urogenital epithelial cells leading to cervicitis in women and 
urethritis in men. Infections are asymptomatic in approximately 70% of women and 50% of men. 
(Harryman et al., 2014). If the infections are left untreated, bacteria ascend to the upper genital tract in 
15 – 40% of the cases and leads to serious sequelae among woman including pelvic inflammatory 
disease (PID), tubal infertility, ectopic pregnancy, and chronic pelvic pain (O’Connell and Ferone, 2016). 
The World Health Organization (WHO) estimated that, in 2012, 131 million new cases of C. trachomatis 
infections occurred among adolescents and adults (15 - 49 years old), which corresponds to a 4.2% 
prevalence of C. trachomatis infections worldwide (Sexually transmitted infections (STIs) Fact Sheet, 
World Health Organization (WHO), 2016). In Portugal, the data on C. trachomatis infections is still limit 
as the report of C. trachomatis infections became mandatory only in 2014. The Portuguese National 
Institute of Health (INSA) inquiry revealed a prevalence of 2.7% of C. trachomatis infections among the 
4,866 people inquired (INSA Inquiry 2015-2016, 2016). 
C. trachomatis serovars L1 to L3 cause lymphogranuloma venereum (LGV), an inguinal syndrome 
normally characterized by genital ulceration and painful inguinal lymphadenopathy (Mabey and Peeling, 
2002). LGV strains are endemic in Africa, Southeast Asia, South America and the Caribbean; however, 
in recent years, LGV has emerged in Europe and North America, mainly in men who have sex with men, 
as a leading cause of ulcerative proctitis (Mabey and Peeling, 2002; Martin-Iguacel et al., 2010). 
 
1.3.3 Diagnostic, treatment and vaccine 
 
Antibiotic therapy has been shown to be effective in the treatment of primary ocular and urogenital 
C. trachomatis infections. The current guidelines of the WHO recommend the use of azithromycin and 
doxycycline (Reyburn, 2010) . Nevertheless, the major concern in C. trachomatis infections is the fact 
that these are commonly asymptomatic and can go undiagnosed and untreated (van de Laar and Morré, 
2007). Repeated infections are also common and associated with a high risk of developing serious 
sequelae, such as blindness due to the ocular infections and infertility due to the urogenital infections 
(Darville and Hiltke, 2010). Therefore, tools to diagnose C. trachomatis are of major importance. 
Infections can be diagnosed either by culturing, direct immunofluorescence assays (DFAs), or enzyme-
linked immunosorbent assays (ELISAs). However, the method of choice have been the nucleic acid 
amplification tests (NAATs), as they are highly sensitive and specific in detection of C. trachomatis in 
medical samples (Meyer, 2016) . 
Currently, there are no licensed vaccines for C. trachomatis and the development of a vaccine still 
has low priority on the public health agenda, as these bacterial infections cause significant morbidity but 
no mortality. Several evidences from animal models and human studies suggested that the vaccine is 
feasible and a MOMP-based vaccine is already in phase I clinical trials (Gottlieb et al., 2016; Poston et 
al., 2017). 
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1.4 C. TRACHOMATIS GENETICS 
 
1.4.1 C. trachomatis genome 
 
The first complete chlamydial genome (C. trachomatis serovar D) was published in 1998 (Stephens, 
1998). However, with the rapid development of the DNA sequencing technologies, the number of 
sequenced C. trachomatis genomes have increased rapidly. To date, there are 85 complete C. 
trachomatis genomes deposited in National Center of Biotechnology Information (NCBI) database. The 
typical C. trachomatis chromosome has approximately 1 Mbp and is predicted to encode about 900 
protein-coding genes. The small genome suggests that, during adaptation to the host, C. trachomatis  
lost a large number of genes, as Chlamydia-like and free living bacteria have larger genomes (~2Mp) 
(Mendonça et al., 2011). Nevertheless, C. trachomatis maintained the minimal machinery required for 
DNA replication, transcription and translation, for protein secretion, for basic lipid metabolism and for 
essential functions in aerobic respiration (Stephens, 1998; Yao, Cherian, et al., 2015). Still, C. 
trachomatis relies on the host to obtain basic nutrients as some of its metabolic pathways are incomplete 
(e.g., tricarboxilic acid cycle or the biosynthesis of some amino acids) (Stephens, 1998) 
 
1.4.2 The virulence plasmid 
 
C. trachomatis harbors a 7.5 kb cryptic plasmid, first described in 1980 (Lovett et al., 1980). The 
plasmid is low copy with up to 8 copies per cell, non-conjugative, non-integrative and, in the majority of 
the Chlamydia species, it does not possess antibiotic resistance genes (Pickett et al., 2005; Ferreira et 
al., 2013). The exception is plasmid of C. suis,  which integrates and contains tetracycline resistance 
genes (Dugan et al., 2004; Dugan et al., 2007).  
The plasmid is highly conserved among different Chlamydia species, ranging from 68 to 99%  of 
nucleotide identity (Thomas et al., 1997; Pickett et al., 2005), and among different C. trachomatis strains 
it only differs in 1% of the nucleotide sequence (Thomas et al., 1997; Ferreira et al., 2013). The 
chlamydial plasmid carries 8 open reading frames (ORFs), which are all transcribed and translated 
during the developmental cycle (Palmer and Falkow, 1986; Ricci et al., 1993; Ricci et al., 1995), and 2 
small antisense RNAs (sRNAs) (Ricci et al., 1993; Albrecht et al., 2009).  The nomenclature is quite 
diverse among different species. pORF1 designates the open reading frame (ORF) immediately 
downstream from the origin of replication of the plasmid. However, in C. trachomatis this corresponds 
to Pgp7. This will be the nomenclature used below. 
The Pgp1, -2, -6 proteins and the DNA sequence within pgp8, but not the Pgp8 protein, are required 
for plasmid maintenance (Gong et al., 2013; Song et al., 2013; Y Liu et al., 2014). Pgp1 is a predicted 
DnaB-like helicase and Pgp8 is a putative integrase/recombinase. Pgp2 and Pgp6 are proteins of 
unknown function (Ricci et al., 1995; Thomas et al., 1997). The pgp8 DNA coding sequence comprises 
a small antisense RNA (sRNA-2), which may play a role in plasmid maintenance although other features 
of the pgp8 DNA coding sequence might contribute to this function (Gong et al., 2013).  
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Pgp4 is a transcriptional regulator of virulence-associated chlamydial genes. Deletion of pgp4 results 
in reduction of gene expression of pgp3 (~ 4-fold) and of chromosomal genes that include glgA, a gene 
associated with accumulation of glycogen within the inclusion lumen (~ 8-fold), and a few genes 
encoding secreted proteins (~2- to 23-fold) (Song et al., 2013). In addition, pgp4 was shown to be 
required to particular egress mechanism (lytic exit) of Chlamydia from host cells (Chunfu Yang et al., 
2015). 
Pgp5 is a negative regulator of the genes regulated by Pgp4, thus leading to the hypothesis that the 
chlamydial plasmid might aid in the modulation of chlamydial gene expression in response to 
environmental cues from the host, microbiome and co-infection (Y Liu et al., 2014). 
Pgp3 protein is associated with the chlamydial outer membrane (Comanducci et al., 1993) and is 
secreted into the inclusion lumen and host cell cytosol (Z Li et al., 2008). It has been demonstrated to 
be one of the most immunodominant antigens in humans infected by C. trachomatis (Wang et al., 2010).  
Different activities have been reported for this plasmid-encoded protein. Pgp3 binds and neutralizes the 
anti-microbial peptide LL-37 (Hou et al., 2015) and activates macrophages to produce inflammatory 
cytokines (Z Li et al., 2008).  In addition, the Pgp3/LL-37 complex is able to induce neutrophils to secrete 
inflammatory cytokines (Hou et al., 2018) In mice, Pgp3 promotes C. muridarum survival in the lower 
genital tract and bacterial ascension to the upper genital tract (Yuanjun Liu et al., 2014). Overall, this 
indicates that Pgp3 is a major virulence factor with an important role in Chlamydia pathogenesis. 
sRNA-2 (antisense to pgp8) is the most abundant of all the plasmid transcripts (Ferreira et al., 2013) 
and may play a role in plasmid maintenance through the regulation of pgp8, as described above (Gong 
et al., 2013). sRNA-7 (antisense to pgp5) is not important to plasmid maintenance (Gong et al., 2013) 
nor to negative transcriptional regulation associated with pgp5 (Y Liu et al., 2014), and its function is 
unknown. 
Plasmid-deficient C. trachomatis strains are rare but have already been detected in patient isolates. 
These plasmidless strains are associated with impaired glycogen accumulation within the inclusion 
(Matsumoto et al., 1998; O’Connell and Nicks, 2006) and have attenuated virulence in mice (O’Connell 
and Nicks, 2006; Sigar et al., 2014). This suggests that the plasmid contributes to Chlamydia 
pathogenicity in vivo. 
 
1.4.3 Genetic manipulation of Chlamydia 
 
The study of the biology, pathogenesis and transmission of C. trachomatis has been hindered by the 
lack of tools for its genetic manipulation. The major constraints have been related with its obligate 
intracellular lifestyle, its characteristic biphasic developmental cycle, and the lack of evidence of recent 
acquisition of foreign DNA. However, in the last 10 years, methods for genetic manipulation broadly 
used in other bacteria have been successfully adapted to C. trachomatis. Although these procedures 
still need optimization, C. trachomatis is no longer genetically intractable. 
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1.4.3.1 Transformation of Chlamydia and development of stable shuttle vectors 
 
In 1994, Tam and colleagues described for the first time the transformation of C. trachomatis (Tam 
et al., 1994). The DNA used consisted in a C. trachomatis–Escherichia coli shuttle plasmid carrying a 
chloramphenicol acetyltransferase (cat) cassette under the control of a Chlamydia native promoter. 
However, the transformation revealed to be transient and the plasmid was lost after 4 passages/rounds 
of infection. Recent data showed that the transformed plasmid lacked a region within pgp1 that is 
essential for plasmid maintenance. 
In 2009, Binet and Maurelli designed a suicide plasmid containing a synthetic rRNA with single 
mutations that conferred resistance to kasugamycin and spectinomycin. By transforming C. psittaci with 
this plasmid using electroporation, a mutant was successfully obtained by means of allelic exchange 
(Binet and Maurelli, 2009). However, the methodology was not followed-up, probably due to the 
extremely low efficiencies of transformation and to the fact that C. psittaci requires high levels of 
containment. 
In 2011, a landmark study by the laboratory of Ian Clarke was published describing a method for 
stable transformation of C. trachomatis (Wang et al., 2011). A shuttle vector comprising the native 
chlamydial plasmid fused to an E. coli cloning vector was constructed to allow replication in both 
bacteria, and a -lactamase gene was also added for selection of the transformants. The reasoning for 
the choice of this selection marker was that in the presence of -lactams C. trachomatis enters a 
persistent state characterized by the arrest of the development cycle, in which bacteria are maintained 
in an aberrant non-infectious form. Therefore, the introduction of this plasmid in C. trachomatis would 
allow the transformed bacteria to avoid this persistent state in the presence of penicillin and continue 
the infection cycle. Another advantage of this marker is the fact that aberrant (non-transformed) and 
non-aberrant (transformed) bacteria have a distinct morphology that can be easily distinguished using 
conventional light microscopy. To introduce the recombinant plasmid in C. trachomatis, the classic 
method of E. coli chemical transformation was adapted. The plasmid DNA and elementary bodies 
(infectious form of the bacteria) were incubated in a CaCl2 buffer followed by infection of epithelial cells 
and selection using penicillin during several rounds of infection. During this process, the native plasmid 
is replaced by the recombinant plasmid due to plasmid incompatibility and transformants can be stably 
maintained over numerous passages, even in the absence of the selection marker.  
The development of the procedure described by the laboratory of Ian Clarke laid the basis for genetic 
manipulation of C. trachomatis. The shuttle vector used has been the backbone to second generation 
recombinant plasmids, which allow expression of a variety of fluorescent proteins (Agaisse and Derré, 
2013; Campbell et al., 2014), native or conditional control of gene expression (Agaisse and Derré, 2013; 
Wickstrum et al., 2013; Bauler and Hackstadt, 2014), and to monitor protein delivery into the cytoplasm 
of infected host cells using different reporter epitope tags or enzymes (FLAG, Cya, GSK, TEM-1, split-
GFP) (Bauler and Hackstadt, 2014; Mueller and Fields, 2015; Wang et al., 2018). 
 
 
1 INTRODUCTION 
11 
1.4.3.2 Mutagenesis 
 
1.4.3.2.1 Random mutagenesis 
 
The development of the techniques to random mutagenize C. trachomatis were also a big step in the 
study of the biology of this bacterium. Kari and colleagues described the construction of an isogenic C. 
trachomatis mutant strain (Kari et al., 2011)  by a method derived from targeting-induced local lesions 
in genomes (TILLING), a plant genetics tool which combines chemical mutagenesis with a sensitive 
DNA screen to identify single nucleotide changes in a target gene. Low-levels of the mutagenizing agent 
ethyl methanesulfonate (EMS) were used to generate C. trachomatis strains with one mutation per 
genome. These mutants were expanded in subpopulations and screened for specific mutations by 
denaturing and reannealing PCR amplicons of the target gene followed digestion of the amplicons with 
a mismatch specific endonuclease (CEL I). Furthermore, subpopulations carrying the mutations in the 
target gene were sequenced. If a desired mutation was present, bacteria were isolated and further 
analyzed. 
Subsequently, Nguyen coupled chemical mutagenesis with genome sequencing and DNA exchange 
to identify mutations responsible for characteristic phenotypes, in a forward genetics approach  (Nguyen 
and Valdivia, 2012). C. trachomatis were again treated with the mutagenizing agent EMS but in higher 
concentrations than those used by Kari and colleagues, thus generating 3 to 20 mutations per genome. 
By plaque assay, clonal populations were isolated, and the morphology of the plaques were analyzed. 
Clones sharing the same plaque morphology were sequenced and searched for common mutations. 
Afterwards, mutants of interest were segregated by lateral gene transfer and homologous 
recombination. This method was further updated by Kokes (Kokes et al., 2015) using as mutagenizing 
agent either EMS or N-ethy-N-nitrosurea (ENU) to create a collection of 934 mutant strains. The screen 
was performed by both plaque morphology and whole genome sequencing analysis. 
 
1.4.3.2.2 Site-directed mutagenesis 
 
Although the random mutagenesis was a great addition to the molecular genetics toolbox of 
Chlamydia, methods to specifically target the chlamydial chromosome were not yet available. In 2013, 
Johnson and Fisher adapted the TargeTron system (at the time marketed by Sigma Aldrich) to perform 
site-specific mutagenesis of C. trachomatis. This system is based on a mobile group II intron that can 
be retargeted by the alteration of DNA sequences within the intron and thus allowing site-specific gene 
insertions. The system was modified with the insertion of a chlamydial native promoter to allow the 
expression of the intron insertion machinery in C. trachomatis. A -lactamase gene (bla) was added as 
a marker to select for the mutated strains. Using this system, it was possible to insertionally inactivate 
the gene encoding IncA, a Chlamydia protein that inserts in the membrane of the inclusion (Johnson 
and Fisher, 2013). Later, a re-modification of the system also allowed the use of spectinomycin as a 
selection marker (Lowden et al., 2015). The success of this method has been proved, as it was used to 
mutate an antagonist of the chlamydial anti-sigma factor (Thompson et al., 2015), other inclusion 
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membrane proteins (Weber, Nicholas F. Noriea, et al., 2016; Sixt et al., 2017; Weber et al., 2017; 
Almeida et al., 2018), and chlamydial GroEL chaperonins (Illingworth et al., 2017). 
In 2016, Mueller et al. described a system for fluorescence-reported allelic exchange mutagenesis 
(FRAEM) (Mueller et al., 2016). The vector used consisted in a plasmid with pgp6 (a gene required for 
plasmid maintenance) under the control of the tetracycline promoter, thus allowing a controlled removal 
of the plasmid upon mutagenesis. In addition, the plasmid contained a cassette encoding both -
lactamase and the green fluorescent protein (GFP) flanked by chlamydial DNA corresponding to 
approximately 3 kb of the genomic sequence upstream and downstream from the gene targeted for 
mutagenesis. This allowed allelic exchange of the gene of interest by the bla/gfp cassette. Stable 
mutations of trpA, tmeA/ct694/ctl0063, tmeB/ct695/ctl0064, and ct696/ctl0065 were successfully 
achieved, confirming the functionality of the FRAEM system. 
More recently, a system using clustered regularly interspaced short palindromic repeats interference 
(CRISPRi) based on an inducible catalytically inactive CRISPR associated protein 9 (Cas9) allowed the 
conditional knockdown of the incA gene. Nevertheless, the system still requires improvements in the 
stability of the plasmid, minimization of off-target effects and leaky expression to be considered 
attainable for mutagenesis of C. trachomatis (Ouellette, 2018). 
 
1.5 CHLAMYDIA TRACHOMATIS PATHOGENESIS 
 
C. trachomatis, like all Chlamydiae, are obligate intracellular bacteria that have a distinctive biphasic 
developmental cycle comprising the interconversion between two distinctive morphological forms, the 
elementary body (EB) and the reticulate body (RB) (Abdelrahman and Belland, 2005) (Figure 1.3). EBs 
are the infectious, non-replicative and extracellular form of the bacteria. They can temporally survive in 
the extracellular environment between infections, due to a highly crosslinked cell wall that confers 
resistance to osmotic and physical stress. These are the smaller form of the bacteria (~ 0.3 µm in 
diameter) and have a highly compact nucleoid. Although previously thought as being metabolically 
inactive, recent studies suggest that their metabolic and biosynthetic activity is high and depends on D-
glucose as a source of energy (Omsland et al., 2014). The RBs (~ 1 µm in diameter) are the non-
infectious but replicative form of the bacteria. They are more fragile than EBs due the lack of a cross-
linked outer membrane. They have a more relaxed chromatin and are metabolically active as they are 
involved in nutrient acquisition and replication (Hackstadt et al., 1985; Barry et al., 1992; Abdelrahman 
and Belland, 2005; Omsland et al., 2014). C. trachomatis RBs can have an enlarged and aberrant 
morphology, designate as aberrant bodies (ABs). These are viable but non-infectious bacteria that result 
from Chlamydia entering in a state of persistence, where metabolism is slowed down and RB to EB 
conversion is hampered. This state is reversible and has been shown to be induced by several factors 
such as cytokines (IFN-), nutrient starvation and antibiotics (e.g., -lactams) (Beatty et al., 1994; Hogan 
et al., 2004). 
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Figure 1.3 Transmission electron micrograph of different C. trachomatis morphologic forms. EB, 
elementary body. RB, reticulate body. IB, intermediate body, a conversion intermediate between EBs and RBs. 
Magnification x160,000. Reprinted form Philips et al. 1984  
 
The developmental cycle of C. trachomatis is completed in 36 to 96 h (depending on the strains, e.g., 
for C. trachomatis LGV strains the cycle is about 48 h) (Miyairi et al., 2006). It comprises an entry phase, 
where bacteria attach to the extracellular side of the host cell plasma membrane and are subsequently 
internalized in a membrane-bound vacuole, normally designated as inclusion. Then, the inclusion 
migrates to the perinuclear region of the host cell (Clausen et al., 1997) and avoids fusion with 
lysosomes, as it mostly devoid of known markers of the endocytic pathway (Heinzen et al., 1996). EBs 
differentiate into RBs thus starting bacterial replication, which is supported by the acquisition of nutrients 
(lipids, amino acids and iron) from the host cell. Chlamydial replication has been presumed to occur by 
binary fission, however recent studies have reported different observations where one supports the 
hypothesis of replication by polarized cell division (Abdelrahman et al., 2016) and the other by binary 
fission (Lee et al., 2018). Those studies have been performed using different microscopy tecniques, and 
thus the mechanism of Chlamydia replication will require further clarification. Chlamydial replication is 
accompanied by the expansion of the inclusion and, later, RBs asynchronously convert into EBs. This 
process has been suggested to be regulated by the size of the RBs (Lee et al., 2018). Finally, EBs are 
released either by host cell lysis or extrusion of the inclusion and can undergo another round of infection 
on neighboring cells (Abdelrahman and Belland, 2005).  
Throughout the developmental cycle, Chlamydia modulates host cellular functions (section 1.5.2) 
and one of the mechanisms used is the type III secretion system (T3SS; see Section 1.5.1), a 
mechanism of bacterial protein transport, that is likely crucial to the growth and survival of the bacteria 
within the host cell. 
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Figure 1.4 Schematic representation of the C. trachomatis developmental cycle. C. trachomatis 
infection starts with the attachment of the infectious elementary bodies (EBs) to the surface of epithelial cells. After 
entry, bacteria become enclosed within a membrane-bound vacuole, named inclusion, where EBs differentiate in 
non-infectious reticulate bodies (RBs). Later in the cycle, RBs differentiate back into EBs and are then released, 
either by host cell lysis or extrusion, to undergo another round of infection.  
 
1.5.1 The type III secretion system of Chlamydia trachomatis  
 
Protein secretion is an essential process for prokaryotic cells (and for all cells), allowing the transport 
of proteins to membrane compartments or to the extracellular space, whether this is the environment, 
another bacterium or a eukaryotic cell. To cross to the extracellular space, proteins from Gram-negative 
bacteria encounter a barrier composed by at least two phospholipid membranes and a peptidoglycan 
layer (Costa et al., 2015). Therefore, it is not surprising that these bacteria have evolved a variety of 
mechanisms of protein secretion, specific to their needs. The type III, type IV and type VI secretion 
systems (T3SS, T4SS, T6SS, respectively) allow the direct delivery of proteins and DNA, in a one-step 
process, through large multiprotein complexes, functioning as nanomachines, spanning both inner and 
outer bacterial membrane. Although these nanomachines appear similar and serve the same purpose, 
they have different evolutionary origins and functions. For instance, proteins of the T3SSs are 
evolutionary related to those of the bacterial flagellum and secrete proteins capable of manipulating 
eukaryotic host cells. The proteins of the T4SSs are evolutionary related to those of bacterial conjugation 
systems possessing a pilus-like structure. T4SS allow the transport of proteins, but its main physiological 
role is the transport of plasmid DNA by conjugation. Lastly, the proteins of T6SSs are homologous to 
those of phage tails. In fact, while T6SSs also transport proteins into eukaryotic cells, their most common 
function is the injection of proteins into other bacteria. They are important to bacterial 
communication/competition and interaction with the environment (Costa et al., 2015).  
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Non-flagellar T3SSs are exclusive of Gram-negative bacteria and are widely spread among bacterial 
pathogens of animals and plants, but are also involved in the establishment of symbiotic relationships 
between bacteria and eukaryotic hosts (Galán et al., 2014). These systems allow the direct delivery into 
the cytoplasm of eukaryotic cells of bacterial proteins, named type III secretion (T3S) effectors, which 
promote bacterial growth and survival by interfering with host cell processes. T3SSs comprise an 
injectisome, a multi-protein complex embedded in the two bacterial membranes consisting in a basal 
apparatus, a needle complex topped by a tip complex and a translocation pore inserted in a host 
membrane (the host plasma membrane and the inclusion membrane, in the case of Chlamydia). The 
injectisome forms a continuous channel that enables the one-step delivery of the T3S effectors, which 
can have specific T3S chaperones to aid their secretion (Figure 1.5) (Cornelis, 2006; Galán and Wolf-
Watz, 2006).  
 
 
Figure 1.5 The T3SS of C. trachomatis. (A) Cryo-electron tomogram of host-free T3SS of C. trachomatis; 
scale 15 nm; Reprinted from Nans et al. 2015 (B) Schematic representation of a prototypical T3SS. The injectisome 
basal apparatus is embedded in the bacterial outer (OM) and inner (IM) membranes and is topped by a needle-like 
structure. Upon activation of the T3SS, translocator proteins are secreted and inserted at the host membrane (HM), 
forming the translocation pore. T3S effectors in bacterial cytosol can interact with T3S chaperones that aid secretion 
through the injectisome.  
 
 
Typically, T3SSs are encoded in a few operons, either in pathogenicity islands in the bacterial 
chromosome (e.g., Salmonella) or in virulence plasmids (e.g., Yersinia and Shigella) (Hueck, 1998). 
These systems have lost the motility genes of the flagellar apparatus and acquired components 
necessary for secretion and delivery of proteins across an eukaryotic cell membrane (Abby and Rocha, 
2012). They are typically horizontally acquired and highly conserved even among bacteria with distinct 
evolutionary origins (Gophna et al., 2003).  
Likely, the first observation of the chlamydial T3SS was made by Matsumoto and colleagues in 1973, 
which described the presence of rosette-like structures and projections on the surface of both EBs and 
RBs in different chlamydial species (Matsumoto, 1973). With the advent of DNA sequencing, genomic 
analysis confirmed the presence of T3S encoding genes in all sequenced Chlamydiaceae and 
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environmental Chlamydiae (Stephens, 1998; Kalman et al., 1999; Read et al., 2000; Read et al., 2003; 
Thomson et al., 2005; Azuma et al., 2006; Bertelli et al., 2010). Normally, T3SS structural components 
are clustered together; however, the genes encoding the T3SS in Chlamydia are in at least four clusters 
(Kalman et al., 1999) organized in multiple operons (Hefty and Stephens, 2007). Genes that code for 
T3SS have usually different G+C content (40-45%) when compared with the genome; however, this 
does not occur in Chlamydia indicating that recent gene integration did not occur and suggesting that 
chlamydial T3SS might represent a primordial system (Stephens, 1998; Abby and Rocha, 2012).  
The chlamydial T3SS is thought to be activated in extracellular EBs upon contact with the host cell 
plasma membrane, resulting in the secretion of translocon proteins and followed by secretion of early 
effectors. Subsequently, within host cells, secretion is maintained in RBs by their association with the 
inclusion membrane which is accompanied by de novo expression of T3SS genes. When the transition 
of RBs to EBs occurs, RBs detach from the inclusion membrane and are thought to lose their protein 
secretion ability (Hansen-Wester and Hensel, 2001). 
 
1.5.1.1 Chlamydial T3S effectors 
 
Although the T3S injectisome is conserved among bacteria, normally T3S effectors do not have 
significant amino acid identity, but often have common structural features and perform similar functions. 
All effectors are thought to share a T3S signal localized at the N-terminus of the protein (approximately 
in the first 20 amino acid residues) (Sory et al., 1995; Lloyd et al., 2001). This signal is responsible to 
direct the protein for secretion and has been showed to be recognized by the T3SSs of different bacteria. 
The T3S signal is not cleavable, is unstructured and disordered, and enriched in serine, threonine, 
isoleucine and proline, but a clear consensus sequence is still unknown, despite of extensive studies 
(Wang et al., 2013). Upon secretion and delivery into the host cell, T3S effectors can perform a variety 
of functions that have been found to be crucial to the survival of many pathogenic bacteria.  
In C. trachomatis, T3S effector genes have been predicted to represent approximately 5-10% of the 
coding capacity of the genome. Their initial identification and study mostly relied on the use of (i) complex 
bioinformatic tools to predict T3S signals (Arnold et al., 2009; Samudrala et al., 2009; Löwer and 
Schneider, 2009), (ii) use of heterologous T3SS such as Salmonella (Ho and Starnbach, 2005), Shigella 
(Subtil et al., 2005; Jewett et al., 2006; Pennini et al., 2010; Muschiol et al., 2011; Furtado et al., 2013), 
or Yersinia (Fields and Hackstadt, 2000; Clifton et al., 2004; Chellas-Géry et al., 2007; Hower et al., 
2009; Pais et al., 2013; Hovis et al., 2013; da Cunha et al., 2014), and (iii) Saccharomyces cerevisiae 
to phenotypically characterize the effects of overexpression of candidate effectors  (Sisko et al., 2006; 
Kumar et al., 2006). In addition, the identification of T3S effectors during C. trachomatis infection relied 
on the ability to produce specific antibodies against the proteins of interest and on their 
immunolocalization within host cells. More recently, the tools to genetically manipulate C. trachomatis 
strains have been used to study chlamydial T3S effectors. 
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1.5.1.1.1 Inc (inclusion membrane) proteins 
 
The inclusion membrane (Inc) proteins are the most studied C. trachomatis T3S effectors. These 
proteins are characterized by a bilobed hydrophobic motif that likely mediates their insertion in the 
inclusion membrane (Rockey et al., 2002). Therefore, they can be identified using bioinformatics 
prediction tools and by immunofluorescence microscopy analysis of their presumed localization in the 
C. trachomatis inclusion. Inc proteins, which are at the host-bacteria interface, have been shown to 
modulate host cytoskeleton dynamics (Kokes et al., 2015; Mital et al., 2015; Dumoux et al., 2015; 
Wesolowski et al., 2017), vesicular and non-vesicular transport (Rzomp et al., 2006; Delevoye et al., 
2008; Derré et al., 2011; Mirrashidi et al., 2015), release of the bacteria from host cells (Lutter et al., 
2013; Nguyen et al., 2018) and inhibition of host cell death (Sixt et al., 2017; Weber et al., 2017). 
Moreover, Inc proteins have been hypothesized to contribute to the different tissue tropism and invasion 
characteristics of different C. trachomatis serovars (Lutter et al., 2012; Almeida et al., 2012). 
 
1.5.1.1.2 Non-Inc T3S effector proteins 
 
In addition to the Inc proteins, there are chlamydial T3S effectors that are delivered into the host cell 
and which do not possess the characteristic bilobed hydrophobic motif and mostly do not localize at the 
inclusion membrane. Their study is more challenging, as their primary structure normally lacks obvious 
distinguishable features.  
CT456/TarP (translocated actin-recruitment phosphoprotein) is likely the most studied T3S effector 
of C. trachomatis. TarP is synthesized at the late stages of the developmental cycle, pre-packed into 
EBs but only delivered into the host cell within minutes after EBs attachment. Once the EBs enter host 
cell, TarP is readily phosphorylated and recruits actin to the entry sites. TarP comprises an actin-binding 
domain at its C-terminus that associates with both G- and F-actin and induces actin nucleation and 
polymerization independently of host cell factors. At the N-terminus, TarP contains tyrosine-repeated 
regions which have been shown to be phosphorylated by the host cell kinases Src, AblI and Syk family 
(Mehlitz et al., 2008; Jewett et al., 2008). Phosphorylated TarP interacts with guanidine exchange 
factors, Sos1/Eps8/Abi1, and Vav2, which activate the small GTPase Rac allowing WAVE2 and Arp2/3-
mediated nucleation of actin at the host cell entry sites (Lane et al., 2008). Both actin nucleators, TarP 
and Arp2/3, act synergistically to enhance the rate of formation of actin filaments (Jiwani et al., 2012). 
TarP has been shown to interact with vinculin to mediate actin recruitment and assembly at the host cell 
plasma membrane, and with adaptor protein SHC1 to induce host cell survival early during chlamydial 
infection (Mehlitz et al., 2010). TarP has also been associated to the tropism of different C. trachomatis 
strains, as LGV strains contain higher number of tyrosine-rich repeat regions and less predicted actin 
binding domains, in contrast with TarP of the ocular strains (Lutter et al., 2010). 
CT694/TmeA (translocated membrane-associated effector A) is a T3S effector important for 
infectivity and invasion of C. trachomatis. TmeA is delivered into the host cell in the early-steps of 
infection (Hower et al., 2009; McKuen et al., 2017). The C-terminus of TmeA interacts with human 
AHNAK affecting the formation of host cell actin stress fibers. However, this does not seem to be 
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essential to invasion, probably due to redundancy among effectors acting at this stage (e.g., TarP) 
(Hower et al., 2009; McKuen et al., 2017).  Furthermore, ANNAK recruitment to the nascent inclusions 
was found to be independent of TmeA  (McKuen et al., 2017). Moreover, TmeA contains a membrane 
binding domain (MDL) at the N-terminus that targets the protein, at least when ectopically expressed, 
to the mammalian plasma membrane. It is believed that this might be important to target the protein to 
the entry sites (Bullock et al., 2012). Moreover, ct695/tmeB, which is co-transcribed with ct694/tmeA, 
encodes a T3S substrate that is transported into the host cell by C. trachomatis during invasion and at 
later times during the development cycle. TmeB localized at the inclusion membrane although no 
predicted transmembrane domain was found in this protein (Mueller and Fields, 2015). No defects for 
invasion and intracellular growth were observed for a C. trachomatis tmeB mutant (McKuen et al., 2017) 
and the function of this protein remains to be elucidated. 
CT875/TepP (translocated early phosphoprotein) is delivered into the host cell where is tyrosine-
phosphorylated by Src family kinases, similarly to TarP (Carpenter et al., 2017). TepP interacts with and 
recruits to the nascent inclusion the host proteins Crk and Crk-L, which are host scaffolding proteins that 
organize cytoskeletal rearrangement and signal transduction events  (Birge et al., 2009; Chen et al., 
2014; Carpenter et al., 2017). TepP also interacts and recruits phosphoinositide-3-kinase (PI3K) to 
nascent inclusions modulating a type I IFN response (Carpenter et al., 2017). Replication of C. 
trachomatis was found to be enhanced by expression of TepP (Carpenter et al., 2017). 
CT847 is a T3S substrate found to interact with the mammalian Grap2 cyclin D interacting protein 
(GCIP). As GCIP levels decreased during infection and by the addition of a T3SS inhibitor, CT847 is 
thought to be implicated in this effect during chlamydial infection (Chellas-Géry et al., 2007). 
CT737/NUE (nuclear effector) is transported into the host cell nucleus during infection where 
associates with chromatin. NUE contains SET [Su(var)3-9, Enhancer-of-zeste and Trithorax] domains, 
characteristic of proteins related to chromatin remodeling, and has histone methyltransferase activity 
with the ability to target host histones. This effector performs auto-methylation that leads to the increase 
of its enzymatic activity (Pennini et al., 2010). 
CT619, CT620, CT621, CT711 and CT712 are T3S substrates all comprising a unique domain of 
unknown function (DUF582). CT620 and CT621 have been shown to be delivered into the host cell 
cytoplasm and CT620 and CT711 were shown to localize in the host cell nucleus of infected cells. 
Although the DUF582 domain was shown to interact with the Hrs host protein (and Tsg101 for CT619), 
depletion of these and of other host proteins involved in the late steps of the endosomal sorting 
complexes required for transport (ESCRT) machinery assembly did not affect C. trachomatis 
internalization and development (Hobolt-Pedersen et al., 2009; Muschiol et al., 2011; Vromman et al., 
2016).  
CT622 is a recently identified T3S effector that is delivered into the host cell cytosol. Although no 
specific function was found for this protein, a C. trachomatis mutant strain with the corresponding gene 
inactivated showed reduced infectivity and a growth defect (Gong et al., 2011; Cossé et al., 2018). 
Chlamydial proteins CT089/CopN and CT529/Cap1, were found to localize at the inclusion 
membrane, although they did not contain the characteristic bilobal hydrophobic domain present in Inc 
proteins (Rockey et al., 2002). Their function as T3S effectors remains unknown. 
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In addition to the T3S effectors described above, other candidate T3S effectors of C. trachomatis 
were found to be delivered into the host cells and to contribute to C. trachomatis pathogenesis: 
CT868/ChlaDub1/Cdu1, CT166/cytotoxin and Lda (Lipid droplet associated) proteins (Belland et al., 
2001; Kumar et al., 2006; Wang et al., 2018). 
ChlaDub1 is a predicted cysteine protease likely to have deubiquitinating and deneddylating activities 
in the host cell, (Misaghi et al., 2006). ChlaDub1 suppressed the NF-κB pathway  when ectopically 
expressed in epithelial cells (Le Negrate et al., 2008). Moreover, ChlaDub1 was shown to localize to the 
inclusion membrane  (Wang et al., 2018) where it  stabilized by deubiquination of the anti-apoptotic host 
protein Mlc-1 (Fischer et al., 2017), and likewise also stabilized GLUT1 (glucose transporter 1), which 
was shown to be upregulated in Chlamydia-infected cells (Wang et al., 2017)  
As already mentioned (section 1.3.1), CT166/cytotoxin is a protein cytotoxic for host cells (Belland 
et al., 2001) and has been suggested to induce actin reorganization, that might involve the glycosylation 
of Rac1 (Thalmann et al., 2010).  
The Lda proteins (Lda1/CT156, Lda2/CT163, and Lda3/CT473) were found to be translocated into 
the eukaryotic host cell and to have affinity for host cell lipid droplets. They were proposed to contribute 
to the recruitment of lipid droplets into the inclusion lumen. Lipid droplets are neutral lipid-rich eukaryotic 
organelles and their recruitment may serve to the transport of essential lipids or vesicular transport 
proteins to the chlamydial inclusion (Kumar et al., 2006). 
 
1.5.1.2 Chlamydial T3S chaperones 
 
T3S chaperones are bacterial strictly cytosolic proteins that bind T3S substrates and aid their 
secretion by different mechanisms, such as: preventing substrate degradation, maintaining substrates 
in a partially unfolded secretion-competent state, preventing aggregation and premature/incorrect 
interactions, targeting substrates to the T3SS, and/or regulating hierarchy of secretion. These T3S 
specific chaperones have been characterized as low molecular mass acidic proteins with ability to form 
dimers and to bind downstream from the T3S signal (Feldman and Cornelis, 2003; Parsot et al., 2003). 
Depending on their substrate, T3S chaperones can be divided in three different classes: class I (Slc1, 
Mcsc, Scc1, Scc4, Scc3, in C. trachomatis) bind T3S effectors, class II (Scc2/Scc3, in C. trachomatis) 
bind proteins forming the translocon, and class III (CdsE and CdsG, in C. trachomatis) bind the T3S 
needle subunit  
In C. trachomatis, although a high number of T3S substrates have already been identified, the 
number of known T3S chaperones it is still reduced. CT043/Slc1 (SycE-like chaperone 1) binds and 
enhances secretion of chlamydial T3S effectors TarP, TmeA, TepP and T3S substrate CT695/TmeB 
(Brinkworth et al., 2011; Pais et al., 2013; Chen et al., 2014). Slc1 has been proposed to control the 
hierarchy of secretion of their interacting T3S effectors (Chen et al., 2014). CT260/Mcsc (multiple cargo 
secretion chaperone) binds and stabilizes Cap1 and Inc proteins CT225 and CT618 (Spaeth et al., 
2009). The T3S chaperone CT584 binds and stabilizes the T3S substrate CT082 promoting its secretion 
(Pais et al., 2013). Furthermore, CT584 has been proposed to be the main component of the chlamydial 
T3S needle tip complex based on an initial biophysical characterization (Markham et al., 2009), however, 
1 INTRODUCTION 
20 
the subsequent elucidation of its three dimensional structure, revealed it does not resembles T3S tip 
proteins (Stone et al., 2012). CT635 has been recently proposed as a candidate T3S chaperone of 
CT622 as both proteins interact. Nevertheless, CT635 could not stabilize or aid secretion of CT622 
(Cossé et al., 2018). 
 
1.5.1.3 Chlamydial T3S-independent effectors 
 
Additionally, other chlamydial proteins are delivered into the host cell independently of the T3SS and 
have been found to play important roles in C. trachomatis infection.  CT441/Tsp is a protease found to 
cleave host NF-κB in C. trachomatis infected cells (Lad, Li, et al., 2007; Lad, Yang, et al., 2007). As 
already mentioned in section 1.4.2, Pgp3 is a plasmid-encoded protein found to be secreted into the 
cytosol of infected cells (Z Li et al., 2008) and which plays an important role in C. trachomatis infection.  
Another protein transported into the host cell is CT858/CPAF (Chlamydia protease-like activity 
factor), a widely studied chlamydial protein with serine protease activity and several proposed functions. 
Initial reports, indicated that CPAF targeted and cleaved several host cell and Chlamydia proteins during 
infection (Pirbhai et al., 2006; Chen et al., 2009; Christian et al., 2010; Jorgensen et al., 2011). However, 
subsequent studies found that the cleavage of many of the described CPAF targets occurred post-lysis 
and not under biological conditions (Chen et al., 2012). The generation of a C. trachomatis cpaf mutant 
strain allowed re-evaluation of the previously characterized functions of CPAF (Snavely et al., 2014).  
CPAF is produced in RBs as an inactive zymogen that upon its secretion into the inclusion lumen, 
possibly by a type II secretion system (T2SS), autocatalyzes into the active protease. This activation 
has been suggested to be regulated by the host cell protease inhibitor protein PI15 (Huang et al., 2008; 
Chen, Lei, Flores, et al., 2010; Chen, Lei, Lu, et al., 2010; Snavely et al., 2014; Prusty et al., 2018). In 
the host cell, after loss of the inclusion membrane integrity, CPAF was found to target vimentin filaments 
and nuclear envelope protein lamin-associated protein-1 (LAP1). This occurs before loss of plasma 
membrane permeability and cell lysis, suggesting a function for CPAF in the release of EBs from the 
host cell during the late stages of infection (Snavely et al., 2014). Moreover, CPAF has been implicated 
in the evasion of the host immune system by suppressing the oxidative burst, interfering with chemical-
mediated activation of neutrophils and targeting host anti-chlamydial peptides to degradation (Tang et 
al., 2015; Rajeeve et al., 2018). CPAF, together with T3S effectors, was found to suppress the innate 
immune signaling (decreased -interferon and proinflammatory cytokine synthesis) by inhibiting NF-κB 
p65 nuclear translocation (Patton et al., 2016). CPAF expression has been found to be negatively 
regulated by the chlamydial plasmid, but only in LGV strains, implicating a function in macrophage 
infection tropism and invasiveness (Patton et al., 2018). In addition, CPAF was found to promote C. 
trachomatis survival in the mouse lower genital tract (Yang et al., 2016), and C. trachomatis CPAF-
deficient mutants displayed impaired intracellular growth (Snavely et al., 2014). Overall, CPAF 
showcases the complexity and diversity of functions for a single chlamydial protein during C. trachomatis 
infection. 
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1.5.2 Modulation of host cells by C. trachomatis 
 
1.5.2.1 Attachment and entry 
 
The attachment of C. trachomatis EBs to the host cell surface begins with a reversible electrostatic 
interaction with host heparan sulphate proteoglycans (Su et al., 1996). This is followed by irreversible 
high affinity binding of host cell receptors, such as manose-6-phophate receptor, PDGFRβ, β1-integrin, 
and Ephrin A2, to bacterial counterparts MOMP, OmcB and PmpD. Chlamydia uses more than one 
receptor for invasion as single depletion of these host receptors is not sufficient to block entry (Elwell et 
al., 2008; Subbarayal et al., 2015). Additionally, host protein disulfide isomerase (PDI) was shown to be 
implicated in the entry of Chlamydia. It was speculated this could be due to reducing disulfide bonds in 
proteins involved in bacterial adhesion, such as host receptors and bacterial proteins (e.g., MOMP, 
Pmps, T3SS needle) (Conant and Stephens, 2007; Abromaitis and Stephens, 2009).  After attachment, 
most of the EBs are internalized in an actin-dependent process orchestrated by C. trachomatis with the 
contribution of known chlamydial effectors TarP, TmeA, TepP and CT166 (see section 1.5.1.1.2). 
 
1.5.2.2 Repositioning and stability of the inclusion in the host cell 
 
Upon entry, C. trachomatis EBs become enclosed in a membrane-bound vacuole (the inclusion) 
whose membrane is readily modified by the insertion of Inc proteins. Insertion of these proteins allows 
interactions between bacteria and the host cell (E I Shaw et al., 2000; Rockey et al., 2002). 
Subsequently, the inclusion is directed from the entry sites towards the centrosome/microtubule-
organizing centre (MTOC) (Grieshaber et al., 2003) via the microtubule motor dynein, in a process 
involving C. trachomatis proteins. Inc protein CT850 interacts with the dynein light chain DYNLT1 (Mital 
et al., 2015) and once at MTOC, Src kinases control the association between the inclusion and 
centrosomes (Mital and Hackstadt, 2011). Inc proteins IncB, CT101 and CT222, have been found at 
these contact points suggesting a potential contribution of these proteins to the transport of the 
inclusions (Mital et al., 2015).  
As the inclusion expands, actin and intermediate filaments progressively associate with inclusion. 
The actin cytoskeleton is key to maintain inclusion stability as disruption of actin filaments results in the 
rupture of the inclusion membrane and leakage of bacteria into the host cell cytoplasm. Host small 
GTPase RhoA is involved in this this process as it is recruited to the inclusion and its depletion leads to 
a decrease of the actin scaffolds around the inclusion (Kumar and Valdivia, 2008). In addition, host 
septins co-localize with the actin surrounding the inclusion and were found to be important to the 
assembly of actin fibers around the inclusion (Ouellette and Carabeo, 2010b).  
 
1.5.2.3 Subversion of host cell trafficking pathways and nutrient acquisition 
 
To survive within the intracellular environment C. trachomatis modulates the host cell trafficking 
pathways either promoting or inhibiting fusion with host cell compartments. 
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Eukaryotic small GTPases of the Rab family are major regulators of vesicle fusion. During C. 
trachomatis infection, Rab4, Rab11 and Rab14, which normally mostly associated with recycling 
endosomes, and Rab1 and Rab6, which are associated with endoplasmic reticulum (ER)-Golgi 
trafficking, are recruited to the inclusion membrane (Rzomp et al., 2003). Moreover, C. trachomatis Inc 
CT229/CpoS binds multiple Rab proteins involved in a multiplicity of pathways (e.g. ER to Golgi 
transport, retrograde transport, exocytosis, and lipid droplet formation), suggesting that this protein could 
be involved in the recruitment of Rabs to the inclusion membrane (Rzomp et al., 2006; Mirrashidi et al., 
2015; Sixt et al., 2017). The recruitment of Rab proteins together with their respective host interacting 
proteins were shown to be involved in nutrient acquisition to the inclusion by fusion or interaction with 
host vesicles. Rab6, Rab11 and Rab14 were shown to be involved in acquisition of sphingomyelin from 
the Golgi (Rejman Lipinski et al., 2009; Moore et al., 2011b) and Rab4 and Rab11 in the acquisition of 
iron from the slow transferrin recycling pathway (Rzomp et al., 2003; Ouellette and Carabeo, 2010a). 
Besides recruiting Rab proteins, C. trachomatis also recruits to the inclusion host Soluble NSF (N-
ethylmaleimide-sensitive factor (SNARE) proteins, which drive vesicle fusion in eukaryotic cells. For 
instance, the normally Golgi-localized SNAREs Syntaxin 6 and GS15 (Moore et al., 2011a; Pokrovskaya 
et al., 2012) and the endocytic SNAREs Vamp3, Vamp7 and Vamp8 (Delevoye et al., 2008; Paumet et 
al., 2009) localize around the inclusion in C. trachomatis infected cells. Interestingly, C. trachomatis Inc 
proteins IncA, InaC and IPAM contain SNARE-like motifs (Delevoye et al., 2008), which bind to host 
SNAREs Vamp3, Vamp7 and Vamp8 and inhibit host membrane fusion (Paumet et al., 2009). Moreover, 
IncA contains two SNARE-like motifs which are required for homotypic fusion of inclusions (Ronzone 
and Paumet, 2013; Ronzone et al., 2014; Weber, Nicholas F Noriea, et al., 2016) and also interacts with 
host Vamp8 likely to inhibit fusion with lysosomes (Delevoye et al., 2008; Weber, Nicholas F Noriea, et 
al., 2016). Although the C. trachomatis inclusion avoids fusion with the lysosomes, this organelle is 
thought to be a source of amino acids to the bacteria (Ouellette et al., 2011). 
Host sorting nexin (SNXs) proteins (Aeberhard et al., 2015), which are involved in protein sorting 
from the endosomes to the Golgi apparatus (Seaman, 2012), are also recruited to inclusion membrane 
by C. trachomatis. The IncE protein interacts and recruits SNX5/6 allowing the bacteria to disrupt 
trafficking to the trans-Golgi network (Mirrashidi et al., 2015; Elwell et al., 2017). 
Moreover, C. trachomatis intercepts multivesicular bodies (MVBs), intermediate endocytic 
compartments that are a source of sphingolipids and cholesterol crucial to chlamydial intracellular 
growth (Beatty, 2006; Beatty, 2008). As already mentioned above (section 1.5.1.1.2), Chlamydia also 
targets lipid droplets. The uptake of lipid droplets by the chlamydial inclusion may involve chlamydial 
proteins Lda1, Lda3, the inclusion membrane-associated effector protein Cap1, and the Inc proteins 
CT618, IncG and IncA (Kumar et al., 2006; Saka et al., 2015).  
C. trachomatis also highjacks non-vesicular trafficking pathways involved in the transport of lipids, 
which have been found to be incorporated into the bacterial cell (e.g., sphingomyelin, cholesterol, 
phosphatidylcholine, and phosphatidylinositol). During infection, the Inc protein CT005/IncV interacts 
with host vesicle-associated membrane proteins (VAPs) present in the ER mediating the formation of 
ER-inclusion multiple contact sites (Stanhope et al., 2017). Moreover, VAPs interact with ceramide 
transport protein (CERT), which is recruited to the inclusion by IncD providing additional stability to these 
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multiple contact sites and also allowing the direct transfer of ceramide (the precursor of sphingomyelin) 
from the ER to the inclusion (Derré et al., 2011; Agaisse and Derré, 2014). In the absence of CERT and 
sphingomyelin, bacterial replication and inclusion size decreases (Derré et al., 2011). Overall these 
suggests that ER-inclusion multiple contact sites are important to the transport of ceramide and 
consequently to the synthesis of sphingomyelin at the inclusion membrane.  
C. trachomatis also acquires saturated fatty acids for de novo membrane synthesis (Yao, Dodson, 
et al., 2015), which have been found to be essential for bacterial replication (Yao et al., 2014; Yao, 
Dodson, et al., 2015)  
 
1.5.2.4 Golgi fragmentation 
 
A hallmark of C. trachomatis infection is the fragmentation of  the Golgi complex into mini stacks that 
surround the inclusion (Heuer et al., 2009). This requires the depolymerization of acetylated and 
detyrosinated tubulin (Al-Zeer et al., 2014), which may act as anchors for the Golgi mini stacks around 
the inclusion. Until now, InaC/CT813 (an Inc protein) is the only chlamydial effector found to be required 
for the repositioning of the Golgi complex. InaC was found to bind and recruit the small GTPases Arf1 
and Arf4 to the inclusion membrane and indirectly activate Arf1. Moreover, absence of InaC, or depletion 
of Arf1 or Arf4 during infection, could prevent Golgi dispersal and decreased the presence of 
detyrosinated or acylated tubulin, suggesting that InaC/CT813 hijacks Arf GTPases to control Golgi 
positioning (Kokes et al., 2015; Wesolowski et al., 2017). 
Golgi fragmentation has been thought to enhance lipid delivery, as depletion of Rab6 and Rab11 
abolished Golgi fragmentation in infected cells and led to a reduction in the infectivity, in the formation 
of EBs and in the delivery of sphingolipids to the inclusion (Rejman Lipinski et al., 2009). However, Golgi 
fragmentation was shown to be dispensable for dynamin-mediated sphingolipid acquisition into C. 
trachomatis inclusions (Gurumurthy et al., 2014) and infection with a C. trachomatis inaC mutant strain 
revealed normal trafficking of sphingolipids into the inclusion (Kokes et al., 2015). Therefore, additional 
studies will be required to clarify the importance of Golgi fragmentation during C. trachomatis infection.  
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Figure 1.6 Chlamydia-host interactions. Following attachment to the host cell plasma membrane, Chlamydia 
enters in the host cell in a process dependent on actin rearrangements involving both host and bacterial proteins. 
The bacteria become enclosed within a bacterially-modified vacuole, named the inclusion. This nascent inclusion 
is transported along microtubules to the MTOC and expands as bacterial replication occurs. During this stage, the 
inclusion interacts, via bacterial effectors, with multiple host cell organelles, including the Golgi complex, the 
endoplasmic reticulum (ER), lipid droplets, multivesicular bodies (MVBs) and lysosomes. Delivery of essential host 
lipids to the inclusion involves vesicular trafficking from Golgi complex, MVBs and lipid droplets and non-vesicular 
trafficking from membrane contact sites (MCS) formed between the ER and the inclusion. Amino acids are acquired 
from protein degradation within the lysosomes.  EB, elementary body; RB, reticulate body. Adaptation of Bastidas 
et al. 2013. 
 
1.5.2.5 Host cell exit 
 
At the end of the developmental cycle, the EBs enclosed in the inclusion can be released either by 
host cell lysis or extrusion of the inclusion. The aggressiveness of C. trachomatis strains seems to be 
related with the exit mechanism, as LGV-strains tend to be release by host cell lysis whereas non-LGV 
genital or ocular strains by extrusion (Hybiske and Stephens, 2007). 
The lytic exit consists in sequential permeabilizations of the inclusion, host organelles and then 
plasma membrane leading to host cell death. Inclusion disruption is dependent on cysteine proteases 
whereas plasma membrane disruption and Chlamydia release is a calcium-dependent process (Hybiske 
and Stephens, 2007).  CPAF has been suggested to play a role in lytic exit, since a C. trachomatis cpaf 
mutant strain failed to lyse infected epithelial cells. However, it was suggested that CPAF has an indirect 
role in this process (Snavely et al., 2014; Chunfu Yang et al., 2015). Moreover, it was shown that 
plasmid-encoded Pgp4, a regulator of chromosomal genes (see section 1.4.2), was required for lysis, 
probably by regulating T3S effector genes related to the modulation of the host cell cytoskeleton (Chunfu 
Yang et al., 2015).   
Exit by extrusion of the inclusion is a process similar to exocytosis, where the contraction of the 
inclusion and plasma membranes results in the detachment of a separate double membrane 
compartment enclosing the bacteria. In opposition to the lytic exit, extrusion exit leaves the host cell 
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intact (Hybiske and Stephens, 2007). For extrusion, actin polymerization and elements of the myosin 
phosphatase pathway are required (Lutter et al., 2013). The Inc protein CT228 was found to interact 
with and recruit myosin phosphatase-targeting subunit 1 (MYPT1), a component of the myosin 
phosphatase complex, to inclusion membrane microdomains rich in Src kinase. Yet the mechanisms 
regulating the activity of myosin phosphatase have not been defined (Lutter et al., 2013). Moreover, 
another Inc protein (MrcA/CT101) interacts with host calcium channel and a receptor for inositol-
trisphosphate, ITPR3. Both ITPR3 and the calcium sensor STIM-1 were found to be recruited to Src rich 
microdomains at the inclusion (Nguyen et al., 2018). Reduction of chlamydial release by extrusion was 
inhibited by disruption of the mrcA gene, depletion of ITPR3 or STIM1, or by using calcium chelator 
(Nguyen et al., 2018). The calcium chelator also led to the loss of myosin motor activity (Nguyen et al., 
2018). Overall, this suggested that the calcium signaling pathways also play an important role in the 
regulation of the extrusion mechanism by C. trachomatis.  
 
1.6 GENERAL AIMS  
 
The general goal of this project was to improve our understanding of the mechanisms used by C. 
trachomatis to infect and survive within host cells and, therefore, to provide insights on how host cells 
can be manipulated by bacterial pathogens. 
Previous results from our laboratory identified chlamydial proteins that were secreted in a T3S-
dependent manner, when using Y. enterocolitica as a heterologous T3SS (Pais et al., 2013; da Cunha 
et al., 2014). In this work, we aimed to characterize and analyze the function of the previously identified 
putative C. trachomatis T3S effectors CT053, CT082, CT105, CT429, CT696 and CT849. To achieve 
this, our specific aims were: 
 
 To construct C. trachomatis strains expressing the putative T3S effectors fused to an epitope tag, 
by using state of the art techniques for genetic manipulation of C. trachomatis; 
 
 To analyze whether these putative T3S effectors were delivered into the host cell during infection 
and where they localized; 
 
 To search for the function of a putative T3S effector shown to be delivered into the host cells and 
analyze its importance during C. trachomatis infection.
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2.1  PLASMIDS, OLIGONUCLEOTIDES, AND DNA MANIPULATION 
 
The plasmids used in this work, their main characteristics and construction details, are described in 
Annexes Table A1. The DNA primers used in their construction are listed in Annexes Table A2. Plasmids 
were constructed and purified using standard molecular biology procedures with Phusion high-fidelity 
DNA polymerase (Thermo Fisher Scientific), restriction enzymes (Thermo Fisher Scientific), T4 DNA 
Ligase (Thermo Fisher Scientific), DreamTaq DNA polymerase (Thermo Fisher Scientific), NZYTaqII 
(NZYTech), DNA clean & concentratorTM-5 kit and ZymocleanTM gel DNA recovery kit (Zymo Research), 
and GeneElute Plasmid Miniprep kit (Sigma Aldrich) or NZYMidiprep kit (NZYTech), according to the 
instructions of the manufacturers. 
The backbone plasmids used in this work were: p2TK2-SW2 (Agaisse and Derré, 2013), used to 
construct Chlamydia trachomatis expression plasmids encoding 2HA, GSK or CyaA; pSVP247 (da 
Cunha et al., 2017), a derivative of p2TK2-SW2 (Agaisse and Derré, 2013), used to generate C. 
trachomatis expression plasmids encoding proteins with a 2HA at their C-termini; pmEGFP-N1 and 
pmEGFP-C1 [both constructed from pEGFP-N1 (Clontech) and pEGFP-C1 (Clontech), respectively, 
where the gene encoding enhanced green fluorescent protein (EGFP) was replaced by a gene encoding 
monomeric EGFP (mEGFP) from pLAMP1-mGFP (Falcón-Pérez et al., 2005) and pEF6/Myc-His A 
(Thermo Fisher Scientific), used to generate mammalian transfection plasmids; pLJM3 used to generate 
Yersinia enterocolitica plasmids for type 3 secretion (T3S) assays, which enabled expression of cloned 
genes driven by the promoter of the Y. enterocolitica yopE gene (Marenne et al., 2003); pYES2-GFP 
(Rodríguez-Escudero et al., 2005) and pKS84 (De Felipe et al., 2008), used to generate yeast 
expression plasmids encoding fusions to the C- or N-terminus of GFP, respectively. Furthermore, 
pBOMB4-Tet-mcherry (Bauler and Hackstadt, 2014) and Lyn11-FRB-mcherry (Hammond et al., 2012) 
were used to amplify the tetracycline promoter (Ptet) and the nucleotide sequence encoding the Lyn11 
peptide, respectively. The accuracy of the nucleotide sequence of all the inserts in the constructed 
plasmids was confirmed by DNA sequencing. 
 
2.2 CELL LINES AND TRANSIENT TRANSFECTION 
 
HeLa 229 and Vero cells (from the European Collection of Authenticated Cell Culture; ECACC) were 
maintained in high-glucose Dulbecco’s modified Eagle Medium (DMEM; Thermo Fisher Scientific) 
supplemented with heat-inactivated 10% (v/v) foetal bovine serum (FBS; Thermo Fisher Scientific) at 
37°C in a humidified atmosphere of 5% (v/v) CO2. Cells were checked for Mycoplasma by conventional 
PCR either using the Venor® GeM Advance kit (Minerva Biolabs) or as described (Uphoff and Drexler, 
2011). 
HeLa 229 cells were transfected by using the jetPEI reagent (Polyplus-transfection) accordingly to 
the instructions of the manufacture. Briefly, to HeLa 229 cells previously seeded in 24-well plates, 250 
ng of plasmid DNA and 1.5 µl of JetPei reagent were added per well. This was scaled-up when 
necessary. The plate was centrifuged at 180 x g for 5 min at room temperature and subsequently 
incubated for 24 h at 37°C in a 5% (v/v) CO2 atmosphere. The transfected cells were then collected for 
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immunoblotting or fixed for immunolabeling. In experiments involving simultaneous infection by C. 
trachomatis and transfection, transfection was performed at time zero of infection (see section 2.4.1). 
 
2.3 E. COLI AND Y. ENTEROCOLITICA GROWTH CONDITIONS 
 
Escherichia coli TOP10 (Thermo Fisher Scientific) or NEB® 10β (New England Biolabs) were used 
for construction and purification of plasmids, and E. coli ER2925 (New England Biolabs) was used to 
amplify and purify plasmids for transformation of C. trachomatis. 
Yersinia enterocolitica HOPEMT (MRS40 pIML421 [yopH1-352, yopO65-
558, yopP23 , yopE21 , yopM23 , yopT135 ]), deficient for the Yersinia T3S effectors YopH, O, P, E, M, and 
T, but T3S-proficient (Iriarte and Cornelis, 1998) and T3S-deficient Y. enterocolitica ΔHOPEMT ΔYscU 
(MRS40 pFA1001 [yopH1-352, yopO65-558, yopP23 , yopE21 , yopM23 , yopT135 , yscU1-354 ) (Almeida et 
al., 2012) were used for T3S assays. The yscU gene encodes an essential component of the Y. 
enterocolitica T3S system, and the yscU1-354 mutation is non-polar (Sorg et al., 2007). 
E. coli or Y. enterocolitica were routinely grown in liquid or solid Luria-Bertani (LB) medium 
(NZYtech) with the appropriate antibiotics and supplements at 37°C and 30°C, respectively. Plasmids 
were introduced into E. coli or Y. enterocolitica by electroporation. 
 
2.4 MAINTENANCE AND MANIPULATION OF C. TRACHOMATIS STRAINS 
 
C. trachomatis prototype strains B/Har36, C/TW3, E/Bour, L2/434, and L3/404 (from the American 
Type Culture Collection; ATCC) and clinical strains F/CS465-95 and L2b/CS19-08 (from the collection 
of the Portuguese National Institute of Health) were propagated in HeLa 229 cells using standard 
techniques [see section 2.4.1; (Scidmore, 2005);]. Throughout this work, the gene nomenclature of the 
annotated C. trachomatis D/UW3 strain was used (Stephens, 1998).  
 
2.4.1 Infection of HeLa 229 cells with C. trachomatis 
 
For immunofluorescence analysis, 5 x 104 HeLa 229 cells were seeded in 24-well plates, previously 
filled with 13 mm glass coverslips (VWR). For immunoblotting, 1 x 105 HeLa 229 cells were seeded in 
24-well plates (2 cm2/well). Scaling-up was done accordingly [6-well plate (10 cm2/well), or tissue culture 
flasks with a surface area of 25 cm2 (T25) or 75 cm2 (T75)]. The next day, cells were incubated with 
Hank’s balanced salt solution (HBSS) for 15 min at 37ºC in a humidified atmosphere of 5% (v/v) CO2, 
while the C. trachomatis inocula (previously titrated infectious particles, as described in (Scidmore, 
2005)) were prepared in sucrose-phosphate-glutamate buffer (SPG; 0.2 mM sucrose, 17 mM Na2HPO4, 
3mM NaH2PO4, 5 mM L-glutamic acid) in the appropriate volume: 0.2 ml for 24-well plates, 0.5 ml for 6- 
well plates, 1 ml for T25 or 3 ml for T75. HBSS was then removed and the C. trachomatis inocula were 
added and incubated for 30 min at 37ºC in a humidified atmosphere of 5% (v/v) CO2 (for 24- and 6-well 
plates) or 1 h at room temperature with gentle rocking (for T25 and T75 flasks). At this point, the inocula 
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were removed and DMEM supplemented with 10% (w/v) FBS and 10 μg/ml of gentamicin was added. 
This step was considered time zero of the infection. In experiments where HeLa 229 cells were infected 
with C. trachomatis L2/434 harboring a plasmid encoding CT105-2HA under the control of a tetracycline 
promoter (pSVP302/pTet-CT105-2HA; Annexes Table A1), anhydrotetracycline was added to 20 ng/ml 
at time zero of infection. Infected cells were harvested at the indicated times post-infection (p.i.) and 
analyzed by immunoblotting or immunofluorescence microscopy. 
 
2.4.2 Transformation of C. trachomatis 
 
Transformation of C. trachomatis, first reported by the laboratory of Ian N. Clarke (Wang et al., 2011), 
was done essentially as described by Agaisse and Derré (Agaisse and Derré, 2013).  Approximately, 
20 µl of a cellular extract containing C. trachomatis EBs stored in SPG were added to 6 μg of plasmid 
DNA diluted in 200 µl of CaCl2 buffer (10 mM Tris pH 7.4, 50 mM CaCl2).  The mixture was then 
homogenized and incubated for 30 min at room temperature. Meanwhile, 4 x 106 HeLa 229 cells were 
trypsinized [using TrypLE™ Express (Thermo Fisher Scientific)] and centrifuged for 5 min at 237 x g 
and at room temperature. Cells were washed with phosphate-buffered saline (PBS) and resuspended 
in 200 µl of CaCl2 buffer. The cells were added to the mixture and incubated 20 min at room temperature. 
The whole mixture (cells, plasmid DNA, and Chlamydia) was split in two wells from a 6-well plate (each 
containing 3 ml of pre-warmed DMEM supplemented with 10% (v/v) FBS) and incubated for 44 h at 
37ºC in a 5% (v/v) CO2 atmosphere. At 16 h after transformation, the medium was replaced with DMEM 
supplemented with 10% (v/v) FBS, 0.3 U/ml penicillin G or 250 µg/ml of spectinomycin. At 44 h after 
transformation, the medium was removed, and the cells were osmotically lysed with 1 ml of sterile H2O 
(MilliQ®) per well. The lysates were pooled together and centrifuged for 5 min at 237 x g at room 
temperature, after which 2 ml of the supernatant were added to 2 ml of 2xSPG (0.4 mM sucrose, 34 mM 
Na2HPO4, 6 mM NaH2PO4, 10 mM L-glutamic acid). This was then used as inoculum to add to newly 
seeded HeLa 229 cells (1.3 x 106 cells in a 25 cm2 surface area flask), previously equilibrated in HBSS. 
After an incubation of 1 h at room temperature with gentle rocking, the inoculum was removed, and 
DMEM supplemented with 10% (v/v) FBS, 0.3 U/ml penicillin G or 250 µg/ml of spectinomycin, and 1 
μg/ml cycloheximide was added. The cells were then incubated for 44 h at 37ºC in a 5% (v/v) CO2 
atmosphere. Then, the infected cells were osmotically lysed with 1 ml of sterile H2O (MilliQ®) and lysate 
was centrifuged for 5 min at 237 x g and at room temperature. After, the 1 ml of the supernatant was 
added to 1 ml of 2xSPG and used to re-infect newly seeded HeLa 229 cells (1.3 x 106 cells in 25 cm2 
surface area flasks), previously equilibrated in HBSS. After an incubation of 1 h at room temperature 
and gentle rocking, the inoculum was removed, and DMEM supplemented with 10% (v/v) FBS, 1 U/ml 
penicillin G or 250 µg/ml of spectinomycin, and 1 μg/ml cycloheximide was added. The cells were then 
incubated for 3 days at 37ºC in a 5% (v/v) CO2 atmosphere. At this point, the presence of wild type 
inclusions, as detected by phase-contrast microscopy, indicated a successful transformation. The 
infected cells containing transformed C. trachomatis were collected, lysed and used to re-infect newly 
seeded HeLa 229 cells (1.3 x 106 cells in a 25 cm2 surface area flask), as previously described, except 
the medium added was DMEM supplemented with 10% (v/v) FBS, 10 U/mL penicillin G or 500 µg/ml of 
2 MATERIALS AND METHODS 
32 
spectinomycin, and 1 μg/mL cycloheximide. The cells were incubated 44 h at 37ºC in a 5% (v/v) CO2 
atmosphere. The transformed C. trachomatis was continually passaged for approximately 5 rounds of 
re-infection, then stored at -80ºC.  
 
2.4.3 Clonal isolation of C. trachomatis by plaque assay purification 
 
Further, the constructed strains were plaque purified similarly as previously described (Nguyen and 
Valdivia, 2013). First, 4 x 105 Vero cells were seeded per well in a 6-well plate. Cells were incubated at 
37ºC in the presence of 5% (v/v) CO2 for about 24 h and allowed to form a confluent and homogeneous 
monolayer. Aliquots of infectious particles of the transformed C. trachomatis strains were thawed on ice 
and six 10-fold serial dilutions in a volume of 1 ml were performed. Prior to infection, Vero cells were 
washed once with HBSS. Each well was infected with 500 μl of the respective dilution, swirled to ensure 
an even mixture and incubated for 30 min at 37ºC in a humidified atmosphere of 5% (v/v) CO2. The 
inocula was removed and DMEM supplemented with 10% (v/v) FBS, 1 U/ml of penicillin G and 1 μg/ml 
of cycloheximide was added. The cells were incubated at 37ºC in the presence of 5% (v/v) CO2 for 24 
h. An overlay solution of 0.54 % (w/v) Seakam® agarose (Lonza) in DMEM (without phenol red) 
containing 10% (v/v) FBS, 1 U/ml of penicillin G and 1 μg/ml of cycloheximide was prepared and kept in 
a warm water bath at 55ºC before adding to the infected cells. The media was carefully aspirated from 
each well of the 6-well plates with the infected Vero cells and 2 ml of the overlay solution was quickly 
added to each well. Agarose was allowed to completely solidify at room temperature for 15 min. 
Additionally, after the overlay solution had solidified, 2 ml of complete DMEM (without phenol red) were 
added on top. Cells were then incubated at 37ºC in the presence of 5% (v/v) CO2 for approximately 6 
days. At this point, plaques were usually visible with naked eye. Isolated plaques were picked using a 
200 μl sterile barrier pipette tip. Tips were then placed in a 1.5 ml tube previously loaded with 100 μl of 
DMEM containing 10% (v/v) FBS, 1 U/ml of penicillin G and 1 μg/ml of cycloheximide. Media was 
carefully removed from a 96-well plate, seeded the day before with 1 x 104 Vero cells per well, and the 
100 μl of DMEM containing each plaque were added. After inoculating the wells, the 96-well plate was 
centrifuged at 2,200 x g for 30 min at 15ºC. Cells were incubated at 37ºC in the presence of 5% (v/v) 
CO2 for 2 days. Each well of the 96-well plate containing Vero cells infected with plaque purified C. 
trachomatis were lysed by osmotic shock through incubation in 100 μl of H2O for 10 min. After this, 100 
μl of 2xSPG were added to each well. This 200 μl solution containing the infectious particles was then 
added to each well of a 24-well plate seeded in the previous day with 2 x 105 HeLa 229 cells per well. 
Infection proceeded as described above. This way each plaque-purified clone was propagated into HeLa 
229 cells providing a higher number of viable bacteria to be stored. Stock aliquots were stored at - 80ºC 
and after titrated for further experiments. 
 
2.4.4 Construction of a C. trachomatis ct105::aadA mutant strain 
 
A C. trachomatis ct105::aadA mutant was generated in collaboration with us by the group of Derek 
J. Fisher (Southern Illinois University, USA)  using group II intron-based insertional mutagenesis, as 
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previously described (Johnson and Fisher, 2013; Key and Fisher, 2017). Briefly, intron-insertion sites in 
the C. trachomatis L2/434 ctl0360 gene (orthologue of ct105 in C. trachomatis strain D/UW3) were 
identified using the TargeTron® algorithm (Sigma). Then, the intron in pDFTT3aadA (Annexes Table 
A1) (Key and Fisher, 2017) was retargeted for ctl0360 using standard molecular biology procedures and 
the DNA primers listed in Annexes Table A2. The ctl0360 mutator plasmid [pDFTT296; (Annexes Table 
A1)] was then used to transform C. trachomatis L2/434.  
 
2.4.5 Quantification of infectious progeny 
 
HeLa 229 cells infected by C. trachomatis strains for different times were lysed by osmotic shock (10 
min incubation in sterile H2O). Dilutions of these lysates in SPG were used to infect freshly seeded HeLa 
229 cells. The newly infected cells were fixed after 24 h post-infection, C. trachomatis were 
immunolabeled using anti C. trachomatis major outer membrane protein (MOMP) antibodies (see 
section 2.7), and the number of inclusion forming units (IFUs/ml) was calculated after determination of 
the number of infected cells/field of view by immunofluorescence microscopy (Scidmore, 2005) (see 
section 2.10). 
 
2.5 Y. ENTEROCOLITICA T3S ASSAYS 
 
T3S assays were done as previously described (Sorg et al., 2007). Briefly, Y. enterocolitica strains 
harboring the plasmids encoding the hybrid proteins were diluted from overnight cultures to an optical 
density at 600 nm (OD600) of 0.1 in brain heart infusion (BHI) medium supplemented with 20 mM sodium 
oxalate, 20 mM MgCl2 and 0.4% (w/v) glucose and grown for 2 h at 28ºC with 150 rpm shaking. The 
bacterial cultures were then quickly shifted to 37ºC and incubated for an additional 4 h with 150 rpm 
shaking. After incubation, OD600 of the cultures was measured and culture supernatants and bacterial 
pellets were separated by a centrifugation of 1 min, at room temperature (RT) and 17,000 x g. Proteins 
in the supernatant were precipitated with 10% (w/v) trichloroacetic acid (TCA). The TCA protein 
precipitate corresponding to 1 ml of the culture was resuspended in OD600 x 10 μl of SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) loading buffer [50 mM Tris-HCl, pH 6.8, 2.0% (w/v) SDS, 10% (v/v) 
glycerol, 0.1 M β-mercaptoethanol, 0.1% (w/v) bromophenol blue], while the bacterial pellet, 
corresponding to 1.5 ml of the culture, was resuspended in OD600 x 100 μl of SDS-PAGE loading buffer. 
Both fractions were denatured at 100ºC for 10 min. 
In these experiments, we used Y. enterocolitica HOPEMT or HOPEMT YscU strains carrying 
the plasmids described in Annexes Table A1. The proteins in bacterial pellets (non-secreted) and culture 
supernatants (secreted) were analyzed by immunoblotting.  
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2.6 YEAST STRAINS, INVERTASE ASSAYS AND TOXICITY ANALYSIS 
 
Saccharomyces cerevisiae strains used in this work (listed in Annexes Table A3) were grown in 
plates with yeast nitrogen base uracil dropout (YNB-Ura) supplemented with 2% (w/v) fructose (non-
inducing media) or 2% (w/v) galactose (inducing media) for 3 days, at 25°C. 
For the qualitative invertase (Inv) assays, S. cerevisiae NSY01-derived strains harboring GFP fusion 
proteins previously grown for 3 days in plates containing inducing and non-inducing media were overlaid 
with agar containing glucostat reagent [125 mM sucrose, 100 mM sodium acetate, pH 5.5, 0.5 mM N-
ethylmaleimide (NEM), 10 μg/ml horseradish peroxidase, 8 U/ml glucose oxidase, and 2 mM O-
dianisidine]. Defects on trafficking were assessed by the intensity of the brow precipitate formed, where 
brown colonies indicate a defect in trafficking in contrast with white colonies (normal trafficking) (Shohdy 
et al., 2005; Franco et al., 2012).  
For the quantitative Inv assays, S. cerevisiae NSY01-derived strains harboring GFP fusion proteins 
were grown for 3 days in plates containing inducing media. Briefly, yeasts scraped from the plates were 
resuspended in 0.1M of sodium acetate buffer, pH 4.9. Then, for total Inv activity, yeasts were lysed by 
addition of Triton-X and four freeze/thaw cycles. For secreted Inv activity yeasts were not lysed. Further, 
the samples were then tested for Inv activity by the addition of glucostat reagent. Reactions were 
stopped by using 6 M HCl, and the absorbance at 540 nm was measured. One unit of Inv activity is 
defined as the amount of enzyme that hydrolyzes sucrose to produce 1 μmol of glucose per minute at 
30°C. Values for secreted and total Inv activity were obtained and used to calculate the percent secreted. 
Relative secreted Inv was normalized by setting GFP as the minimum value and Vps4E233Q as the 
maximum value (Darsow et al., 2000; Shohdy et al., 2005). 
For the phenotypic characterization of yeast growth defects of S. cerevisiae expressing GFP fusion 
proteins were grown to late-log phase and 10-fold serial dilutions (cells corresponding to an OD600 of 1 
correspond to the first dilution) were spotted on yeast nitrogen base uracil dropout (YNB-Ura) 
supplemented with 2% (w/v) fructose (non-inducing media) or 2% (w/v) galactose (inducing media) agar 
plates and grown 3 days at 30°C.  
 
2.7 ANTIBODIES AND FLUORESCENT DYES 
 
For immunoblotting the following primary antibodies were used: mouse monoclonal anti-chlamydial 
Hsp60 (A57-B9; Thermo Fisher Scientific; 1:1,000); goat polyclonal anti-MOMP of C. trachomatis 
(Abcam; 1:1,000 ); rat monoclonal anti-HA (3F10; Roche; 1:1,000); mouse monoclonal anti-α-tubulin 
(clone B-5-1-2; Sigma Aldrich; 1:1,000); mouse monoclonal anti-TEM-1 (QED Bioscience; 1:500); rabbit 
polyclonal anti-SycO (1:1,000) (Letzelter et al., 2006); goat polyclonal anti-GFP (Sicgen; 1:1,000); 
mouse anti-phosphoglycerate kinase 1(PGK1) (Life Technologies; 1:1,000).  
For immunofluorescence the following primary antibodies were used: goat anti-C. trachomatis 
fluorescein isothiocyanate (FITC)-conjugated polyclonal antibody (Millipore; 1:100); goat polyclonal anti-
MOMP of C. trachomatis (Abcam; 1:500), rat monoclonal anti-HA (3F10; Roche; 1:200); mouse anti-
CT442 (a gift from Guangming Zhong; (Zhongyu Li et al., 2008); 1:200); rabbit polyclonal anti-Cap1 (a 
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gift from Agathe Subtil; (Gehre et al., 2016); 1:2,000; rabbit polyclonal anti-GM130 (Sigma Aldrich; 
1:200); mouse monoclonal anti-TGN46 (clone TGN46-8; Sigma Aldrich; 1:200), mouse monoclonal anti-
α-tubulin (clone B-5-1-2; Sigma Aldrich; 1:200); mouse monoclonal anti-vimentin (Sigma Aldrich; 1:200). 
For immunoblotting, the secondary antibodies were all horseradish peroxidase (HRP)-conjugated 
(GE Healthcare and Jackson ImmunoResearch; 1:10,000). For immunofluorescence, the secondary 
antibodies were all from Jackson ImmunoResearch and used at 1:200: Rhodamine Red-X-conjugated 
anti-rat; DyLight 488-conjugated anti-goat; AF488-conjugated anti-mouse; DyLight 405-conjugated anti-
goat; AF488-conjugated anti-rabbit; Cy5-conjugated anti-mouse. Acti-stain™ 670 phalloidin 
(Cytoskeleton), and DAPI (Thermo Fisher Scientific) were used to stain filamentous actin and DNA, 
respectively. 
 
2.8 DRUG TREATMENTS 
 
To induce Golgi fragmentation, HeLa 229 cells were incubated with 1 µg/ml of brefeldin A (BFA) 
[Sigma; stock solution at 5 mg/ml in dimethyl sulfoxide (DMSO)] for 1 h and then either fixed immediately 
or washed with medium without BFA and incubated for 1 h before fixation. To disrupt microtubules, 
HeLa 229 cells were incubated in the presence of 1 µg/ml nocodazole (stock solution at 5 mg/ml in 
DMSO; Sigma). To disrupt the actin cytoskeleton, C. trachomatis-infected cells were incubated in the 
presence of 2 µM cytochalasin D (stock solution at 5 mg/ml in DMSO; Sigma) or 500 nM latrunculin B 
(stock solution at 1 mg/ml in DMSO; Sigma) in serum-free DMEM.  
 
2.9 IMMUNOBLOTTING 
 
To harvest infected or transfected HeLa 229 cells, they were washed once with PBS and then 
trypsinized using TrypLE™ Express (Thermo Fisher Scientific) by incubation during 5 min at 37°C in a 
5% (v/v) CO2 atmosphere. The cells were then collected, pelleted by a brief centrifugation, washed 2 
times with ice-cold PBS, and stored as a pellet at -20°C until use. Prior to SDS-PAGE, the cells were 
thawed, resuspended in an appropriate volume of SDS-PAGE loading buffer. The proteins were further 
denatured by an incubation of 5 min at 100°C, followed by addition of benzonase (Novagen) to destroy 
DNA and reduce the viscosity of the samples.  
To prepare Chlamydia-enriched extracts, the infected HeLa 229 cells were lysed by osmotic shock 
(15 min in sterile H2O). Lysates were centrifuged at 170 x g for 10 min at 4°C. The supernatants were 
then centrifuged at 24,000 x g for 10 min at 4°C and resulting pellets washed 2 times with ice-cold PBS. 
The bacteria-enriched pellets were resuspended in an appropriate volume of SDS-PAGE loading buffer 
and the proteins were further denatured by an incubation of 5 min at 100°C. 
To prepare yeast extracts, cells were grown for 3 days at 30ºC in YNB-Ura plates supplemented with 
2% (w/v) fructose and then streaked into YNB-Ura supplemented with 2% (w/v) galactose. Cells 
corresponding to an OD600 of 2.5 were used for immunoblotting.  
Samples were separated by 12% (v/v) SDS-PAGE and transferred onto 0.2 μm nitrocellulose 
membranes (Bio-Rad) using Trans-Blot Turbo Transfer System (BioRad). Immunoblot detection was 
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done with SuperSignal® West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) or 
SuperSignal® West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) (as indicated in 
figure legends) and exposure to Amersham Hyperfilm ECL (GE Healthcare). 
 
2.10 FLUORESCENCE MICROSCOPY 
 
Infected and uninfected HeLa 229 cells were fixed either in PBS containing 4% (w/v) 
paraformaldehyde (PFA) for 10 min at room temperature or in methanol (-20°C) for 10 min, as indicated 
in figure legends. For immunostaining, the antibodies were diluted in PBS containing 10% (v/v) horse 
serum (when fixation was done with PFA, 0.1% (v/v) Triton X-100 was added to allow permeabilization 
of cells). After immunolabeling, the cells were consecutively washed with PBS and H2O. The coverslips 
were assembled using Aqua-poly/Mount (Polysciences) on microscopy glass slides, and the cells were 
examined by conventional fluorescence microscopy or by confocal microscopy.  
S. cerevisiae expressing GFP fusion proteins were grown in YNB-Ura supplemented with 2% (w/v) 
galactose (inducing media) agar plates and grown 3 days at 30°C. Live cells were scrapped from the 
plates, resuspended in water and imaged live using brightfield and conventional fluorescence 
microscopy. Images were processed and assembled using Fiji software (Schindelin et al., 2012).  
 
2.11 REAL-TIME QUANTITATIVE PCR (RT-qPCR) 
 
To quantify the mRNA levels of ct105 during the developmental cycle of C. trachomatis strains 
B/Har36, C/TW3, E/Bour, F/CS465-95, L2/434, L2b/CS19-08 and L3/404, RT-qPCR measurements 
were performed in collaboration with us by the group of João Paulo Gomes (Instituto Nacional de Saúde 
Dr. Ricardo Jorge, Portugal) as previously described (Almeida et al., 2012), using primers listed in 
Annexes Table A2. To compare by RT-qPCR the mRNA levels of ct105 during the developmental cycle 
of C. trachomatis strains L2/434 or L2/434 harboring pCT105-2HA (pSVP264/pCT105-2HA; Annexes 
Table A1), a 6-well plate seeded with HeLa 229 cells was inoculated by each strain at a multiplicity of 
infection of 50 and cells were harvested at the indicated times post-infection by trypsinization. Total RNA 
was isolated using NZY Total RNA Isolation Kit (NZYtech). For each RNA sample, cDNA was generated 
using iScript cDNA Synthesis Kit (Bio-Rad) accordingly with the manufacturer’s instructions. RT-qPCR 
was performed using ct105 and 16S primers (Annexes Table A2) and SsoFast EvaGreen Supermix 
(Bio-Rad). For each time point, quantitative PCR was performed on each cDNA sample (including an 
RT-negative sample) using Rotor Gene 6000 (Corbett Life Science). For normalization, ratios to the 16s 
rRNA transcript were obtained. Data analysis was carried out with Rotor-Gene 6000 software. Unless 
otherwise indicated, RT-qPCR results were based in three independent experiments.
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3.1 IDENTIFICATION OF CANDIDATE TYPE III SECRETION EFFECTORS OF 
CHLAMYDIA TRACHOMATIS 
 
In previous studies, the Chlamydia trachomatis proteins CT053, CT082, CT105, CT429, CT696 and 
CT849 were identified as candidate type III secretion (T3S) substrates, using Yersinia enterocolitica as 
a heterologous host (Pais et al., 2013; da Cunha et al., 2014). Here, we analyzed whether these 
previously identified proteins localized at specific sites within mammalian cells or if they were delivered 
by C. trachomatis into host cells, which could indicate a potential function in the host cytoplasm during 
chlamydial infection. 
 
3.1.1 Ectopic expression of candidate T3S effectors of C. trachomatis in mammalian cells 
 
To investigate the localization of the candidate T3S effectors of C. trachomatis when ectopically 
expressed in mammalian cells, we constructed transfection plasmids encoding enhanced green 
fluorescent protein (EGFP, 27 kDa) and C. trachomatis candidate T3S effectors fused to the C-terminus 
of EGFP (EGFP-CT053, 44 kDa; EGFP-CT082, 86 kDa; EGFP-CT105, 95 kDa; EGFP-CT429, 66 kDa; 
EGFP-CT696, 72 kDa; EGFP-CT849, 44 kDa). HeLa cells were transfected for 24 h with the constructed 
plasmids and subsequent immunoblotting of whole cell extracts confirmed the expression of EGFP-
CT429, EGFP-CT696 and EGFP-CT849 proteins of the predicted molecular mass (Figure 3.1A). EGFP-
CT053, EGFP-CT082 and EGFP-CT105 migrated on SDS-PAGE at higher molecular mass than 
predicted. However, the differences between the predicted and observed molecular mass were similar 
to when 2HA-tagged versions of the proteins were expressed in Y. enterocolitica (Pais et al., 2013, da 
Cunha et al., 2014). 
Next, to determine the localization in HeLa cells of the ectopically expressed proteins, the transfected 
cells were fixed 24 h after transfection, stained with 4',6-diamidino-2-phenylindole (DAPI) and analyzed 
by fluorescence microscopy (Figure 3.1B). EGFP-CT053 and EGFP-CT429 showed a cytosolic 
localization similarly to EGFP alone (Figure 3.1B). For EGFP-CT082 and EGFP-CT849 the proteins 
were mostly cytosolic (Figure 3.1B), but not comparable to EGFP alone, and in some transfected cells 
they appeared to localize at the cell periphery (Figure 3.1B; indicated with arrows). EGFP-CT105 
accumulated at the cell periphery (Figure 3.1B) but filamentous structures and aggregates could also 
be observed, as will be described in further detail (Figure 3.26). As for EGFP-CT696, the protein 
aggregated in rod-like structures spread in the cell (Figure 3.1B).  Overall, among the proteins studied, 
this indicated CT105 and CT696 as the stronger candidates to be chlamydial T3S effectors. 
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Figure 3.1 Localization of candidate T3S effectors of C. trachomatis when ectopically expressed 
in mammalian cells. HeLa 229 cells were transfected for 24 h with plasmids encoding EGFP or candidate T3S 
effector fused to the C-terminus of EGFP. (A) Whole cell extracts of transfected cells were analyzed by 
immunoblotting using antibodies against GFP and -tubulin (HeLa loading control) using SuperSignal® West Pico 
detection kit (Thermo Fisher Scientific). (B) Transfected cells were fixed with 4% (w/v) PFA, stained with DAPI, and 
imaged by fluorescence microscopy. Arrows indicate accumulation of the proteins at the periphery of the cell. Scale 
bars, 10 µm. A region of EGFP-CT696 (delimitated by the white square) was zoomed to show the rod-like structures 
(right lower panel). Scale bar, 5 µm. 
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3.1.2 Expression of epitope-tagged candidate chlamydial T3S effectors in C. trachomatis  
 
The description of a methodology allowing the transformation of C. trachomatis was a breakthrough 
in the Chlamydia field (Wang et al., 2011). Since then, several improvements have been made to the 
protocol, including the development of second generation plasmid vectors with different selection 
markers, promoters and epitope tags (Agaisse and Derré, 2013; Wickstrum et al., 2013; Campbell et 
al., 2014; Bauler and Hackstadt, 2014; Mueller and Fields, 2015; Wang et al., 2018). To directly analyze 
the delivery of the chlamydial candidate T3S effectors into the host cell cytoplasm during infection, we 
took advantage of the methods for transformation of C. trachomatis. We constructed suitable Chlamydia 
expression plasmids and, subsequently, C. trachomatis strains individually expressing from a plasmid 
tagged candidate T3S effectors. 
  
3.1.2.1 Construction of C. trachomatis transformation vectors 
 
We started by constructing vectors that would allow expression of candidate T3S effector proteins in 
C. trachomatis using as backbone the vector p2TK2-SW2 (Agaisse and Derré, 2013). All the constructed 
transformation vectors were derivatives of the native virulence plasmid of C. trachomatis (pSW2) and 
therefore contained all elements necessary for the replication and maintenance of the plasmid in C. 
trachomatis. Also, they comprised an E. coli origin of replication to allow the shuttle between the two 
bacteria, therefore facilitating molecular cloning. In addition, all these vectors encoded for β-lactamase, 
enabling selection during transformation of C. trachomatis, and contained the terminator of the incDEFG 
operon (incD terminator) to halt transcription (Figure 3.2). Three different vectors were constructed to 
express proteins fused either to a double hemagglutinin (2HA) peptide (pSVP247; Figure 3.2A), 
glycogen synthase kinase (GSK) peptide (pSVP277; Figure 3.2B), or calmodulin-dependent adenylate 
cyclase (CyaA) from Bordetella pertussis (pSVP268; Figure 3.2C). The pSVP247 vector was designed 
to allow the visualization of the protein by immunofluorescence microscopy using the 2HA epitope-tag 
and its localization upon delivery. In the case of pSVP277, if the fusion proteins were delivered into the 
host, the GSK tag would be phosphorylated by host cell kinases and this could be detected by 
immunoblotting using an antibody against phosphorylated GSK (Bartra and Plano, 2017). As for 
pSVP268, upon delivery, the calmodulin-dependent CyaA would lead to an increase of the production 
of cyclic adenosine monophosphate (cAMP) in the host cell that could be detected using a specific 
enzymatic assay (Sory and Cornelis, 1994). 
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Figure 3.2 C. trachomatis transformation vectors. Different vectors were constructed to allow fusion of 
selected proteins (A) to a double hemagglutinin (2HA) or (B) GSK (brown) epitope tags or (C) to calmodulin-
dependent CyaA (green). The pSW2 plasmid backbone (Wang et al., 2011) is shown in black, the Escherichia coli 
origin of replication (ori) in yellow, the ampicillin resistance gene (bla) in blue, the multiple cloning site (MCS) in grey 
and incD terminator in dark red. The DNA sequence of the MCS with unique restriction sites are depicted in the box 
below the plasmid map (Details of plasmid construction are in Annexes Table A1)
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Table 3.1 Predicted promoter regions of candidate T3S effectors of C. trachomatis.  
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Sequences of the predicted promoter region 
CT053 CTLon0304 CTL0309 
382456..382902, 
complement 
383902 
…AATACTTTGGAATGAGTATTTTACTAGCCAAAATCTCTCCTGATCTATTTGTTTATGCCTGCTCAC 
                          -35                                                                                                                          -10               
TTGCTCTATCTGAGCAAAAGATGCAGTTACCCTTGGTAGGAAGCAAGTAAATTGGCTCTCAGG 
                               +1 
GGGTTTCCGGTTTCAATCATAGAACAGGACTATTTACGAATG… 
                                                                                                            Start 
CT082 CTLon0333 CTL0338 416611..418293 416578 
…TCATAATTCACTGTTTCAGTTTAAAATTATTATTACCCATTCATTGGTTTTTTGTTTTTTAGGAAAA 
                          -35                                                   -10                 +1 
AATCATG 
          Start 
CT105 CTLon0356 CTL0360 442875..444845 442794 
…AATAATTTGTTTTAACAACTGTTTAATAGTTTTAATTTTTAAAGTGTGAAAAACAGGTTTTATATGT 
                          -35                                                         -10                       +1 
AGAATTTCCTGTTAAAAATAAAAAATCCTTACAAGAATCCGGGAGTTAAAGGTATG… 
                                                                                                                                                 Start 
CT429 CTLon0684 CTL0688 
817103..818092, 
complement 
818099 
…ATAAAATTGAGGATAACACAAGAGAGAGTTGCTATCTAACAGAGCATCCCCTATACTGGAGCCT 
                          -35                                                                               -10                                              +1    
ATG… 
Start 
CT696 CTLon0065 CTL0065 78483..79661 78440 
…GGAATATCTAAGAACATTTTCTAATAGGGAAGAGGATAAATAGCGTGAAATAATACTGATTATGT 
                     -35                                                                                     -10                                   +1    
GAAGAATAGGCAAAAAGACCTAAATCCTTATATG… 
                                                                                     Start 
CT849 CTLon0221 CTL0221 
277967..278446, 
complement 
278480 
…CTTATTTTTAAAACAAATTATTATTTTTATTAAAGAGAGAAATTGCTGGTAAAATAAAAAATAAAAA 
                         -35                                                          -10                                                     +1    
CCAAAAAAATTTTTTAGAATATG… 
                                                     Start 
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Our strategy consisted in first constructing pSVP247 derived plasmids encoding 2HA epitope-tagged 
proteins because they would allow a more direct assessment of the delivery of the proteins and could 
provide additional information on protein subcellular localization. Moreover, the candidate T3S effectors 
were expressed under the control of their predicted promoters, based on  previously identified 
transcription start sites (TSS) (Albrecht et al., 2009) from where the σ66-like promoter regions -10 and -
35 were deduced (Table 3.1). The reasoning to express the genes under the control of their endogenous 
promoter instead of an inducible promoter, such as the tetracycline promoter (Wickstrum et al., 2013), 
was to allow regulation, and therefore a timing of expression, similar to the respective endogenous 
genes during the C. trachomatis developmental cycle. As will be described, because we could identify 
a potential T3S effector using the pSVP247 plasmid backbone, and considering the time required to 
generate transformed C. trachomatis strains, plasmids pSVP277 and pSVP268 were not further used 
in this work. 
 
3.1.2.2 Construction of strains with plasmid-encoded candidate C. trachomatis 
T3S effectors 
 
The next step was the construction of C. trachomatis strains expressing the candidate T3S effectors. 
The transformation was performed as described in the Materials and Methods (see section 2.4.2).  We 
constructed C. trachomatis L2/434 derived strains harboring plasmids encoding the candidate T3S 
substrates with a 2HA tag at their C-termini (pCT053-2HA, pCT082-2HA, pCT105-2HA, pCT429-2HA, 
CT696-2HA and pCT849-2HA). Next, to confirm transformation with the correct plasmids, PCR was 
performed using as template whole cell extracts of the C. trachomatis L2/434 derived strains and specific 
primers (Annexed Table A2). Amplicons of the expected size were obtained for all strains (pCT053-2HA, 
1.4 kb; pCT082-2HA, 2.4 kb; pCT105-2HA, 2.7 kb; pCT429-2HA, 1.8 kb; pCT696-2HA, 1.9 kb; and 
pCT849-2HA, 1.4 kb) (Figure 3.3A). 
The expression of the candidate T3S substrates was assessed by immunoblotting of extracts of HeLa 
cells infected for 40 h with the C. trachomatis strains harboring plasmids encoding CT053-2HA 
(predicted molecular mass of 17 kDa), CT082-2HA (60 kDa), CT105-2HA (68 kDa), CT429-2HA (39 
kDa), CT696-2HA (46 kDa) or CT849-2HA (18kDa). The production of 2HA-tagged proteins was 
confirmed (Figure 3.3B). However, the strains producing CT053-2HA, CT082-2HA and CT105-2HA also 
showed species migrating on SDS-PAGE at a molecular mass different from the one predicted for the 
full-length proteins (Figure 3.3B), as previously observed when identical 2HA-tagged versions of the 
proteins were produced in Y. enterocolitica (Pais et al., 2013; da Cunha et al., 2014) and when EGFP 
versions were ectopically expressed in mammalian cells (Figure 3.1A). Moreover, CT696-2HA and 
CT849-2HA were produced in much lower amounts than the other proteins (Figure 3.3B). Overall, these 
experiments confirmed that the constructed C. trachomatis strains expressed the expected 2HA-epitope 
tagged proteins.  
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Figure 3.3 Construction of C. trachomatis L2/434-derived strains expressing candidate 
chlamydial T3S effectors. HeLa cells were infected by C. trachomatis L2/434-derived strains harboring the 
indicated plasmids, encoding the indicated candidate T3S effectors with a 2HA epitope tag at their C-termini. (A) 
Transformation of the indicated plasmids was confirmed by PCR using specific primers of the plasmid (primers 
1978 and 1979; Annexes Table A2) (B) At 40 h post-infection (p.i.), whole cell extracts were analyzed by 
immunoblotting with antibodies against HA, C. trachomatis major outer membrane protein (MOMP) (bacterial 
loading control) and α-tubulin (HeLa loading control) using SuperSignal® West Pico detection kit (Thermo Fisher 
Scientific), or SuperSignal® West Femto detection kit (Thermo Fisher Scientific) for CT696-2HA and CT849-2HA. 
Asterisks indicate the bands likely corresponding to the full-length proteins. 
 
3.1.3 Assessment of the delivery of candidate chlamydial T3S effectors by C. trachomatis 
into the host cell cytoplasm  
 
To analyze the subcellular localization of CT053-2HA, CT082-2HA, CT105-2HA, CT429-2HA, 
CT696-2HA, and CT849-2HA in Chlamydia-infected cells, HeLa cells were infected with C. trachomatis 
L2/434-derived strains harboring the corresponding plasmids. The infected cells were fixed at 20 or 40 
h post-infection (p.i.), immunolabeled for HA and for C. trachomatis major outer membrane protein 
(MOMP), stained with DAPI, and then analyzed by fluorescence microscopy. At 20 h or 40 h p.i. (Figure 
3.4), CT053-2HA, CT082-2HA, CT429-2HA, CT696-2HA, and CT849-2HA were only detected within 
the inclusion and/or co-localizing with the C. trachomatis MOMP signal (Figure 3.4). In agreement with 
the immunoblotting data (Figure 3.3B), the levels of CT849-2HA were very low and nearly undetectable 
by fluorescence microscopy (Figure 3.4). In contrast, at both times p.i. analyzed, CT105-2HA was 
detected outside of the inclusion, indicating it is bacterially-delivered into the cytoplasm of infected host 
cells (Figure 3.4).  
Altogether, as plasmid-encoded CT105-2HA was the only protein showed to be delivered into the 
host cell by C. trachomatis and as ectopically expressed EGFP-CT105 localized at specific sites of the 
mammalian cells, this suggests that CT105 might be a potential T3S effector of C. trachomatis. 
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Figure 3.4 Analysis of the delivery of the candidate T3S effectors by C. trachomatis L2/434 into 
the host cell. HeLa cells were infected by C. trachomatis L2/434-derived strains harboring the indicated plasmids, 
encoding chlamydial candidate T3S effectors (CT053, CT082, CT429, CT105, CT696, CT849) with a 2HA epitope 
tag at their C-termini. At 20 h and 40 h p.i., cells were fixed with 4% (w/v) PFA, stained with DAPI (blue), 
immunolabeled with antibodies against HA (red), C. trachomatis MOMP (green) and appropriate fluorophore-
conjugated secondary antibodies, and imaged by fluorescence microscopy. Scale bars, 10 µm.  
 
3.1.4 The first 20 amino acids of CT105 contain a T3S signal 
 
A common feature of T3S effectors proteins is the presence of a secretion signal at their N-terminal 
region (Sory et al., 1995; Lloyd et al., 2001). Although the T3S signal has been extensively 
characterized, a clear consensus sequence was not yet identified. In addition, the T3S signal is universal 
and thus a T3S substrate of one bacterial system can be recognize and secreted by other bacterial T3S 
systems (T3SSs). 
To analyze the T3S signal of CT105, Y. enterocolitica was used as a heterologous T3SS. In vitro 
T3S assays were performed using Y. enterocolitica T3S-proficient (HOPEMT) and T3S-deficient 
(HOPEMT YscU) strains expressing the mature form of TEM-1 β-lactamase (TEM-1) or the first 20 
or 40 amino acids of CT105 fused to TEM-1 (CT10520-TEM-1 and CT10540-TEM-1). Subsequently, 
bacterial pellets and culture supernatants were immunoblotted and secretion by the T3S-proficient 
strains was verified for CT10520-TEM-1, as previously described (da Cunha et al., 2014),  and for 
CT10540-TEM-1 (Figure 3.5A). In the T3S-deficient strain neither of the proteins was secreted (Figure 
3.5A). Next, in vitro T3S assays were performed using Y. enterocolitica T3S-proficient strains expressing 
full-length CT105 and CT105 lacking the first 20 or 40 amino acids with a 2HA epitope tag at their C-
terminus (CT105FL-2HA, CT105Δ20-2HA and CT105Δ40-2HA). The analysis of the bacterial pellets and 
culture supernatants revealed that CT105FL-2HA was secreted, as previously described (da Cunha et 
al., 2014), but not CT105Δ20-2HA or CT105Δ40-2HA (Figure 3.5B).  
Overall, these results indicate that secretion of CT105 was dependent on a functional T3SS and that 
the first 20 amino acids of CT105 were sufficient and necessary to drive T3S in Y. enterocolitica. 
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Figure 3.5 The first 20 amino acids of CT105 are sufficient and necessary to drive T3S by Y. 
enterocolitica. (A) Y. enterocolitica T3S-proficient (ΔHOPEMT) and T3S-deficient (ΔHOPEMT ΔYscU) strains 
were used to analyze secretion of TEM-1 (mature form of TEM-1 β-lactamase) and TEM-1 fusions to the first 20 or 
40 amino acids of CT105 (CT10520-TEM-1 and CT10540-TEM-1, respectively). (B) Y. enterocolitica T3S-proficient 
(ΔHOPEMT) strains were used to analyze secretion of full-length CT105 (CT105FL), CT105 lacking the first 20 
amino acids (CT10520), and CT105 lacking the first 40 amino acids (CT10540) with a C-terminal 2HA epitope tag. 
After performing in vitro T3S assays, proteins in culture supernatants (secreted proteins) and in bacterial pellets 
(non-secreted proteins) were analyzed by immunoblotting with antibodies against TEM, HA and SycO using 
SuperSignal® West Pico detection kit (Thermo Fisher Scientific). SycO is a strictly cytosolic Yersinia T3S chaperone 
and it was used as a control to show that proteins in the culture supernatant did not result from bacterial lysis or 
contamination during fractionation. This experiment was performed in collaboration with Maria Beatriz Costa 
(master student in the host laboratory).  
 
To confirm that the first 20 amino acids of CT105 were necessary to drive secretion in C. trachomatis, 
HeLa cells were infected with C. trachomatis strains carrying plasmids encoding full-length CT105 or 
CT105 lacking the first 20 amino acids with a 2HA epitope tag at the C-terminus (respectively, pCT105-
2HA and pCT105Δ20-2HA). At 40 h p.i., extracts of infected cells were analyzed by immunoblotting and 
expression of CT105-2HA (68 kDa) and CT105Δ20-2HA (66 kDa) was confirmed (Figure 3.6A; indicated 
with asterisks). However, for CT105-2HA, an additional form of the protein migrated in the SDS-PAGE 
at a higher molecular mass (Figure 3.6A; indicated with an arrow). 
Moreover, HeLa cells infected with C. trachomatis strains harboring pCT105-2HA or pCT105Δ20-2HA 
were fixed at 20 h and 40 h p.i. and analyzed by fluorescence microscopy using antibodies against HA 
and Cap1/CT529 (a chlamydial protein localized at the inclusion membrane). CT105-2HA was delivered 
into the host cell as previously described (Figure 3.4), but CT105Δ20-2HA was only detected inside the 
bacteria and not in the host cell (Figure 3.6B). Overall, we found that CT105 has a T3S signal within its 
first 20 amino acids, which allowed the delivery of CT105 by C. trachomatis into the host cell cytoplasm. 
 
 49 
 
Figure 3.6 The first 20 amino acids of CT105 are necessary for the delivery of the protein into the 
host cell by C. trachomatis L2/434. HeLa cells were infected by C. trachomatis L2/434 and derived strains 
harboring full-length CT105 and CT105 lacking the first 20 amino acids with a C-terminal 2HA epitope tag (pCT105-
2HA and pCT105Δ20-2HA, respectively). (A) At 40 h p.i., whole cell extracts were analyzed by immunoblotting with 
antibodies against HA, C. trachomatis Hsp60 (bacterial loading control) and α-tubulin (HeLa loading control) using 
SuperSignal® West Pico detection kit (Thermo Fisher Scientific) for Hsp60 and α-tubulin, or SuperSignal® West 
Femto detection kit (Thermo Fisher Scientific) for HA. Asterisks indicate the bands likely corresponding to the full-
length proteins. Arrow indicates protein species migrating at higher molecular mass. (B) At 20 h and 40 h p.i., 
infected cells were fixed with 4% (w/v) PFA and immunolabeled with antibodies against HA (red), C. trachomatis 
Cap1 (chlamydial protein located at the inclusion membrane; green) and appropriate fluorophore-conjugated 
secondary antibodies, and imaged by fluorescence microscopy. Scale bars, 10 µm. This experiment was performed 
in collaboration with Maria Beatriz Costa (master student in the host laboratory). 
 
3.1.5 Full-length orthologues of CT105 are only present in C. muridarum and C. suis 
 
Chlamydiaceae infect a wide range of hosts and T3S effectors are among the proteins thought to be 
implicated in the adaptation to the different niches. T3S effectors are involved in interactions with the 
host and therefore can elucidate on Chlamydiaceae evolution (Jewett et al., 2010; Lutter et al., 2010; 
Almeida et al., 2012). 
CT105 is a protein of 656 amino acid residues whose sequence does not show significant similarity 
to other proteins except for potential orthologues in another Chlamydia spp. However, full-length 
orthologues of CT105 were only found in C. muridarum and C. suis (Table 3.2). In C. suis and in other 
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Chlamydia spp. different open reading frames might encode proteins with some identity (between 30-
22%) to only some parts of the amino acid sequence of CT105 (Table 3.2). 
 
Table 3.2 Potential orthologues of C. trachomatis CT105 (CTL0360) in other Chlamydiaea 
 Cover Id Protein 
aa range 
(CTL0360) 
aa range 
(target 
protein) 
Protein 
length 
(aa) 
E-value 
C. abortus 38% 28% CAB376 361-612 400-683 732 2e-14 
C. avium 
14% 
23%b 
30% 
22%b 
M832_01180 
M832_01160 
334-428 
277-429 
121-212 
51-183 
304 
479 
7e-4 
0.14b 
C. caviae 
41% 
56% 
12% 
15% 
27% 
26% 
27% 
25% 
CCA_00389 
CCA_00390 
CCA_00297 
CCA_00298 
297-570 
282-651 
290-370 
294-397 
339-570 
416-782 
55-125 
77-168 
726 
898 
445 
533 
4e-20 
3e-17 
0.003 
0.003 
C. felis 
69% 
54% 
15% 
20% 
26% 
24% 
25% 
23% 
CF0619 
CF0618 
CF0705 
CF0706 
143-601 
301-656 
294-397 
290-422 
223-644 
406-758 
79-170 
55-176 
737 
816 
536 
447 
2e-19 
2e-12 
2e-05 
9e-04 
C. gallinacea 
24% 
26%b 
22% 
24%b 
M787_003335 
M787_003340 
269-429 
300-427 
51-194 
69-179 
439 
451 
0.005 
0.057b 
C. muridarum 99% 53% TC_0381 1-651 1-644 650 0.0 
C. pecorum 
56% 
55% 
39% 
28% 
26% 
23% 
CpecS_0642 
CpecS_0639 
CpecS_0640 
284-654 
290-652 
331-587 
143-509 
181-533 
190-444 
597 
566 
463 
6e-29 
2e-24 
3e-16 
C. pneumoniae 
17% 
23% 
30% 
22% 
CPn0405 
CPn0404 
233-350 
401-555 
132-245 
12-165 
258 
339 
8e-10 
7e-07 
C. psittaci 
71% 
35% 
25% 
27% 
CPSIT_0422 
CPSIT_0421 
189-654 
366-597 
72-523 
403-643 
610 
733 
9e-26 
2e-13 
C. suis 
99% 
72% 
47% 
28% 
Q499_0113 
Q499_0114 
4-654 
177-651 
7-648 
141-603 
650 
607 
7e-170 
3e-44 
 
a Orthologues of the C. trachomatis protein CT105 in other Chlamydiae were searched by PSI-BLAST. An individual 
PSI-BLAST search was performed between CT105 (using the amino acid sequence of CTL0360, from C. 
trachomatis serovar L2 strain 434/Bu) and a representative strain from each Chlamydia spp. (C. abortus strain 
S26/3, C. avium strain 10DC88, C. caviae strain GPIC, C. felis Fe/C-56, C. gallinacean 08-1274/3, C. muridarum 
strain Nigg, C. pecorum VR-629, C. pneumoniae strain CWL029, C. psittaci strain 6BC, C. suis strain MD56). 
Another individual PSI-BLAST search was performed between each protein and members of the other Chlamydiae 
families, but no significant hits were found. Cover, indicates % of coverage, and Id indicates % of identity; aa, amino 
acid. 
b E-value worse than threshold. 
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3.1.6 The C. trachomatis ct105 gene is likely only expressed in lymphogranuloma 
venereum (LGV) strains  
 
Depending on the invasiveness and tissue tropism, C. trachomatis can be grouped into ocular 
(serovars A to C), urogenital (serovars D to K) and LGV (serovars L1 to L3) strains. Moreover, tissue 
tropism differences have been previously linked to T3S effectors (Lutter et al., 2012; Almeida et al., 
2012). 
As previously noted (Borges and Gomes, 2015), analysis of the mRNA levels of ct105 by reverse 
transcription quantitative PCR (RT-qPCR) in different C. trachomatis strains revealed that the gene is 
significantly expressed in LGV strains (serovars L1 to L3) (Figure 3.7).  
 
 
Figure 3.7 mRNA levels of ct105 in different C. trachomatis strains. The mRNA levels of ct105 were 
analyzed by real-time quantitative PCR (RT-qPCR) during the developmental cycle of C. trachomatis ocular 
(B/Har36, C/TW3), urogenital (E/Bour, F/CS465-95) or lymphogranuloma venereum (LGV) (L2/434, L2b/CS19-08, 
L3/404) strains, at the indicated time-points. The expression values (mean ± standard error of the mean) resulted 
from raw RT-qPCR data (x105) of ct105 gene normalized to that of the 16S rRNA gene and are from two 
independent experiments (except for strain C/TW3 where only one experiment was performed). This experiment 
was performed in collaboration with Vítor Borges and João Paulo Gomes (National Institute of Health Dr. Ricardo 
Jorge, Portugal). 
 
Furthermore, also as previously noted (Borges and Gomes, 2015), considering the promoter region 
of ct105 based on the transcription start site identified in C. trachomatis LGV strain L2b/UCH-1/proctitis 
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(Albrecht et al., 2009), C. trachomatis non-LGV strains (serovars A to K) lack 74 nucleotides upstream 
from the putative -10 region recognized by C. trachomatis σ66 (Figure 3.8). It has also been previously 
shown that ct105 is a pseudogene in C. trachomatis ocular strains (serovars A to C), where a stop codon 
in position 379 inactivates the gene or leads to the production of a protein with 126 amino acid residues 
(Borges et al., 2012). Therefore, among C. trachomatis serovars, active CT105 is mostly produced by 
LGV strains. 
Summarizing, our results showed that the first 20 amino acid of CT105 contained a T3S signal and 
were necessary to the delivery of the protein into the host cell. Moreover, as mRNA levels of ct105 were 
mostly expressed in LGV strains and as ct105 promoter region in LGV strains contained specific 
nucleotides, altogether this suggests that CT105 might contribute to characteristic tropism of LGV 
strains. 
 
Figure 3.8 Putative promoter region of ctl0360/ct105 in different C. trachomatis strains. (A) 
Representation of the genetic organization of ctl0360/ct105 and the nucleotide sequence of the putative promoter 
region of ctl0360/ct105 in C. trachomatis L2/434 (LGV strain), C/TW-3 (ocular strain) and D/UW-3/CX (urogenital 
strain).The sequences have the annotation of the putative transcription start site (+1), the predicted -10 and -35 
hexamers, the start codon (Start) and the 74-bp LGV-specific nucleotides, based on the transcription start site 
identified in C. trachomatis LGV strain L2b/UCH-1/proctitis (Albrecht et al., 2010). (B) BLAST nucleotide (BLASTn) 
analysis of the genomic region of ctl0360/ct105 highlights the LGV-specific nucleotides (arrow). This analysis was 
performed in collaboration with Vítor Borges and João Paulo Gomes (National Institute of Health Dr. Ricardo Jorge, 
Portugal). 
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3.2 THE C. TRACHOMATIS EFFECTOR CT105 ASSOCIATES WITH THE GOLGI 
COMPLEX AND PLASMA MEMBRANE OF INFECTED HOST CELLS 
 
The chlamydial protein CT105 was identified as a T3S substrate that is delivered by C. trachomatis 
into the host infected cells, thus indicating a possible function for CT105 in the modulation of host cell 
functions to aid growth and survival of C. trachomatis within the intracellular environment.  
Here, we carried out a more detailed analysis of the expression and localization of CT105-2HA. First, 
we analyzed the effects of overexpression of the plasmid-encoded CT105-2HA in C. trachomatis and 
further analyzed the subcellular localization of CT105 and the protein regions responsible for specific 
targeting which could contribute to uncovering the function of CT105 during C. trachomatis infection. 
 
3.2.1 Characterization of the C. trachomatis strain producing plasmid-encoded CT105-
2HA 
 
To further analyze the expression and subcellular localization of CT105 in infected cells, we 
characterized the C. trachomatis L2/434 strain harboring pCT105-2HA (L2/434+pCT105-2HA), which 
expresses endogenous CT105 from the chromosome and CT105-2HA from a plasmid. 
 The profile of expression of ct105 (based on its mRNA levels detected by RT-qPCR) during the 
developmental cycle of C. trachomatis was similar between the parental (L2/434) and derived 
(L2/434+pCT105-2HA) strains (Figure 3.9A). In agreement with previous observations (Figure 3.7) (da 
Cunha et al., 2014), the highest levels of ct105 mRNA were detected at 2 h p.i. (Figure 3.9A). 
Furthermore, at 2 h p.i., the strain harboring pCT105-2HA showed a 10-fold increase in the mRNA levels 
of ct105 relative to the parental strain (Figure 3.9A). This is consistent with the approximetely 8 copies 
per cell of the Chlamydia-virulence plasmid (Pickett et al., 2005; Ferreira et al., 2013), which is the 
backbone of plasmid pCT105-2HA. As judged by quantifying the number of infectious progeny at 
different times of the developmental cycle, expression of plasmid-encoded CT105-2HA in C. trachomatis 
had no significant impact on chlamydial growth in cell culture (Figure 3.9B) and did not affect the size of 
the inclusion (Figure 3.9C). 
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Figure 3.9 Characterization of C. trachomatis L2/434 strain harboring pCT105-2HA. (A) ct105 mRNA 
levels of C. trachomatis L2/434 and C. trachomatis L2/434 harboring pCT105-2HA were analyzed by real-time 
quantitative PCR (RT-qPCR) at the indicated times post-infection. The expression values (mean ± standard error of 
the mean) resulted from raw RT-qPCR data of the ct105 gene normalized to that of the 16S rRNA gene and are 
from three independent experiments. (B) HeLa cells were infected with the indicated C. trachomatis strains at a 
multiplicity of infection of 1, in the absence (-P) or presence (+P) of 1 U/mL of penicillin G. Recoverable inclusion 
forming units (IFUs) were determined at 24, 30, and 40 h post-infection. Data are mean ± standard error of the 
mean of three independent experiments. P-values were obtained by one-way ANOVA and Dunnett post-test 
analyses relative to the parental L2/434 strain; ns, not significant (P > 0.05). (C) Hela cells were infected by the 
indicated C. trachomatis strains for 20 h. Cells were fixed with 4% (w/v) PFA, immunolabeled with antibodies against 
C. trachomatis MOMP and appropriate fluorophore-conjugated secondary antibody and imaged by fluorescence 
microscopy. The inclusion area was measured for 30 particles randomly chosen from independent images using 
Fiji software. P-values were obtained by t-test analyses; ns, not significant (P ≥ 0.05). 
 
In extracts of HeLa cells infected with C. trachomatis L2/434 harboring pCT105-2HA, we could detect 
CT105-2HA by immunoblotting from 16 h to 40 h p.i. (Figure 3.10B). Moreover, several other protein 
species were consistently observed between 20 h to 40 h p.i., which were particularly evident at 30 h or 
40 h p.i. (Figure 3.10B), suggesting modification and/or degradation of CT105-2HA. We performed an 
identical analysis using a C. trachomatis strain harboring a plasmid encoding CT105-2HA under the 
control of a tetracycline-inducible promoter (pTet-CT105-2HA). Nevertheless, a similar expression 
kinetics and the same protein species were observed (Figure 3.10A and 3.10C). 
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Figure 3.10 Kinetics of expression of CT105-2HA during infection by C. trachomatis L2/434. (A) 
HeLa cells were left uninfected (UI) or infected for 40 h by C. trachomatis L2/434, L2/434 harboring pCT105-2HA 
or L2/434 harboring pTet-CT105-2HA. In cells infected by L2/434 harboring pTet-CT105-2HA, anhydrotetracycline 
was either not added (-Tet) or added (+Tet). Total extracts were analyzed by immunoblotting with antibodies against 
HA, C. trachomatis Hsp60 (bacterial loading control) and α-tubulin (HeLa loading control). (B) and (C) Total extracts 
of UI cells or of cells infected for 8, 16, 20, 30, or 40 h by (B) C. trachomatis L2/434 harboring pCT105-2HA or by 
(C) C. trachomatis L2/434 harboring pTet-CT105-2HA were analyzed by immunoblotting with antibodies against 
HA, C. trachomatis MOMP (bacterial loading control) and α-tubulin (HeLa loading control). Immunoblotting detection 
was done using SuperSignal® West Pico detection kit (Thermo Fisher Scientific) for C. trachomatis Hsp60 or 
MOMP, and α-tubulin, or SuperSignal® West Femto detection kit (Thermo Fisher Scientific) for HA. In cells infected 
by C. trachomatis L2/434 harboring pTet-CT105-2HA, anhydrotetracycline was added to 20 ng/mL at time zero of 
infection. 
 
To understand if these protein species that appear in anti-HA immunoblots of HeLa cells infected 
by C. trachomatis producing CT105-2HA were dependent of bacterial or host cell factors, extracts of E. 
coli, Y. enterocolitica and C. trachomatis strains harboring pTet-CT105-HA were analyzed by 
immunoblotting. Although the lower molecular mass protein species were similar among the analyzed 
bacterial strains (Figure 3.11A), the protein species with the highest molecular mass was only detected 
in C. trachomatis whole cell extracts (Figure 3.11A), suggesting a modification of CT105 during 
chlamydial infection. Next, we questioned whether this modification occurred inside or outside the 
bacteria. Therefore, immunoblotting of extracts of HeLa cells infected by C. trachomatis L2/434 
harboring either pCT105-2HA or pTet-CT105-2HA, or of corresponding Chlamydia-enriched extracts, 
showed the presence of the protein species with the highest molecular mass both in whole cell and 
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Chlamydia-enriched extracts (Figure 3.11B). In addition, for CT105Δ20-2HA, which was not secreted by 
Y. enterocolitica (Figure 3.5B) and apparently not delivered into the host cells by C. trachomatis (Figure 
3.6B), an additional protein species of high molecular mass was not detected by immunoblotting (Figure 
3.6A). Altogether, these results suggest a modification of CT105 inside C. trachomatis that requires the 
first 20 amino acid residues of the protein. 
 
 
Figure 3.11 CT105-2HA is modified in C. trachomatis L2/434. (A) Total extracts of the indicated bacterial 
strains harboring pTet-CT105-2HA were analyzed by immunoblotting with antibodies against HA. The induction 
conditions to express CT105-2HA in each bacterial strain are described in Materials and Methods. (B) HeLa cells 
were infected for 40 h by the indicated C. trachomatis strains. In cells infected by L2/434 harboring pTet-CT105-
2HA, anhydrotetracycline was either not added (-Tet) or added (+Tet) to 20 ng/mL at time zero of infection. Whole 
cell (WC) and Chlamydia-enriched (CE) extracts (see Materials and Methods) were analyzed by immunoblotting 
with antibodies against HA, C. trachomatis Hsp60 (bacterial loading control) and α-tubulin (HeLa loading control). 
Immunoblotting detection was done using SuperSignal® West Pico detection kit (Thermo Fisher Scientific) for 
Hsp60 and α-tubulin, or SuperSignal® West Femto detection kit (Thermo Fisher Scientific) for HA. This experiment 
was performed in collaboration with Inês Serrano Pereira (PhD student in the host laboratory).  
 
3.2.2 Analysis of the delivery of CT105-2HA into host cells during C. trachomatis 
developmental cycle 
 
To further detail the kinetics of delivery of CT105-2HA during infection, HeLa cells were infected by 
C. trachomatis L2/434 harboring pCT105-2HA. Infected cells were fixed at 2, 4, 8, 16, 20, 30, and 40 h 
p.i., immunolabeled with antibodies against HA, C. trachomatis MOMP, and Inc protein CT442, and 
analyzed by fluorescence microscopy. At 2, 4, and 8 h. p.i., CT105-2HA could be detected co-localizing 
with the signal for C. trachomatis Hsp60 (Figure 3.12), indicating its presence within the bacterial cells. 
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Figure 3.12 C. trachomatis L2/434 produces CT105-2HA early during infection. HeLa cells were 
infected by C. trachomatis L2/434 harboring pCT105-2HA for 2, 4, and 8 h p.i. Cells were fixed with 4% (w/v) PFA, 
stained with DAPI (blue), immunolabeled with antibodies against HA (red) and C. trachomatis Hsp60 (green), and 
appropriate fluorophore-conjugated secondary antibodies, and imaged by fluorescence (2 h and 4 h p.i.) or confocal 
fluorescence (8 h p.i.) microscopy. Confocal image corresponds to single z section. Scale bars, 10 µm. 
 
 
At 16 and 20 h p.i., CT105-2HA was detected outside of the inclusion in approximately 37% and 90% 
of the infected cells, respectively (Figure 3.13); at 30 and 40 h p.i., the protein was found outside of the 
inclusion in all infected cells (Figure 3.13). While at 16, 20, and 30 h p.i. CT105-2HA was detected in 
the host cell cytoplasm concentrated at one of the sides of the inclusion, at 30 h p.i. the protein was also 
detected at the periphery of the infected cells (Figure 3.13). Furthermore, at 40 h p.i., CT105-2HA was 
mostly seen at the periphery of the infected cells (Figure 3.13). A similar localization was observed for 
C. trachomatis L2/434 harboring pTet-CT105-2HA (Figure 3.14). 
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Figure 3.13 The subcellular localization of bacterially-delivered CT105-2HA changes in infected 
cells as the C. trachomatis developmental cycle progresses. HeLa cells were infected by C. trachomatis 
L2/424 harboring pCT105-2HA for 16, 20, 30, or 40 h. Infected cells were fixed with 4% (w/v) PFA and 
immunolabeled with antibodies against HA (red), C. trachomatis MOMP (blue), and the inclusion membrane protein 
CT442 (green), and appropriate fluorophore-conjugated secondary antibodies, and imaged by confocal 
fluorescence microscopy. Images correspond to single z sections. The values indicate the number of infected cells 
showing CT105-2HA outside of the inclusion, in the cytoplasm of the infected host cell. Data are the mean 
± standard error of the mean of three independent experiments (n ≥ 25). In the area delimited by a white square 
(upper panels) images were zoomed (lower panels). Scale bars, 10 µm. 
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Figure 3.14 CT105-2HA expressed under the control of the tetracycline promoter is delivered into 
the host cell by C. trachomatis L2/434. HeLa cells were infected by C. trachomatis L2/434 harboring pTet-
CT105-2HA and fixed with 4% (w/v) PFA at 24 h p.i. During infection, anhydrotetracycline was either not added (-
Tet) or added (+Tet) to 20 ng/mL at time zero of infection. Fixed cells were immunolabeled with antibodies against 
HA (red) and C. trachomatis MOMP (blue), and appropriate fluorophore-conjugated secondary antibodies. Cells 
were imaged by fluorescence microscopy. Scale bars, 10 µm. 
 
3.2.3 CT105-2HA localizes at the Golgi complex in C. trachomatis-infected cells 
 
The accumulation of CT105-2HA near the inclusion in the cytoplasm of infected cells suggested it 
could localize at the Golgi complex. This immunofluorescence signal of CT105-2HA also appeared less 
compact at longer times of infection, which was evocative of the Golgi fragmentation seen in C. 
trachomatis infected-cells (Heuer et al., 2009). To analyze this, HeLa cells infected by C. trachomatis 
L2/434 harboring pCT105-2HA were fixed at 16, 20, 30, and 40 h p.i. and then immunolabeled using 
antibodies against HA, C. trachomatis MOMP, GM130 (cis-Golgi marker), and TGN46 (trans-Golgi 
network [TGN] marker). Subsequent analysis by fluorescence microscopy revealed that CT105-2HA 
localized in the Golgi region at 16, 20, and 30 h, and that this was much less evident at 40 h p.i. (Figure 
3.15A). There was not a perfect co-localization of CT105-2HA with the cis- and trans-Golgi markers, but 
the immunofluorescence signal of CT105-2HA near the inclusion accompanied the dispersion of the 
Golgi complex during infection (Figure 3.15A). To further confirm the association of CT105-2HA with the 
Golgi, HeLa cells infected by the L2/434 strain harboring pCT105-2HA were treated with brefeldin A 
(BFA), which induces reversible Golgi fragmentation (Lippincott-Schwartz et al., 1989). Specifically, at 
19 h p.i., the infected cells were either incubated for 1 h with BFA or with dimethyl sulfoxide (DMSO)-
solvent alone (as control) and then fixed. In addition, the infected cells were incubated for 1 h with BFA, 
washed out from the BFA, incubated for 1 h, and then fixed. The cells were immunolabeled with 
antibodies against HA, C. trachomatis MOMP, and GM130, and analyzed by fluorescence microscopy. 
In the DMSO-treated infected cells, CT105-2HA accumulated in the Golgi region (Figure 3.15B), 
similarly to untreated cells infected for 16 or 20 h p.i. (Figure 3.15A). In cells treated with BFA, the 
GM130-labeled Golgi fragmented into small vesicles and the immunofluorescence signal of CT105-2HA 
became dispersed and mostly below the limit of detection (Figure 3.15B). In cells treated with BFA and 
subsequently washed-out of the drug, both the GM130-labeled Golgi and CT105-2HA appeared mostly 
compact and near the inclusion (Figure 3.15B). Overall, this showed that CT105-2HA associates with 
the Golgi upon the detection of its delivery by C. trachomatis into the cytoplasm of infected host cells, 
at 16-20 h p.i. 
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Figure 3.15 CT105-2HA associates with the Golgi complex in C. trachomatis-infected cells. HeLa 
cells were infected by C. trachomatis L2/434 encoding CT105-2HA. (A) At the indicated times p.i., cells were fixed 
with 4% (w/v) PFA, immunolabeled with antibodies against HA (red), C. trachomatis MOMP (gray), GM130 (green), 
and TGN46 (blue), and appropriate fluorophore-conjugated secondary antibodies. In the area delimited by a white 
square (left-side panels) images were zoomed (middle and right-side panels). (B) At 19 h p.i., cells were treated for 
1 h with DMSO or 1 µg/ml BFA. Then, the cells were either fixed with 4% (w/v) PFA (upper and middle panels) or 
washed with complete medium lacking BFA and incubated for an additional 1 h and then fixed with 4% (w/v) PFA 
(lower panels). Fixed cells were immunolabeled with antibodies against HA (red), C. trachomatis MOMP (gray), and 
GM130 (green), and appropriate fluorophore-conjugated secondary antibodies. In the area delimited by a white 
square (left-side panels) images were zoomed (right-side panels). All immunolabeled cells were examined by 
confocal fluorescence microscopy, and images correspond to single z sections. Scale bars, 10 µm. 
 
 
3.2.4 CT105-2HA localizes at the host cell plasma membrane in C. trachomatis-infected 
cells 
 
CT105-2HA was also detected in the periphery of host cells at 30 or 40 h p.i. by C. trachomatis 
(Figure 3.16A), which suggested it could localize at or near the plasma membrane. To analyze this, 
HeLa cells were infected for 30 and 40 h p.i. by C. trachomatis L2/434 harboring CT105-2HA and 
transfected with a plasmid encoding a palmitoylated/myristoylated peptide from Lyn kinase (Lyn11) 
[targeting proteins to the plasma membrane (Inoue et al., 2005) fused to monomeric EGFP (Falcón-
Pérez et al., 2005) (Lyn11-mEGFP)]. The cells were then fixed, immunolabeled using antibodies against 
HA and C. trachomatis MOMP, stained for the actin cytoskeleton with fluorescent-conjugated phalloidin, 
and analyzed by fluorescence microscopy. Although CT105-2HA did not show a perfect co-localization 
with either Lyn11-mEGFP or with phalloidin-stained cortical actin (Figure 3.16B and 3.16C), this showed 
that at 30 and 40 h p.i., CT105-2HA localizes at the plasma membrane. 
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Figure 3.16 CT105-2HA localizes at the host cell plasma membrane in C. trachomatis-infected 
cells. HeLa cells were infected by C. trachomatis L2/434 encoding pCT105-2HA and transfected with a plasmid 
encoding the plasma membrane marker Lyn11-mEGFP (green). (A) At 30 or 40 h p.i., cells were fixed with 4% 
(w/v) PFA, stained with phalloidin (blue), and immunolabeled with antibodies against HA (red) and C. trachomatis 
MOMP (gray), and appropriate fluorophore-conjugated secondary antibodies. Cells were imaged by confocal 
fluorescence microscopy and images correspond to single z sections. Scale bars, 10 µm. (B) Images were zoomed 
in the area delimited by a white square in (A). (C) Co-localization profile graphs of the fluorescence signal of CT105-
2HA, Lyn11 and phalloidin at the region indicated with a line in (B). 
 
3.2.5 Bacterially-delivered CT105-2HA changes its main localization in the host cell 
cytoplasm as the C. trachomatis developmental cycle progresses 
 
The number of infected cells showing bacterially-translocated CT105-2HA outside of the inclusion 
and at the Golgi or at the plasma membrane were enumerated. HeLa cells were infected by strain L2/434 
harboring pCT105-2HA and fixed at 16, 20, 30, and 40 h p.i. Then cells were immunolabeled for HA, for 
GM130 and for C. trachomatis MOMP and analyzed by fluorescence microscopy for CT105-2HA in the 
Golgi region or in the cell periphery. At 16 h p.i., CT105-2HA accumulated at the Golgi region in all 
infected cells showing the protein outside of the inclusion (Figure 3.17). At 20, 30, and 40 h p.i., the 
number of cells showing CT105-2HA outside of the inclusion and only at the Golgi region was 
progressively less frequent (88 ± 6%, 17 ± 7%, and 7 ± 2%, respectively) (Figure 3.17). In contrast, at 
20, 30, and 40 h p.i., the number of cells showing CT105-2HA outside of the inclusion and only in the 
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periphery of the cell was progressively more frequent (2 ± 1%, 15 ± 1%, and 61 ± 9%, respectively) 
(Figure 3.17). Infected cells showing CT105-2HA outside of the inclusion and both at the Golgi region 
and in the periphery of the host cell could also be identified and were much more frequent at 30 h p.i. 
(69 ± 8%) than at 20 and 40 h p.i. (10 ± 6%, and 33 ± 9%, respectively) (Figure 3.17).  
 
 
Figure 3.17 CT105-2HA changes its subcellular localization during C. trachomatis infection. HeLa 
cells were infected by C. trachomatis L2/434 harboring pCT105-2HA. Infected cells were fixed with 4% (w/v) PFA 
at 16, 20, 30 or 40 h p.i. and immunolabeled with antibodies against HA, C. trachomatis MOMP, and GM130, and 
appropriate fluorophore-conjugated secondary antibodies. Fluorescence microscopy was used to enumerate cells 
showing CT105-2HA only at the Golgi, only at the plasma membrane (PM), or both at the Golgi and at the plasma 
membrane (Golgi + PM). Data are mean ± standard error of the mean (SEM) of three independent experiments (n 
≥ 25). 
 
Altogether, in C. trachomatis-infected cells, initial delivery of CT105-2HA into the host cell cytoplasm 
(first detected at 16 h p.i.) results in its accumulation at the Golgi region, but as infection progresses this 
localization of the protein becomes less frequent and CT105-2HA accumulates more often at the 
periphery of the cell.  These observations were recapitulated by the analysis of HeLa cells infected by 
C. trachomatis L2/434 harboring pTet-CT105-2HA (Figure 3.18). 
 
 
Figure 3.18 Subcellular localization of CT105-2HA expressed under the control of the tetracycline 
promoter in C. trachomatis-infected cells. HeLa cells were infected by C. trachomatis L2/434 harboring 
pTet-CT105-2HA and fixed with 4% (w/v) PFA at the indicated times post-infection (p.i.). During infection, 
anhydrotetracycline was added to 20 ng/mL at time zero of infection. Fixed cells were immunolabeled with 
antibodies against HA (red), C. trachomatis MOMP (blue), and GM130 (green), and by appropriate fluorophore-
conjugated secondary antibodies. Cells were imaged by fluorescence microscopy. Scale bars, 10 µm. 
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3.2.6 The change in the main localization of CT105-2HA during infection from the Golgi to 
the plasma membrane is independent of intact host microfilaments and 
microtubules  
 
The previous results suggested that CT105-2HA could be transported from the Golgi to the plasma 
membrane in vesicles associated with the microtubule and actin cytoskeleton. To test this possibility, 
we infected HeLa cells with C. trachomatis harboring pCT105-2HA and at 20 h p.i., when CT105-2HA 
mostly localizes at the Golgi region (Figure 3.17), we incubated the cells in the presence of dimethyl 
sulfoxide (DMSO) solvent as control, of cytochalasin D or lantrunculin B (to inhibit actin polymerization, 
but each drug promotes depolymerization of microfilaments by different mechanisms), or of nocodazole 
(to prevent tubulin polymerization, and thereby depolymerize microtubules) (Figure 3.19A). The cells 
were then fixed at 30 h p.i., when CT105-2HA mostly localizes near the plasma membrane (Figure 3.17), 
and immunolabeled for HA and C. trachomatis MOMP.  Fluorescence microscopy was then used to 
enumerate infected cells showing CT105-2HA near the plasma membrane (Figure 3.19B). We observed 
a statistically significant difference in the localization of CT105-2HA near the plasma membrane when 
microfilaments were disrupted with cytochalasin D (Figure 3.19B). However, the small difference relative 
to DMSO-treated cells, and the absence of a significantly different effect upon disruption of the 
microfilaments with lantrunculin B (Figure 3.19B), suggests this should have no biological significance. 
Furthermore, disruption of the microtubule network also did not significantly affect the localization of 
CT105-2HA near the plasma membrane (Figure 3.19B). Therefore, CT105-2HA changes its 
predominant localization during infection of host cells by C. trachomatis from the Golgi to the plasma 
membrane, but this is likely independent of intact host microfilaments and microtubules.  
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Figure 3.19 CT105-2HA changes in its subcellular localization during C. trachomatis infection is 
independent of intact host microfilaments and microtubules. HeLa cells were infected by C. trachomatis 
L2/434 encoding pCT105-2HA. At 20 h p.i., infected cells were treated with DMSO, 1 µg/ml nocodazole, 2 µM 
cytochalasin D or 500 nM latrunculin. At 30 h p.i., the cells were fixed with 4% (w/v) PFA or methanol. (A) Cells 
were immunolabeled with an antibody against -tubulin and an appropriate fluorophore-conjugated secondary 
antibody or stained with fluorescent-conjugated phalloidin. (B) To enumerate cells showing CT105-2HA at the 
periphery of the cell/plasma membrane by fluorescence microscopy, cells were immunolabeled with antibodies 
against HA (red), C. trachomatis MOMP (blue), and appropriate fluorophore-conjugated secondary antibodies. Data 
are mean ± SEM of three independent experiments (n = 50). P-values were obtained by one-way ANOVA and 
Bonferroni post-test analyses; *statistical significant (P < 0.05); ns, not significant. Cells were imaged by 
fluorescence microscopy. Scale bars, 10 µm. 
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3.2.7 The localization of bacterially-delivered CT105-2HA at the host cell plasma 
membrane is independent of the timing of the protein expression during the C. 
trachomatis developmental cycle  
 
Moreover, we analyzed whether the delivery and subcellular localization of CT105-2HA at the plasma 
membrane required expression of CT105-2HA at a specific stage on the developmental cycle of C. 
trachomatis. HeLa cells were infected with C. trachomatis L2/434 harboring pTet-CT105-2HA and 
anhydrotetracycline was not added (-Tet) or added to 20 ng/mL (+Tet) at time 0 h, 20 h, and 30 h p.i. 
(Figure 3.20) to induce CT105-2HA expression. At 40 h p.i. cells were fixed, immunolabeled with 
antibodies against HA, GM130 and C. trachomatis MOMP and analyzed by fluorescence microscopy. 
At the different times of induction, pTet-CT105-2HA localized at the host cell plasma membrane similarly 
to pCT105-2HA expressed under the control of ct105 endogenous promoter (Figure 3.20). This indicates 
that the subcellular localization of CT105-2HA at the plasma membrane is not dependent on timing of 
the protein expression during the developmental stage of C. trachomatis. 
 
 
Figure 3.20 Bacterially-translocated CT105-2HA localizes at the host cell plasma membrane 
regarding the timing of its expression by C. trachomatis. HeLa cells were infected by C. trachomatis 
L2/434 harboring pTet-CT105-2HA. Anhydrotetracycline was not added (-Tet) or added to 20 ng/mL (+Tet) at 0, 20 
or 30 h p.i.. At 40 h p.i. cells were fixed with 4% (w/v) PFA and immunolabeled with antibodies against HA (red), C. 
trachomatis MOMP (blue), GM130 (green) and appropriate fluorophore-conjugated secondary antibodies. Cells 
were imaged by fluorescence microscopy. Scale bars, 10 µm. 
 
3.2.8 The first 100 amino acid residues of CT105 are sufficient to target the protein to the 
Golgi of uninfected mammalian cells 
 
To map the regions of CT105 that could determine its different localizations within the cytoplasm of 
mammalian cells, we started by constructing transfection plasmids encoding full-length CT105 fused to 
the C- or N-termini of mEGFP (mEGFP-CT105FL and CT105FL-mEGFP, respectively) or CT105-2HA. 
HeLa cells were transfected for 24 h with the constructed plasmids and immunoblotting of whole cell 
extracts confirmed the production of proteins of the predicted molecular mass (Figure 3.21A). Analysis 
of the transfected cells by fluorescence microscopy, showed that mEGFP-CT105FL, CT105FL-mEGFP, 
or CT105-2HA localized predominantly at the periphery of the cell (Figure 3.21B), recapitulating a main 
localization of CT105-2HA in cells infected by C. trachomatis for 30 h or 40 h (Figure 3.16 and 3.17).  
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Figure 3.21 Ectopic expression of CT105 in HeLa cells. HeLa cells were either left untransfected or 
transfected for 24 h with plasmids encoding monomeric EGFP (mEGFP), CT105 fused to the C-terminus of mEGFP 
(mEGFP-CT105), CT105 fused to the N-terminus of mEGFP (CT105-mEGFP), and CT105 with a double 
hemagglutinin tag at its C-terminus (CT105-2HA) (A) Total extracts of the indicated untransfected or transfected 
cells were analyzed by immunoblotting with antibodies against GFP, HA and α-tubulin (HeLa loading control) using 
SuperSignal® West Pico detection kit (Thermo Fisher Scientific). (B) Cells were fixed with 4% (w/v) PFA, stained 
with DAPI (blue), and immunolabeled with an antibody against HA (red) and the appropriate fluorophore-conjugated 
secondary antibody. Scale bars, 10 µm. 
 
We then constructed plasmids encoding different truncated/mutated versions of CT105 fused to the 
C-terminus of mEGFP (mEGFP-CT1051-100, mEGFP-CT105Δ100, mEGFP-CT1051-320, mEGFP-
CT105Δ320, mEGFP-CT105Δ100-320, or mEGFP-CT105PDZ) (Figure 3.22A). Examination of the primary 
structure of CT105 revealed no predicted transmembrane domains or other obvious targeting motifs, 
except for a possible Postsynaptic Density95/Disc Large/Zonula Occludens-1 (PDZ) domain at the C-
terminus of CT105 consisting in 3 amino acid residues (Ser-Ser-Ile) (Mu et al., 2014), which is thought 
to be involved in protein-protein interactions. Therefore, the truncations were designed only considering 
the predicted secondary structure of CT105 [deduced using JPred4;  (Drozdetskiy et al., 2015)] and the 
mutation of the possible PDZ domain comprised the substitution of the three relevant  amino acids 
residues by alanines. HeLa cells were then transfected with plasmids encoding mEGFP-CT105FL 
(predicted molecular mass of 96 kDa) mEGFP-CT1051-100 (38 kDa), mEGFP-CT105Δ100 (86 kDa) 
mEGFP-CT1051-320 (60 kDa), mEGFP-CT105Δ320 (65 kDa), mEGFP-CT105Δ100-320 (74 kDa), or mEGFP-
CT105PDZ (96 kDa). Immunoblotting of whole cell extracts confirmed the production of mEGFP-CT105FL, 
mEGFP-CT1051-100, mEGFP-CT105Δ100, mEGFP-CT105Δ100-320, mEGFP-CT105Δ320 and mEGFP-
CT105PDZ proteins of the predicted molecular mass (Figure 3.22B). The production of mEGFP-CT1051-
320 and mEGFP- CT105Δ320 proteins of the predicted molecular mass was not detected (Figure 3.22B), 
and they were not further analyzed. HeLa cells ectopically expressing mEGFP-CT105FL, mEGFP-
CT1051-100, mEGFP-CT105Δ100, mEGFP-CT105Δ100-320 or mEGFP-CT105PDZ were fixed, immunolabeled 
with antibodies against GM130, and enumerated by fluorescence microscopy for localization of the 
fusion protein at the cell periphery and at the Golgi. mEGFP-CT105FL localized near the plasma 
membrane in 68 ± 8% of the transfected cells, and at the Golgi in 7 ± 2% of the transfected cells (Figure 
3.22C and 3.22D). However, the fluorescent signal was generally weak in the Golgi region (Figure 
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3.22C). Strikingly, mEGFP-CT1051-100 localized at the Golgi region in almost all transfected cells (98 ± 
1%) and was not detected at the plasma membrane (Figure 3.22C and 3.22D). In contrast, mEGFP-
CT105Δ100 was mostly cytosolic and was never seen at the Golgi complex and only seldom (2 ± 0%) 
near the plasma membrane (Figure 3.22C and 3.22D). mEGFP-CT105Δ100-320 showed a 
punctate/vesicular appearance with reduced localization at the Golgi (4 ± 1%) or plasma membrane (18 
± 1%), particularly when compared with mEGFP-CT105Δ100 or mEGFP-CT105FL (Figure 3.22C and 
3.22D). mEGFP-CT105PDZ had similar localization as mEGFP-CT105FL and localized near the plasma 
membrane in 64 ± 3% of the transfected cells, and at the Golgi in 6 ± 3% of the transfected cells (Figure 
3.22C and 3.22D). Similar observations were made in HeLa cells ectopically expressing truncated 
versions of CT105 fused to the N-terminus of mEGFP (Figure 3.23).   
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Figure 3.22 The first 100 amino acids of CT105 are targeted to the Golgi complex. HeLa cells were 
transfected for 24 h with plasmids encoding monomeric EGFP (mEGFP) or different versions of CT105 fused to the 
C-terminus of mEGFP. (A) Schematic representation of the mEGFP-CT105 proteins analyzed. (B) Total extracts 
of transfected cells were analyzed by immunoblotting with antibodies against GFP and α-tubulin (HeLa loading 
control) using SuperSignal® West Pico detection kit (Thermo Fisher Scientific). (C) Transfected cells were fixed 
with 4% (w/v) PFA, labeled with antibodies against TGN46 (red) and the appropriate fluorophore-conjugated 
secondary antibody, and imaged by confocal fluorescence microscopy. Images correspond to single z sections. 
Scale bars, 10 µm. (D) Cells immunolabeled as described in (C) were enumerated by fluorescence microscopy for 
localization of mEGFP-CT105 only at the Golgi, only at the plasma membrane (PM), or both at the Golgi and plasma 
membrane (Golgi + PM). Data are mean ± standard error of the mean of three independent experiments (n=100).  
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Figure 3.23 CT105 fusions to the N-terminus of mEGFP. HeLa cells were transfected for 24 h with 
plasmids encoding monomeric EGFP (mEGFP) or different versions of CT105 fused to the N-terminus of mEGFP. 
(A) Schematic representation of the CT105-mEGFP proteins analyzed. (B) Total extracts of transfected cells were 
analyzed by immunoblotting with antibodies against GFP and α-tubulin (HeLa loading control) using SuperSignal® 
West Pico detection kit (Thermo Fisher Scientific). (C) Transfected cells were fixed with 4% (w/v) PFA, labeled with 
antibodies against GM130 (red) and the appropriate fluorophore-conjugated secondary antibody, and imaged by 
confocal fluorescence microscopy. Images correspond to single z sections. Scale bars, 10 µm. (D) Cells 
immunolabeled as described in (C) were enumerated by fluorescence microscopy for localization of mEGFP-CT105 
only at the Golgi, only at the plasma membrane (PM), or both at the Golgi and plasma membrane (Golgi + PM). 
Data are mean ± standard error of the mean of three independent experiments (n=100).  
 
To confirm the association of mEGFP-CT1051-100 with the Golgi, and to analyze its localization within 
the Golgi complex, HeLa cells that had been transfected for 24 h were either incubated for 1 h with BFA 
or DMSO (as control), and then fixed. In addition, the transfected cells were incubated for 1 h with BFA, 
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washed out from the BFA, incubated for 1 h, and fixed. The cells were then immunolabeled with 
antibodies against GM130 or TGN46 and analyzed by fluorescence microscopy. In the control DMSO-
treated cells, mEGFP-CT1051-100 localized at the Golgi region, and showed significant co-localization 
with TGN46 (Figure 3.24B) but not with GM130 (Figure 3.24A). BFA-induced Golgi fragmentation 
resulted in near complete dispersion of the fluorescence signal of mEGFP-CT1051-100 (Figure 3.24A and 
3.24B). However, BFA-induced Golgi fragmentation followed by BFA wash out revealed again a 
compact Golgi complex and mEGFP-CT1051-100 in that region mostly co-localizing with TGN46 (Figure 
3.24B) but not with GM130 (Figure 3.24A), as observed in the DMSO-treated cells.  
 
 
Figure 3.24 The first 100 amino acids of CT105 associate with the trans-Golgi. HeLa cells were 
transfected for 24 h with plasmids encoding mEGFP-CT1051-100. Cells were treated for 1 h with DMSO or 1 µg/ml 
BFA. Then, the cells were either fixed with 4% (w/v) PFA (upper and middle panels) or washed with complete 
medium lacking BFA and incubated for an additional 1 h and then fixed with 4% (w/v) PFA (lower panels). The fixed 
cells were immunolabeled with antibodies against (A) GM130 (red) or (B) TGN46 (red), and the appropriate 
fluorophore-conjugated secondary antibody, and examined by confocal fluorescence microscopy. Images 
correspond to single z sections. In the area delimited by a white square (left-side panels) images were zoomed 
(right-side panels). Scale bars, 10 µm. 
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To test the importance of the different regions of CT105 for its localization in infected cells, HeLa 
cells were infected by C. trachomatis strains harboring full-length CT105 (pTet-CT105-2HA), and 
truncations of CT105 containing the first 100 amino acids (pTet-CT1051-100-2HA, pTet-CT1051-320-2HA, 
pTet-CT105Δ100-320-2HA), as they include the T3S signal (Figure 3.5 and 3.6) and possible T3S 
chaperone binding sites (Woestyn et al., 1996; Boyd et al., 2000). At 20 h and 40 h p.i., cells were fixed 
and immunolabeled for HA and Cap/CT5291 (chlamydial protein localized at the inclusion membrane) 
and analyzed by fluorescence microscopy (Figure 3.25). Although all the proteins were expressed, 
neither of them was detected in the cytoplasm of host cell, and therefore we could not proceed with the 
analysis of the role of the different regions of CT105 in subcellular targeting during C. trachomatis 
infection. 
Altogether, these results showed that ectopically expressed full-length CT105 (mEGFP-CT105FL, 
CT105FL-mEGFP, and CT105-2HA) and mutated CT105 at the PDZ domain (mEGFP-CT105PDZ) mostly 
localized near the plasma membrane and mEGFP-CT1051-100 at the Golgi, generally recapitulating the 
localization of CT105-2HA in infected cells. As mEGFP-CT1051-100 showed a striking association with 
the TGN in uninfected cells, the first 100 amino acids of CT105 should contain a Golgi-targeting region.  
 
 
Figure 3.25 C. trachomatis L2/434 strains harboring plasmids encoding truncated versions of 
CT105 were not detected in the host cell cytoplasm. HeLa cells were infected with C. trachomatis L2/434 
harboring pTet-C105-2HA, pTet-CT1051-100-2HA, pTet-CT1051-320-2HA and pTet-CT105Δ100-320-2HA, and at time 
zero of infection anhydrotetracycline was added to 20 ng/mL. At 20 h and 40 h p.i., cells were fixed with 4% (w/v) 
PFA and immunolabeled with antibodies against HA (red), C. trachomatis Cap1 (chlamydial protein located at the 
inclusion membrane; green) and appropriate fluorophore-conjugated secondary antibodies. Cells were imaged by 
fluorescence microscopy. Scale bars, 10 µm. 
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3.2.9 CT105 appears in filamentous structures within host cells 
 
In addition to the localization of CT105 at the Golgi and at the plasma membrane during C. 
trachomatis infection, CT105 appeared in filamentous structures in the host cell, which could be 
observed at 20 h p.i. but that become more visible in later times of infection (30 h and 40 h p.i.). These 
filamentous structures appeared spread in the host cell, were not associated with the inclusion 
membrane, and were reminiscent of host cytoskeletal filaments. Therefore, HeLa cells were infected by 
C. trachomatis harboring pTet-CT105-2HA for 30 h, fixed and labeled with antibodies against -tubulin 
or vimentin to detect microtubules and intermediate filaments, respectively, or with fluorescent-
conjugated phalloidin to stain the F-actin. However, significant co-localization of the filamentous CT105-
2HA with the labeled host cytoskeleton components was not observed (Figure 3.26A). In addition, 
several other host cell proteins were labeled [endoplasmic reticulum (KDEL and PDI), Golgi (GM130, 
TGN46, Mannosidase II), early endosomes (EEA1), lysosomes (LAMP1 and LAMP3/CD63), cation-
dependent mannose 6-phosphate receptor (CD-M6PR) and transferrin (Trf); data not shown)] but 
significant co-localization with filamentous CT105-2HA was not observed.  
When HeLa cells were transfected by 24 h with plasmids encoding mEGFP-CT105, similar 
filamentous structures could be observed (Figure 3.26B). Moreover, when HeLa cells were infected with 
C. trachomatis L2/434 encoding pTet-CT105-2HA and transfected with a plasmid encoding mEGFP-
CT105, fixed 24 h p.i. and immunolabeled with antibodies against HA and C. trachomatis MOMP, the 
filamentous CT105-2HA and filamentous mEGFP-CT105 co-localize (Figure 3.26C). Overall this 
suggests that CT105 forms filamentous structures that are not dependent on additional C. trachomatis 
factors but which seemingly do not significantly co-localized with the tested host cell markers. 
 
Summarizing, a CT105-2HA immunofluorescence signal was detected in the host cell at 16 - 20 h 
p.i, where it mostly associated at the Golgi complex; as the infection progressed, at 30 and 40 h p.i., 
CT105-2HA predominately localized at the host cell plasma membrane. This change in the localization 
of CT105-2HA during infection was found to be independent of intact microfilaments or microtubules. In 
addition, we identified a Golgi targeting region within CT105 comprising the first 100 amino acid residues 
of the protein. 
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Figure 3.26 CT105 localizes in filamentous structures in non-infected and Chlamydia-infected 
cells. HeLa cells were infected C. trachomatis L2/434 harboring pTet-C105-2HA and at time zero of infection 
anhydrotetracycline was added to 20 ng/mL. At 40 h p.i., cells were fixed with 4% (w/v) PFA or methanol and 
immunolabeled with antibodies against HA (red) and stained/immunolabeled for the host cell cytoskeleton 
components (fluorescent-conjugated phalloidin or antibodies against α-tubulin and vimentin and appropriate 
fluorophore-conjugated secondary antibodies; green). (B) HeLa cells were transfected for 24 h with a plasmid 
encoding mEGFP-CT105, fixed with 4% (w/v) PFA and stained with fluorescent-conjugated phalloidin. (C) HeLa 
cells were infected with C. trachomatis L2/434 encoding pTet-CT105-2HA and transfected with a plasmid encoding 
mEGFP-CT105. At time zero of infection anhydrotetracycline was added to 20 ng/mL.  At 24 p.i., cells were fixed 
with 4% (w/v) PFA, and immunolabeled with antibodies against HA (red) and C. trachomatis MOMP (blue), and 
appropriate fluorophore-conjugated secondary antibodies. Cells were imaged by fluorescence microscopy. In the 
area delimited by a white square (left-side panels) images were zoomed (right-side panels). Scale bars, 10 µm. 
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3.3 THE CHLAMYDIA TRACHOMATIS EFFECTOR CT105 CAN INTERFERE 
WITH VESICULAR TRAFFICKING IN EUKARYOTIC CELLS 
 
We have identified CT105 as a novel C. trachomatis T3S substrate that is delivered into the host cell 
and localizes at host cell Golgi and plasma membrane during C. trachomatis infection. However, to 
designate CT105 as a T3S effector of C. trachomatis its function must be investigated. Although its 
subcellular localization has been determined, little can be inferred on the CT105 function during 
infection, as other bacterial T3S effectors with a Golgi localization display a variety of functions and 
activities such as induction of Golgi fragmentation, activity of an ubiquitin E3 ligase, interference with 
vesicular trafficking, causing microtubule destabilization, inactivating the host inflammasome or 
suppressing the host immune system (Salcedo and Holden, 2003; Gruenheid et al., 2004; Tomson et 
al., 2005; Shaw et al., 2005; Jinoh Kim et al., 2007; Thanabalasuriar et al., 2010; Clements et al., 2011; 
Yen et al., 2015; Lin et al., 2015; Yu et al., 2016; Bayer-Santos et al., 2016).  Here, we used the recently 
developed methodologies to genetically manipulate C. trachomatis to construct and characterize a C. 
trachomatis ct105 mutant strain (Johnson and Fisher, 2013). In addition we used Saccharomyces 
cerevisiae, an eukaryotic model organism previously used in the study of bacterial effector proteins 
(Curak et al., 2009), to phenotypically characterize the effects of overexpression of CT105. 
 
3.3.1 CT105 is not essential for intracellular replication of C. trachomatis in infected tissue 
culture cells. 
 
To examine the importance of CT105 during the infection of tissue culture cells by C. trachomatis, a 
L2/434-derived strain where the ct105 gene was inactivated by an insertion between nucleotides 261 
and 262 of a modified group II intron containing a spectinomycin-resistance gene (aadA) was 
constructed (Figure 3.27A). The correct insertion of the intron in the ct105::aadA mutant strain was 
verified by PCR (Figure 3.27B) and locus-specific DNA sequencing. To confirm that insertion of the 
intron prevented production of CT105, in the absence of a specific anti-CT105 antibody, a C. trachomatis 
strain harbouring a plasmid (pCT105::aadA-2HA; Annexes Table A1) was constructed with the 
ct105::aadA mutant allele and the sequence encoding 2HA fused to the 3´end of ct105, and carrying 
the ct105 promoter and incD terminator (as in pCT105-2HA; Annexes Table A1). HeLa cells were then 
infected for 40 h with C. trachomatis L2/434 harbouring either pCT105-2HA or pCT105::aadA-2HA and 
analysed by immunoblotting. This confirmed that the intron insertion within ct105-2HA prevented 
production of a protein detectable with anti-HA antibodies (Figure 3.27C), suggesting that the 
ct105::aadA mutant strain should not produce CT105. 
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Figure 3.27 Verification of intron insertion in the C. trachomatis ct105::aadA mutant strain. A C. 
trachomatis ct105::aadA insertional mutant was generated in the strain L2/434 by the targeted insertion of a 
modified group II intron carrying a spectinomycin-resistance gene. (A) Representation of the ctl0360 (orthologue of 
ct105 in strain D/UW3) locus in C. trachomatis L2/434 and of the ctl0360 locus in the corresponding ct105:aadA 
mutant derivative. The arrows indicate the approximate hybridization position of the DNA primers used (Annexes 
Table A2) in PCR reactions, yielding DNA products of the indicated length in base pairs (bp). (B) Agarose gel 
displaying the result from the PCR with the indicated primers (Annexes Table A2) and DNA templates. (C) Hela 
cells were infected by C. trachomatis L2/434 harboring a plasmid encoding CT105-2HA or by an identical plasmid 
carrying a ct105::aadA-2HA mutant allele. Whole cell extracts were analyzed by immunoblotting with antibodies 
against HA, C. trachomatis Hsp60 (bacterial loading control) and α-tubulin (HeLa loading control) using 
SuperSignal® West Pico detection kit (Thermo Fisher Scientific) for Hsp60 and α-tubulin, or SuperSignal® West 
Femto detection kit (Thermo Fisher Scientific) for HA. This experiment was performed in collaboration with Charlotte 
E. Key and Derek J. Fisher (Southern Illinois University, USA). 
 
The intracellular growth of C. trachomatis L2/434 (parental strain), ct105::aadA mutant, and 
ct105::aadA mutant harboring pCT105-2HA (complemented strain) was then monitored by quantifying 
the production of infectious progeny during the chlamydial developmental cycle. Based on this, no 
significant differences between the three strains were detected (Figure 3.28A). Then, HeLa cells infected 
by the same strains for 24 h were fixed and immunolabeled using antibodies against C. trachomatis 
MOMP. Analysis by fluorescence microscopy revealed that the inclusion size appeared smaller in the 
mutant and complemented strains by comparison to the parental strain (Figure 3.28B). This was 
confirmed by measuring the inclusion area in cells infected by these three C. trachomatis strains (Figure 
3.28C). Similar observations were made in cells infected by these strains for 40 h (data not shown). 
Because this difference in inclusion size between the mutant and the parental strain was also observed 
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in the complemented strain, the defect is likely not due to the absence of CT105. It is possible that intron 
insertion within ct105 might have caused a polar effect in the neighboring genes. In summary, this 
showed that CT105 is not required for C. trachomatis growth in tissue culture cells. 
Moreover, HeLa cells were infected by C. trachomatis parental, mutant or complemented strains for 
20 h and cells were fixed and immunolabeled using antibodies against C. trachomatis MOMP and 
GM130 (cis-Golgi). In addition, considering the localization of CteG at the Golgi, we analyzed if its 
morphology was altered in HeLa cells infected by the ct105::aadA mutant, by comparison to cells 
infected by the parental L2/434 strain. However, significant differences in Golgi morphology were not 
detected between cells infected by these two C. trachomatis strains (Fig. 3.29A, 3.29B).    
 
 
Figure 3.28 A C. trachomatis ct105::aadA insertional mutant is not defective for intracellular 
growth in tissue culture cells. HeLa cells were infected for 24, 30, or 40 h by C. trachomatis L2/434, 
ct105::aadA mutant or ct105::aadA mutant harboring pCT105-2HA at the multiplicity of infection of 1, and 
recoverable inclusion forming units (IFUs) were enumerated. Data ± standard error of the mean of 3 independent 
experiments. For each time-point, P-values were obtained by one-way ANOVA and Dunnett post-test analyses 
relative to the L2/434 parental strain; ns, not significant (P ≥ 0.05). (B) Hela cells were infected for 24 h by C. 
trachomatis L2/434, ct105::aadA mutant, or ct105:aadA harbouring pCT105-2HA. Cells were fixed with methanol 
and labeled with goat anti-C. trachomatis FITC-conjugated antibody. (C) The inclusion area was measured (from 
images as those depicted in (B) for 50 particles randomly chosen from independent images using Fiji software. P-
values were obtained by one-way ANOVA and Dunnett post-test analyses; *statistical significant (P < 0.05). 
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Figure 3.29 CT105 does not affect host cell Golgi morphology during infection. HeLa cells were 
infected by C. trachomatis L2/434 or ct105::aadA mutant for 24 h, fixed with methanol, and then immunolabeled 
with antibodies against GM130 (a cis-Golgi marker; red) and chlamydial Hsp60 (green), and appropriate 
fluorophore-conjugated secondary antibodies. (A) Cells were imaged by fluorescence microscopy. The length of 
the Golgi complex around the inclusion was measured as described (Wesolowski et al., 2017), which is illustrated 
by the red line. Scale bars, 5 µm. (B) Percentage of cells infected by C. trachomatis with Golgi around the inclusion 
of the indicated length. Data is average ± standard error of the mean from 3 independent experiments where at 
least 50 infected cells were analyzed for each strain. P-values were calculated by a two-tailed unpaired Student’s 
t-test; ns, not significant (P > 0.05). This experiment was performed in collaboration with Inês Serrano Pereira (PhD 
student in the host laboratory). 
 
3.3.2 CT105 induces a vacuolar protein sorting defect when ectopically expressed in S. 
cerevisiae 
 
Given the localization of CT105 at the Golgi and plasma membrane in both infected and transfected 
mammalian cells, we hypothesized that the protein could interfere with eukaryotic vesicular trafficking. 
To test this, we asked if CT105 could cause a vacuolar protein sorting (VPS) defect in S. cerevisiae 
(Shohdy et al., 2005), an eukaryotic model organism that has been often used to study bacterial effector 
proteins (Curak et al., 2009). The VPS assay consists in a yeast reporter strain NSY01 (Annexes Table 
A3) that produces a hybrid protein composed of carboxypeptidase Y and Invertase (CPY-Inv), which 
normally travels to the yeast vacuole but goes to the cell surface if trafficking is disrupted. As strain 
NSY01 does not produce endogenous Invertase, an enzyme that hydrolyzes sucrose into glucose and 
fructose, normal (Vps+) or aberrant (Vps-) trafficking of CPY-Inv can be scored by using an agar overlay 
solution indicating glucose production at the cell surface by formation of a brown precipitate (Vps+, white 
colonies; Vps-, brown colonies) (Shohdy et al., 2005). 
Strain NSY01 was transformed with yeast expression plasmids encoding either CT105 fused to the 
N-terminus or C-terminus of GFP (CT105-GFP or GFP-CT105, respectively) under the control of a 
galactose inducible promoter (Figure 3.30A). The controls used were a NSY01 derivative strain that 
expressed only GFP (Figure 3.30A), which leads to a Vps+ phenotype (Franco et al., 2012), and NSY01 
derivative strains expressing a dominant-negative form of the yeast ATPase Vps4 (Vps4E233Q) (Babst et 
al., 1998) or the Legionella pneumophila effector protein VipA (Figure 3.30A), both known to cause a 
Vps- phenotype (Shohdy et al., 2005; Franco et al., 2012). In the qualitative colorimetric enzymatic assay 
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in solid media, it was consistently observed that GFP-CT105 or CT105-GFP induced a Vps- phenotype 
(Figure 3.30B). In addition, quantitative analyses in liquid media were performed and the amounts of 
secreted and total invertase were assessed for each strain. In this assay, both GFP-CT105 and CT105-
GFP caused an increase in the levels of secreted invertase (relative to those of the control strains 
expressing GFP or Vps4E233Q), but the difference was only statistically significant for GFP-CT105 (Figure 
3.30C).  
 
 
Figure 3.30 CT105 induces a vacuolar protein sorting defect in S. cerevisiae. S. cerevisiae reporter 
strain NSY01 producing CPY-invertase (Annexes Table A3) was transformed with plasmids encoding GFP, VipA-
GFP, GFP-CT105, or CT105-GFP, where their expression is induced by 2% (w/v) galactose. A NSY01 derivative 
strain encoding a dominant-negative form of the yeast ATPase Vps4 (Vps4E233Q) was also used. (A) Whole cell 
extracts of S. cerevisiae NSY01 producing the indicated proteins were analyzed by immunoblotting with antibodies 
against GFP and PGK1 (yeast loading control), using SuperSignal® West Pico detection kit (Thermo Fisher 
Scientific). (B) S. cerevisiae NSY01 strains encoding the indicated proteins were grown in solid medium in the 
presence of 2% (w/v) galactose (inducing conditions, +GAL) or in the presence of 2% (w/v) fructose (non-inducing 
conditions; +FRU). The vacuolar protein sorting (VPS) phenotype was analyzed using a sucrose overlay to assess 
activity of secreted invertase. A vacuolar protein sorting defect (VPS-) leads to the formation of a brown precipitate. 
(C) S. cerevisiae NSY01 strains encoding the indicated proteins were grown in liquid medium in the presence of 
2% (w/v) galactose (inducing conditions) and the relative activity of secreted invertase was quantified (see Materials 
and Methods). Data are mean ± standard error of the mean of five independent experiments. P-values were 
obtained by one-way ANOVA and Dunnett post-test analyses relative to GFP (0% of relative secreted invertase; 
not shown); *statistical significant (P < 0.05); ns, not significant. 
 
After growing the previously described S. cerevisiae NSY01 strains in inducing galactose-
supplemented agar plates (inducing conditions) we observed by fluorescence microscopy that GFP-
CT105 and CT105-GFP localized in puncta in the yeast cytoplasm, although for GFP-CT105 the protein 
was mainly cytosolic (Figure 3.31A). Nevertheless, neither of the CT105 fusions was detected at the 
yeast plasma membrane. Furthermore, after growth of the strains in liquid media containing glucose, 
they were serially-diluted and plated on fructose-supplemented (non-inducing conditions; +FRU) and 
galactose-supplemented (inducing conditions; +GAL) agar plates. After incubation at 30C for 3 days, 
yeast growth was similar between non-inducing and inducing conditions (Figure 3.31B) in each of the 
analyzed strains suggesting that overexpression of GFP, GFP-CT105 or CT105-GFP is not toxic and 
does not affect yeast growth, in contrast with previous observations (Sisko et al., 2006). Also, this 
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indicated that the induction of the VPS defect by CT105 was not a consequence of an overall impact on 
yeast physiology.  
 
 
Figure 3.31 Phenotypic characterization of S. cerevisiae strains expressing CT105. (A) S. cerevisiae 
NSY01 strains harboring plasmids encoding GFP, GFP-CT105, or CT105-GFP were grown in 2% (w/v) galactose 
supplemented agar plates and cells were imaged by brightfield and fluorescence microscopy. White square shows 
zoomed region. Scale bars 5 m. (B) S. cerevisiae NSY01 strains harboring plasmids encoding GFP, GFP-CT105, 
or CT105-GFP were grown to late log phase in 2% (w/v) glucose. Dilutions of 10-fold were spotted onto 2% (w/v) 
fructose (non-inducing conditions; +FRU) and 2% (w/v) galactose (inducing conditions; +GAL) supplemented agar 
plates and incubated at 30C for 3 days. 
 
In summary, CT105 was found as a non-essential gene of C. trachomatis infection in tissue cell 
culture model. However, ectopic expression of CT105 in S. cerevisiae induced a VPS defect, suggesting 
that this C. trachomatis protein could interfere with vesicular trafficking in infected cells. Furthermore, 
this is not a consequence of an overall toxic effect of CT105 in yeast cells. 
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The main goal of this project was the identification and characterization of novel type III secretion 
(T3S) effectors of Chlamydia trachomatis using the techniques available to genetically modify these 
bacteria. Here, we have identified and characterized CT105 as a novel type III secretion (T3S) effector 
protein of C. trachomatis and as the first chlamydial effector known to be targeted to the Golgi complex 
of infected host cells. Upon detection of its delivery into the host cell (~ 16 - 20 h post-infection), CT105 
associates with the Golgi complex possibly through its first 100 amino acid residues; as the 
developmental cycle progresses (~30 - 40 h post-infection), CT105 accumulates at the host plasma 
membrane, in a process independent from intact host cell microfilaments and microtubules. 
CT105 disrupted vesicular trafficking in a yeast model but it was not essential to the developmental 
cycle of C. trachomatis, as a ct105 mutant strain did not display an intracellular growth defect, at least 
in an tissue cell culture model. Furthermore, the analysis of different C. trachomatis strains revealed that 
ct105 was mostly transcribed in lymphogranuloma venereum (LGV) strains, indicating that CT105 might 
be important to the tissue tropism characteristic of the LGV group. 
Overall, we have demonstrated that the tools for genetic modification of C. trachomatis are valuable 
to the identification of novel T3S effectors. The identification of CT105 illustrates the diversity among 
chlamydial effector proteins (e.g. subcellular localization, function) despite the small genome of the 
bacteria. Moreover, the study of T3S effectors contributes to unveil how C. trachomatis interacts with 
the host cell and how it modulates the host cellular mechanisms to survive in the intracellular 
environment, thus improving our knowledge on C. trachomatis pathogenesis. 
 
4.1 MECHANISM OF DELIVERY OF CT105 
 
It had been previously shown that CT105 contains a (T3S) signal recognizable by the type III 
secretion system (T3SS) of Yersinia enterocolitica (da Cunha et al., 2014). Here, we found that the T3S 
signal of CT105, which is comprised within the first 20 amino acid residues of the protein, was necessary 
and sufficient to drive T3S in Y. enterocolitica. This is not unexpected as T3S signals commonly locate 
within the first 15 - 40 amino acid residues of T3S substrates (Michiels and Cornelis, 1991). In addition, 
we also showed that the first 20 amino acid residues of CT105 were necessary for its delivery into the 
host cells infected by C. trachomatis. Surprisingly, when truncated versions of CT105 (CT1051-100, 
CT1051-320 and CT105100-320) were expressed in C. trachomatis, these could not be detected in the 
cytoplasm of host cells, although they all contained the T3S signal. While T3S signals are normally 
sufficient to target the protein to the secretion apparatus, in some substrates the region of the protein 
required for their delivery into host cells was found to be longer than the one sufficient to export by the 
T3SS (Sory et al., 1995; Schesser et al., 1996). Delivery of CT105 into the cytoplasm of infected host 
cells might require a region of the protein downstream from the T3S signal containing a hypothetical 
T3S chaperone-binding domain (Woestyn et al., 1996; Boyd et al., 2000; Pais et al., 2013). However, a 
specific T3S chaperone for CT105 has not been yet identified. 
Although the T3S signal frequently locates at the N-terminus of the protein substrate, this is not 
strictly conserved. For instance, in different bacteria, signals required for secretion/delivery were found 
to locate at the C-terminus of T3S substrates (e.g. T3S effector Tir from enteropathogenic Escherichia 
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coli (EPEC)  (Allen-Vercoe et al., 2005), T3S translocators EspB from enterohaemorrhagic Escherichia 
coli (EHEC) (Chiu et al., 2003), SipB from Salmonella spp. (Bae Hoon Kim et al., 2007), and PopD from 
Pseudomonas (Tomalka et al., 2012), and T3S regulatory proteins YscU and YscP from Yersinia (Agrain 
et al., 2005; Login and Wolf-Watz, 2015).   
In the case of CT105, either other unidentified regions of the protein are required for its delivery into 
the host cell or truncated versions of CT105 have alterations in their native conformation which made 
such fusion proteins non-competent for T3S. Alternatively, competition between the endogenous and 
truncated versions of CT105 could lead to a decrease of the efficiency of delivery of the truncated 
proteins explaining why these could not be detected in the host cell. Experiments where the plasmids 
encoding the truncated versions of CT105 are introduced in the C. trachomatis ct105::aadA mutant 
strain might clarify this point.  
In brief, although CT105 has a signal within its first 20 amino acid residues allowing its T3S, other 
determinants on the protein are required for its delivery by C. trachomatis into the cytoplasm of infected 
host cells.  
 
4.2 CT105 IS MODIFIED WITHIN C. TRACHOMATIS 
 
We found that CT105 is likely subjected to a modification within C. trachomatis that requires the first 
20 amino acid residues of the protein. Although we could not define the nature of this modification, an 
obvious hypothesis is that CT105 is post-translationally modified by a C. trachomatis factor. Post-
translational modifications (PTMs) were thought to be exclusive of eukaryotic cells for many years, but 
more recently they have been also found in bacteria and linked to various cellular functions including 
bacterial cell division and morphology (Grangeasse et al., 2015). Most of the described bacterial PTMs 
related to virulence involve modification of host proteins, but a few modifications of bacterial proteins 
have been described. An example is the Salmonella transcription factor (HilD) that regulates Salmonella 
pathogenesis island-1 (SPI-1) genes and was found to be acylated by a bacterial acetyltransferase (Pat) 
thus allowing the stability of the protein and the decrease of its DNA-binding activity, which was linked 
to the regulation of the Salmonella SPI-1 T3SS (Sang et al., 2016; Sang et al., 2017). Moreover, the 
Chlamydia protease-like activity factor (CPAF) requires activation upon its secretion, as CPAF requires 
autoprocessing for proteolytic activity, where the CPAF zymogen is cleaved into the active form of the 
protein (Huang et al., 2008; Chen, Lei, Flores, et al., 2010; Chen, Lei, Lu, et al., 2010; Snavely et al., 
2014; Prusty et al., 2018). Altogether, we could speculate that the modification of CT105 could be a 
mechanism to regulate or to activate the protein before its delivery by C. trachomatis into the host cell 
cytoplasm. However, we could not rule out that instead of being post-translationally modified, CT105 is 
an unstable protein requiring a C. trachomatis factor such as a T3S chaperone. For example, chlamydial 
T3S chaperone CT584 has been shown to bind and stabilize candidate T3S effector CT082, thus 
enhancing its T3S (Pais et al., 2013).  
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4.3 CT105 HAS A DUAL LOCALIZATION WITHIN HOST CELLS DURING C. 
TRACHOMATIS INFECTION 
 
After its delivery into infected host cells, CT105 accumulates at the Golgi complex (16 - 30 h p.i.) 
and/or at the host cell plasma membrane (30 - 40 h p.i.), thus illustrating that C. trachomatis effectors 
can have distinct subcellular localizations (and possibly different functions) during the chlamydial 
developmental cycle. In addition to CT105, the C. trachomatis effector CT867, a deubiquitinase enzyme 
known as ChlaDub2/Cdu2 (Misaghi et al., 2006; Fischer et al., 2017) has been detected at the inclusion 
membrane and at the host cell plasma membrane at distinct times of infection (Wang et al., 2018). Such 
dual localization during infection as a likely strategy to diversify effector function is reminiscent of the 
Salmonella SopB effector, which initially localizes at the host cell membrane to mediate bacterial 
invasion but is then redirected to the Salmonella-containing vacuole by host-mediated ubiquitination to 
modulate bacterial intracellular growth (Patel et al., 2009). This precise spatial and temporal subcellular 
targeting of bacterial effector proteins during infection is an essential feature of their function (Hicks et 
al., 2011). 
CT105 is the first chlamydial effector shown to localize at the Golgi complex, yet at least three other 
bacterial effector proteins have been shown to localize at this organelle in infected host cells. These are 
EspI/NleA from Escherichia coli (Gruenheid et al., 2004), GobX from Legionella pneumophila (Lin et al., 
2015), and SteD from Salmonella enterica (Bayer-Santos et al., 2016). EspI/NleA interferes with 
coatomer protein II complex (COPII) function and inhibits host cell protein secretion (Jinoh Kim et al., 
2007), and also disrupts intestinal tight junctions (Thanabalasuriar et al., 2010). In addition, EspI/NleA 
inhibits NLRP3 inflammasome activation (Yen et al., 2015). GobX displays E3 ubiquitin ligase activity, 
but how this promotes L. pneumophila infection is unknown (Lin et al., 2015). Finally, SteD interferes 
with the activity of a host E3 ubiquitin ligase, leading to a reduction of surface-localized major 
histocompatibility complex (MHC) class II  molecules and suppression of T cell activation (Bayer-Santos 
et al., 2016). Even more diverse functions have been reported among other bacterial effectors shown 
to interact with Golgi proteins or to localize at this organelle after ectopic expression in mammalian cells 
(Salcedo and Holden, 2003; Clements et al., 2011; Selyunin et al., 2011; Ge et al., 2012; Zhe Yang et 
al., 2015; Kim and Satchell, 2016; Yu et al., 2016; Beyer et al., 2017; Miller et al., 2017). Overall, this 
shows that no specific function can be predicted for CT105 based on its localization at the Golgi.  
However, CT105, and as already mentioned above, the C. trachomatis deubiquitinase 
CT867/ChlaDub2/Cdu2, was also detected at the host cell plasma membrane at late times of infection 
of tissue culture cells (Wang et al., 2018). It is likely that effector proteins involved in chlamydial entry 
might also associate with the host cell plasma membrane during or immediately after bacterial uptake 
(Hower et al., 2009; Bullock et al., 2012; McKuen et al., 2017), but such localization of CT105 and 
CT867/ChlaDub2/Cdu2 later in infection could indicate a function in host cell exit.  
It is unknown how CT105 and CT867/ChlaDub2/Cdu2 are differentially directed to different host cell 
localizations. In the case of CT105, it is unlikely that vesicular trafficking is involved as disruption of 
microfilaments and microtubules did not affect its localization at the plasma membrane in infected cells. 
One hypothesis could be that CT105 is specifically directed to different subcellular localizations by 
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covalent modifications it might be subjected to and/or by changes in the lipid and/or protein composition 
of host cellular membranes. It is also interesting that the changes of localization of CT105 are timed with 
the Golgi fragmentation observed in Chlamydia-infected cells, suggesting that the fragmentation of the 
Golgi could allow the plasma membrane localization of CT105 during Chlamydia infection. 
Analyses of the localization of hybrid proteins comprising full-length or truncated CT105 and mEGFP 
upon their ectopic expression in HeLa cells led to the identification of the first 100 amino acid residues 
of CT105 as sufficient for Golgi localization. However, this region does not display obvious motifs found 
in other relevant eukaryotic or bacterial proteins, and the exact molecular determinants of the Golgi 
localization of CT105 remain to be identified.   
Other effector proteins that localize at the Golgi in infected cells use distinct mechanisms directing 
them to this organelle (Lee et al., 2008; Thanabalasuriar et al., 2010; Lin et al., 2015; Bayer-Santos et 
al., 2016). In the case of EspI/NleA, Golgi targeting is partially mediated by a Postsynaptic 
Density95/Disc Large/Zonula Occludens-1 (PDZ) domain on its C-terminus (Lee et al., 2008). CT105 
also possesses a putative PDZ domain (Mu et al., 2014), but the relevant residues were not involved in 
its subcellular localization after ectopic expression in mammalian cells. Moreover, in contrast with our 
observations in infected and transfected mammalian cells, CT105 did not localize at the plasma 
membrane in Saccharomyces cerevisiae suggesting that this localization requires factor(s) not present 
in yeast. Other relevant questions which remain to be analyzed are whether the same determinants are 
responsible for Golgi localization in infected cells and which characteristics of the full-length CT105 
protein enable its targeting to the plasma membrane in infected and transfected cells.   
CT105 also appeared in filamentous structures spread in infected and transfected cells, suggesting 
that the protein can oligomerize or interact with host cell filamentous proteins independently of additional 
C. trachomatis factors. We could not identify host proteins/organelles that co-localize with these 
structures (e.g., host cytoskeleton and vesicular trafficking markers). Filamentous structures have been 
observed in C. trachomatis-infected cells for several Inc proteins (Bannantine et al., 1998). However, 
they seem to emanate from the inclusion which is not the case for CT105. In the case of IncA and IncE, 
these tubules have been show to interact with host cell sorting nexins (SNX1, SNX2, SNX5 and SNX6), 
which are proteins involved in retromer endosomal membrane trafficking (Aeberhard et al., 2015; 
Mirrashidi et al., 2015). The overexpression of IncE has been associated with enhanced inclusion 
tubulation. Because the sorting nexin-marked tubules originate from the inclusion, it seems that they 
should not be involved in the tubules marked by CT105. Other components of host cell trafficking might 
be involved in the formation of these filamentous structures or CT105 might enhance/stabilize their 
formation. 
 
4.4 CT105 DISRUPTS VESICULAR TRAFFICKING IN EUKARYOTIC CELLS 
 
Considering the localization of CT105 within the host cell (Golgi and plasma membrane), an 
appealing possibility for its function would be that it contributes to nutrient acquisition by the inclusion 
and/or avoidance of fusion with hydrolytic compartments. However, the C. trachomatis ct105::aadA 
mutant did not reveal an obvious intracellular growth defect, which does not support these hypotheses. 
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The ct105 mutant revealed smaller inclusions relative to the parental strain (suggesting a possible defect 
in vacuolar membrane expansion), but this could not be restored by reintroduction of ct105 in trans. The 
inability to complement intracellular growth-like phenotypes in intron insertional mutants of C. 
trachomatis was also recently described for ct101/mrcA (Nguyen et al., 2018), while other specific 
phenotypes of this mutant strain could be complemented (Nguyen et al., 2018). We are currently 
analyzing whether the intron insertion affects the genes adjacent to ct105 in the chromosome of C. 
trachomatis. Nevertheless, the lack of an intracellular growth defect is also not uncommon amongst C. 
trachomatis effector gene mutants characterized thus far (Weber et al., 2017; Stanhope et al., 2017; 
McKuen et al., 2017), which might reflect redundancy in effector function or inexistence of adequate 
infection models (Galán, 2009). Moreover, in cells infected by the C. trachomatis ct105::aadA mutant 
the Golgi distribution around the inclusion appears to be unaltered, but we cannot exclude that CT105 
could be involved in other Golgi-related processes subverted in C. trachomatis-infected cells 
(Pokrovskaya et al., 2012). 
We also showed that ectopic expression of CT105 in Saccharomyces cerevisiae induces a vacuolar 
protein sorting (Vps) defect, indicating a potential capacity of the protein to interfere with vesicular 
trafficking in infected cells. The carboxypeptidase Y - invertase (CPY-Inv) assay has been used to 
screen for Legionella pneumophila type IV secretion effectors interfering with endocytic trafficking 
(Shohdy et al., 2005; De Felipe et al., 2008). The function of most Legionella pneumophila effectors 
identified in these screens was subsequently described in further detail (Franco et al., 2012; Gaspar and 
Machner, 2014; Shi et al., 2016; Young et al., 2016). A potential activity of CT105 on vesicular trafficking 
in infected cells could also affect, e.g., cytokine secretion (Murray and Stow, 2014) or immune signaling 
(Gleeson, 2014), which would not have an impact on chlamydial intracellular growth in tissue culture 
cells.  
 
4.5 CT105 IS LIKELY RELEVANT FOR THE TROPISM OF LGV STRAINS 
 
Analysis of the primary structure of CT105 revealed that full-length orthologues were only present in 
Chlamydia muridarum and Chlamydia suis, consistent with the fact that these species are the closer 
relatives of C. trachomatis (Sachse et al., 2015). Interestingly, among the truncated and/or duplicated 
potential orthologues of CT105 found in other Chlamydia species, some (CAB376 in Chlamydia abortus, 
CCA_00389 in Chlamydia caviae, CF0618 and CF0619 in Chlamydia felis, CPSIT_0422 and 
CPSIT_0421 in Chlamydia psittaci) have been proposed to be T3S substrates (Voigt et al., 2012). 
Furthermore, ct105 is mostly expressed in C. trachomatis LGV strains and a deletion of 74-bp within the 
predicted promoter region among the non-LGV strains was also observed. There is also a considerable 
representation of protein-changing substitutions when comparing genital and LGV strains (Borges et al., 
2012). Therefore, CT105 displays a striking variability within C. trachomatis serovars, revealing LGV-
specific genetic and transcriptomic traits. Overall, this suggests that CT105 could have a specific 
function related with the unique characteristics of infections by these strains, which, unlike ocular and 
urogenital C. trachomatis strains, can infect mononuclear phagocytes and disseminate into regional 
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lymph nodes (Thomson et al., 2008; Borges and Gomes, 2015). This also indicates that features of the 
infection by LGV strains could be an evolutionary pressure to maintain an active ct105 gene. 
 
4.6 OUTLOOK ON OTHER CANDIDATE T3S EFFECTORS OF C. TRACHOMATIS 
 
Regarding the C. trachomatis proteins CT053, CT082, CT429, CT696 and CT849 (da Cunha et al., 
2014), which possess a T3S signal but were not detected in the host cell during chlamydial infection, 
we cannot conclude that these proteins are not T3S effectors. These proteins could be expressed and/or 
delivered into host cells in amounts too low, or too much dispersed in the host cytosol, to allow detection 
by fluorescence microscopy. For these cases, alternative approaches to monitor transport into host cells 
would be using the split-GFP system (Wang et al., 2018), or reporter proteins such as β-lactamase 
(Mueller et al., 2015), CyaA (Bauler et al., 2014), or GSK (Bauler et al., 2014). Nevertheless, when 
ectopically expressed in mammalian cells, EGFP-CT082, EGFP-CT696 and EGFP-CT849 localized at 
specific sites, further suggesting that these might be chlamydial T3S effectors. Furthermore, CT082 has 
been shown to interact and be stabilized by CT584, a chlamydial T3S chaperone (Pais et al., 2013). As 
for CT696, the corresponding gene localizes in a chromosomal region near a known chlamydial T3S 
substrates genes tmeA/ct694 and tmeB/ct695, which encoding proteins were shown to be delivered into 
the host cell by C. trachomatis. Moreover, T3S effector TmeA is involved in the remodeling of actin  
during chlamydial entry into host cells (Hower et al., 2009; Bullock et al., 2012; McKuen et al., 2017) 
and found to be necessary for normal intracellular growth of C. trachomatis (McKuen et al., 2017). 
However, in a previous study using the β-lactamase system as a reporter to monitor protein delivery into 
host cell, CT696 could also not be detected into the host cell (Mueller et al., 2015). Finally, ct849 
localizes in the chromosome near ct847, which encodes for a later cycle T3S effector that interacts with 
human GCIP, a protein degraded during C. trachomatis infection (Chellas-Géry et al., 2007). Also near 
in the chromosome is ct848, which encodes a candidate T3S effector of C. trachomatis, as it was shown 
to be type III secreted by the Shigella flexneri T3SS (Subtil et al., 2005). Moreover, CT847, CT848 and 
CT849, all share a domain of unknown function (DUF720), suggesting that they all could be T3S 
effectors of C. trachomatis.  
 
4.7 HYPOTHETIC MODE OF ACTION FOR CT105 DURING C. TRACHOMATIS 
INFECTION 
 
Taking together all the results, we could speculate a mechanism of action for CT105 during C. 
trachomatis infection. CT105 is expressed in C. trachomatis early during infection where it might bind a 
T3S chaperone and/or be modified by a chlamydial enzyme. Upon delivery into the host cells, CT105 is 
targeted and associates to the Golgi through its first 100 amino acids where it alters eukaryotic vesicular 
trafficking. In Chlamydia-infected epithelial cells, fragmentation of the Golgi would lead to the re-
localization of CT105 to the host plasma membrane where it could be involved in the processes of 
Chlamydia exit from the host cell.  
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Figure 4.1 Schematic model for CT105 mode of action during C. trachomatis infection of 
epithelial cells. Inside de bacteria CT105 is either modified by a chlamydial enzyme (ChlaE) or/and requires a 
specific T3S chaperone (T3SC). Upon delivery into the hos cell by a T3SS, CT105 (represented in red) associates 
with the Golgi, where it could modify (red arrows) the vesicular trafficking pathways (EE, early endosomes; LE, late 
endosomes; LY; lysosomes) of the host cell. As the developmental cycle progresses and the Golgi becomes more 
fragmented, CT105 localizes at the plasma membrane where it might contribute to processes of host cell exit. 
 
4.8 FUTURE WORK 
 
Our results suggest a complex mode of action for CT105 during C. trachomatis infection both before 
and after its delivery into the host cell. Here, we summarize the most prominent questions raised from 
this work. 
CT105 was found to potentially require additional bacterial factors to be delivered into the host cell 
and to be modified within the bacteria. Thus, we could propose the identification of bacterial interacting 
partners that we hypothesize as T3S chaperones or enzymes capable of catalyzing PTMs. Furthermore, 
constructing C. trachomatis strains expressing additional truncated versions or chimeras of CT105 might 
give insights in which regions are important for modification and delivery of the protein. Although our 
data suggests that CT105 is delivered into the host cell by a T3S-dependent mechanism, this causal 
association could only be confirmed by abolishing T3S using chemical inhibitors or, better, using a C. 
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trachomatis T3S-deficient strain. The latter may not be feasible due to the obligate intracellular lifestyle 
of C. trachomatis.  
Regarding the targeting of CT105 to distinct localizations in the host cell, the Golgi targeting region 
of CT105 is likely comprised within the first 100 amino acids of the protein, but its nature was not 
identified. We are currently constructing truncated versions of CT105 containing different regions of the 
first 100 amino acid residues and performing single amino acid mutations in these regions to determine 
the specific motif that allows the targeting of CT105 to the Golgi. A similar approach should be taken to 
study the plasma membrane targeting region of CT105, which was also not identified.  
Moreover, the whole process that leads to the change of the localization of CT105 must be 
investigated. For instance, CT105 targeting to the Golgi might be required for its subsequent re-direction 
to the plasma membrane. Alternatively, CT105 could be directed to the plasma membrane, 
independently of the previous Golgi localization. In addition, as we have found that the transport of 
CT105 unlikely occurs through vesicle trafficking, another hypothesis to be examined is whether there 
could be a modification of the Golgi-targeting region of CT105 during infection or if this could be 
dependent on the fragmentation of the Golgi or of Chlamydia-dependent changes in the lipid and/or 
protein composition of host cellular membranes.  
Thus, analysis of additional truncations of CT105 both in transfected and infected cells would allow 
a detailed mapping and further identification of protein motifs required to target CT105 to the different 
regions in the host cell. Moreover, maintenance of a compact Golgi (in infected cells) would be helpful 
to answer if the change of localization was dependent on the morphology of the Golgi, as the timing of 
fragmentation and change of localization overlaps in C. trachomatis-infected cells. For this, a C. 
trachomatis ct813/inaC mutant could be used as in this strain the Golgi fragmentation is abolished 
(Kokes et al., 2015; Wesolowski et al., 2017).  
Furthermore, an analysis of the C. trachomatis ct105 mutant strain should be performed with 
emphasis on the effects on the vesicular trafficking of epithelial cells. Additionally, other infection models, 
such as macrophages and animal models, should be used and infection with C. trachomatis ct105 
mutant strain should be detailed in terms of invasion, intracellular growth, vesicular trafficking and 
immune signaling responses.  Above all, the identification of host cell interacting partners of CT105 
would be crucial to a more focused analysis and to the understanding of the function of the protein 
during C. trachomatis infection. We have attempted to use yeast two-hybrid system to identify host 
interacting partners of CT105 with no success. Moreover, due to the membrane localization of CT105, 
we tested interaction of this protein with lipids immobilized in a membrane, but again we could not detect 
any interaction.  Currently, we are planning to perform a mass spectrometry analysis of mammalian 
proteins pulled down by ectopically expressed EGFP-CT105. 
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4.9 CONCLUSIONS AND FINAL REMARKS 
 
The intracellular lifecycle of C. trachomatis requires these bacteria to maintain a fine balance on its 
interactions with the host cells. While these bacteria exploit the host cell for their replication they also 
must avoid host cell death to complete its developmental cycle. T3S effectors are thought to play a key 
role in these interactions.  
The work developed in this PhD thesis resulted in the identification of a novel T3S effector of C. 
trachomatis, using the newly discovered methodologies for genetic manipulation of this bacterium. Our 
main findings were the identification of CT105 as a T3S effector of C. trachomatis that localizes to the 
Golgi and plasma membrane in infected cells at distinct times of the chlamydial developmental cycle, 
and that can disrupt eukaryotic vesicular trafficking in eukaryotic cells. Furthermore, CT105 appears to 
reveal LGV-specific features. Considering its striking association with the Golgi complex, we named it 
CteG (for C. trachomatis effector associated with the Golgi). 
Overall, this expands the portfolio of known chlamydial effector proteins and uncovers the first 
Chlamydia effector that associates with the Golgi complex. Moreover, it further illustrates that C. 
trachomatis effectors can have distinct subcellular localizations (and possibly different functions) during 
the chlamydial developmental cycle. Nevertheless, more questions have been raised than those 
answered and future work should be directed to the identification of CT105/CteG function, subcellular 
targeting mechanisms, diversity and specificity within C. trachomatis and among Chlamydia species.
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Table A.1 Plasmids used in this work. 
 
Plasmid Description Source/Reference Chapter 
pBOMB4-Tet-
mCherry 
C. trachomatis vector for expression of proteins, under 
the control of a tetracycline-inducible promotor (AmpR). 
(Bauler and 
Hackstadt, 2014) 
3.2 
p2TK2--SW2 C. trachomatis vector for expression of proteins (AmpR). (Agaisse and 
Derré, 2013) 
3.1 
pSVP247 Derivative of p2TK2--SW2 (Agaisse et al., 2013) for 
expression of proteins with a C-terminal double HA (2HA) 
tag. Contains the terminator of the incDEFG operon 
(TincD) of C. trachomatis L2/434 (AmpR). 
(da Cunha et al., 
2017) 
3.1 
pSVP277 Derivative of p2TK2--SW2 (Agaisse et al., 2013) for 
expression of proteins with a C-terminal GSK peptide. 
Contains the terminator of the incDEFG operon (TincD) 
of C. trachomatis L2/434. A DNA fragment containing the 
DNA sequence of the GSK peptide was amplified by PCR 
using primers 1749 and 1751. The DNA sequence of 
TincD was amplified by PCR from DNA of C. trachomatis 
L2/434 using primers 1750 and 1483. The two products 
were fused by overlapping PCR using primers 1749 and 
1483; the resulting DNA product was digested with NotI 
and SalI and ligated into those sites of p2TK2-SW2 
(AmpR). 
This work 3.1 
pSVP268 Derivative of p2TK2--SW2 (Agaisse et al., 2013) for 
expression of proteins with a C-terminal adenylate 
cyclase (CyaA). Contains the terminator of 
the incDEFG operon (TincD) of C. trachomatis L2/434. A 
DNA fragment containing cyaA was amplified by PCR 
from pJB2581 using primers 1693 and 1695. The DNA 
sequence of TincD was amplified by PCR from DNA of C. 
trachomatis L2/434 using primers 1694 and 1696. The 
DNA fragments of cyaA and TincD were fused by 
overlapping PCR using primers 1693 and 1696. The 
resulting DNA product was digested with NdeI and NotI 
and ligated into those sites of p2TK2-SW2 (AmpR). 
This work 3.1 
pLJM3 Derivative of the low copy vector pBBR1MCS-2 (Kovach 
et al., 1994). Expresses YopE under the control of its own 
promoter (PyopE) (KmR).  
(Marenne et al., 
2003) 
3.1 
pEGFP-N1 Transfection vector. Fusions at the N-terminus of EGFP 
under the control of the CMV promoter (KmR). 
Clontech 3.1 
pEGFP-C1 Transfection vector. Fusions at the N-terminus of EGFP 
under the control of the CMV promoter (KmR). 
Clontech 3.1 
pLAMP1-mGFP Transfection vector encoding human LAMP1 fused to 
monomeric GFP (mGFP) (KmR) 
Addgene plasmid 
# 34831 (Falcon-
Perez et al., 2005) 
3.2 
Lyn11-FRB-
mcherry 
Mammalian expression vector encoding a Lyn Src kinase 
N-terminal sequence (Lyn11) fused to FRB (fragment of 
mTOR that binds rapamycin) and to mCherry. 
Addgene plasmid 
# 38004 
(Hammond et al., 
2012) 
3.2 
pmEGFP-
N1/pALT1 
Mammalian transfection vector for expression of proteins 
fused to the N-terminus of mEGFP under the control of 
the CMV promoter (KmR). The DNA fragment encoding 
mEGFP was amplified by PCR from pLAMP1-mEGFP 
using primers 1851 and 1852. The resulting DNA product 
was digested with AgeI and NotI and ligated into those 
sites of pGFP-N1. 
This work 3.2 
pmEGFP-
C1/pALT2 
Mammalian transfection vector for expression of proteins 
fused to the C-terminus of mEGFP under the control of 
the CMV promoter (KmR). The DNA fragment encoding 
mEGFP was amplified by PCR from pLAMP1-mEGFP 
using primers 1852 and 1853. The resulting DNA product 
was digested with XhoI and NotI and ligated into those 
sites of pGFP-C1. 
This work 3.2 
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pEF6/Myc-His A Mammalian transfection vector for expression of proteins, 
under the control of the EF-1α promoter (KmR). 
Thermo Fisher 
Scientific 
3.2 
pDFTT3aadA Group II intron donor plasmid. (Key et al., 2017) 3.3 
pYES2-GFP Yeast vector for expression of proteins fused to the C-
terminus of GFP, under the control of a galactose-
inducible promoter (AmpR). 
(Rodriguez-
Escudero et al., 
2005) 
3.3 
pKS84 Yeast vector for expression of proteins fused to the N-
terminus of GFP, under the control of a galactose-
inducible promoter (AmpR). 
(de Felipe et al., 
2008) 
3.3 
pCM46 Transfection vector encoding EGFP-CT053. A DNA 
fragment containing ct053 was amplified from C. 
trachomatis L2/434 chromosomal DNA using primers 997 
and 998. The resulting DNA product was digested with 
HindIII and SalI and inserted into those sites of pEGFP-
C1 (KmR). 
This work 3.1 
pSG13 Transfection vector encoding EGFP-CT082. A DNA 
fragment containing ct082 was amplified from C. 
trachomatis L2/434 chromosomal DNA using primers 650 
and 651. The resulting DNA product was digested with 
XhoI and BamHI and inserted into those sites of pEGFP-
C1 (KmR). 
This work 3.1 
pSG19 Transfection vector encoding EGFP-CT105. A DNA 
fragment containing ct105 was amplified from C. 
trachomatis L2/434 chromosomal DNA using primers 652 
and 653. The resulting DNA product was digested with 
SalI and KpnI and inserted into those sites of pEGFP-C1 
(KmR). 
This work 3.1 
pSG10 Transfection vector encoding EGFP-CT429. A DNA 
fragment containing ct429 was amplified from C. 
trachomatis L2/434 chromosomal DNA using primers 670 
and 671. The resulting DNA product was digested with 
XhoI and BamHI and inserted into those sites of pEGFP-
C1 (KmR). 
This work 3.1 
pLJM1070 Transfection vector encoding EGFP-CT696. A DNA 
fragment containing ct696 was amplified from C. 
trachomatis L2/434 chromosomal DNA using primers 938 
and 939. The resulting DNA product was digested with 
XhoI and SalI and inserted into those sites of pEGFP-C1 
(KmR). 
This work 3.1 
pSG9 Transfection vector encoding EGFP-CT849. A DNA 
fragment containing ct849 was amplified from C. 
trachomatis L2/434 chromosomal DNA using primers 684 
and 685. The resulting DNA product was digested with 
XhoI and BamHI and inserted into those sites of pEGFP-
C1 (KmR). 
This work 3.1 
pSVP261/pCT053
-2HA 
Expresses CT053-2HA under the control of the predicted 
ct053 promoter. A DNA fragment containing ct053 and its 
endogenous promoter was amplified from C. trachomatis 
L2/434 chromosomal DNA using primers 1677 and 1678. 
The resulting DNA product was digested with KpnI and 
NotI and inserted into those sites of pSVP247 (AmpR). 
This work 3.1 
pSVP263/pCT082
-2HA 
Expresses CT082-2HA under the control of the predicted 
ct082 promoter. A DNA fragment containing ct082 and its 
endogenous promoter was amplified from C. trachomatis 
L2/434 chromosomal DNA using primers 1679 and 1549. 
The resulting DNA product was digested with KpnI and 
NotI and inserted into those sites of pSVP247 (AmpR). 
This work 3.1 
pSVP264/pCT105
-2HA 
Expresses CT105-2HA under the control of the predicted 
ct105 promoter. A DNA fragment containing ct105 and its 
endogenous promoter was amplified from C. trachomatis 
L2/434 chromosomal DNA using primers 1680 and 1552. 
The resulting DNA product was digested with KpnI and 
NotI and inserted into those sites of pSVP247 (AmpR). 
This work 
3.1, 3.2, 
3.3 
pSVP265/pCT429
-2HA 
Expresses CT429-2HA under the control of the predicted 
ct429 promoter. A DNA fragment containing ct429 and its 
endogenous promoter was amplified from C. trachomatis 
This work 3.1 
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L2/434 chromosomal DNA using primers 1681 and 1682. 
The resulting DNA product was digested with KpnI and 
NotI and inserted into those sites of pSVP247 (AmpR). 
pSVP266/pCT696
-2HA 
Expresses CT696-2HA under the control of the predicted 
ct696 promoter. A DNA fragment containing ct696 and its 
endogenous promoter was amplified from C. trachomatis 
L2/434 chromosomal DNA using primers 1685 and 1564. 
The resulting DNA product was digested with KpnI and 
NotI and inserted into those sites of pSVP247 (AmpR). 
This work 3.1 
pSVP267/pCT849
-2HA 
Expresses CT849-2HA under the control of the predicted 
ct849 promoter. A DNA fragment containing ct849 and its 
endogenous promoter was amplified from C. trachomatis 
L2/434 chromosomal DNA using primers 1686 and 1687. 
The resulting DNA product was digested with KpnI and 
NotI and inserted into those sites of pSVP247 (AmpR). 
This work 3.1 
pFA3 Expresses the mature form of TEM-1 -lactamase (TEM-
1) under the yopE promoter (KmR). 
(Almeida et al., 
2012) 
3.1 
pRM11 Expresses CT10520-TEM-1 under the control of the yopE 
promoter (KmR). 
(da Cunha et al., 
2014) 
3.1 
pMBC1 Expresses CT10540-TEM-1 under the control of the yopE 
promoter. A DNA fragment encoding the first 40 amino 
acids of CT105 was amplified from pRM7 using primers 
28 and 1801. TEM-1 was amplified from pFA3 using 
primers 1802 and 60. The two DNA fragments were then 
fused by overlapping PCR using primers 28 and 60. The 
resulting DNA product was digested with NdeI and HindIII 
and inserted into those sites of pLJM3 (KmR). 
This work 3.1 
pRM7 Expresses CT105FL-2HA under the control of the yopE 
promoter (KmR). 
(da Cunha et al., 
2014) 
3.1 
pMBC2 Expresses CT10520-2HA under the control of the yopE 
promoter. A DNA fragment encoding CT105 without its 
first 20 amino acids was amplified from C. trachomatis 
L2/434 chromosomal DNA using primers 1799 and 174. 
The resulting DNA product was digested with NdeI and 
KpnI and inserted into those sites of pLJM3 (KmR). 
This work 3.1 
pMBC3 Expresses CT10540-2HA under the control of the yopE 
promoter. A DNA fragment encoding CT105 without its 
first 40 amino acids was amplified from C. trachomatis 
L2/434 chromosomal DNA using primers 1800 and 174. 
The resulting DNA product was digested with NdeI and 
KpnI and inserted into those sites of pLJM3 (KmR). 
This work 3.1 
pMBC5/pCT1052
0-2HA 
Expresses CT10520-2HA under the control of the 
predicted ct105 promoter.  A DNA fragment encoding the 
predicted ct105 promoter was amplified from pSVP264 
using primers 1680 and 1812. A DNA fragment encoding 
CT105 without its first 20 amino acids was amplified from 
C. trachomatis L2/434 chromosomal DNA using primers 
1813 and 1552. The two DNA fragments were then fused 
by overlapping PCR using primers 1680 and 1552. The 
resulting DNA product was digested with KpnI and NotI 
and inserted into those sites of pSVP247 (AmpR). 
This work 3.1 
pSVP302/pTet-
CT105-2HA 
Expresses CT105-2HA under the control of the 
tetracycline-inducible promoter (Ptet). A DNA fragment 
containing Ptet was amplified from pBOMB4-Tet-mCherry 
using primers 1803 and 1804. A DNA fragment 
containing ct105 was amplified from C. trachomatis 
L2/434 chromosomal DNA using primers 1805 and 1552. 
The two DNA fragments were then fused by overlapping 
PCR using primers 1803 and 1552. The resulting DNA 
product was digested with KpnI and NotI and inserted into 
those sites of pSVP247 (AmpR). 
This work 3.2 
pSVP294 Transfection vector encoding LYN11-mEGFP. A DNA 
fragment encoding Lyn11 was amplified from pLYN11-
FRB-mCherry using primers 1824 and 1848. A DNA 
fragment encoding mEGFP was amplified from pLAMP-
1-mEGFP using primers 1847 and 1851. The two coding 
This work 3.2 
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regions were fused by overlapping PCR using primers 
1858 and 1859. The resulting DNA product was digested 
with HindIII and NotI and inserted into those sites of 
pEGFP-N1 (KmR). 
pALT4 Transfection vector encoding mEGFP-CT105. A DNA 
fragment containing ct105 was amplified from C. 
trachomatis L2/434 chromosomal DNA using primers 652 
and 653.  The resulting DNA product was digested with 
KpnI and SalI and inserted into those sites of pmEGFP-
C1 (KmR).  
This work 3.2 
pSVP292 Transfection vector encoding CT105-2HA. A DNA 
fragment encoding CT105-2HA was amplified from 
pSVP264 using primers 1780 and 1783. The resulting 
DNA product was digested with KpnI and NotI and 
inserted into those sites of pEF6/Myc-His A (AmpR). 
This work 3.2 
pSVP310 Transfection vector encoding mEGFP-CT1051-100. A DNA 
fragment encoding the first 100 amino acid residues of 
CT105 was amplified from C. trachomatis L2/434 
chromosomal DNA using primers 652 and 2128. The 
resulting DNA product was digested with KpnI and SalI 
and inserted into those sites of pmEGFP-C1 (KmR). 
This work 3.2 
pSVP314 Transfection vector encoding mEGFP-CT105Δ100. A DNA 
fragment encoding CT105 without its first 100 amino acid 
residues (but maintaining the ATG start codon) was 
amplified from C. trachomatis L2/434 chromosomal DNA 
using primers 2155 and 653. The resulting DNA product 
was digested with KpnI and SalI and inserted into those 
sites of pmEGFP-C1 (KmR). 
This work 3.2 
pSVP303 Transfection vector encoding mEGFP-CT1051-320. A DNA 
fragment encoding the first 320 amino acid residues of 
CT105 was amplified from C. trachomatis L2/434 
chromosomal DNA using primers using primers 652 and 
2129.  The resulting DNA product was digested with KpnI 
and SalI and inserted into those sites of pmEGFP-C1 
(KmR). 
This work 3.2 
pSVP316 Transfection vector encoding mEGFP-CT105Δ320. A DNA 
fragment encoding CT105 without its first 320 amino acid 
residues (but maintaining the ATG start codon) was 
amplified from C. trachomatis L2/434 chromosomal DNA 
using primers 2161 and 653. The resulting DNA product 
was digested with KpnI and SalI and inserted into those 
sites of pmEGFP-C1 (KmR). 
This work 3.2 
pSVP311 Transfection vector encoding mEGFP-CT105Δ100-320. A 
DNA fragment encoding the first 100 amino acid residues 
of CT105 was amplified from C. trachomatis L2/434 
chromosomal DNA using primers 652 and 2125. A DNA 
fragment encoding the region from the amino acid 
residue 320 to the C-terminus of CT105 was amplified 
from C. trachomatis L2/434 chromosomal DNA using 
primers 2124 and 653. The two DNA products were fused 
by overlapping PCR using primers 652 and 653.  The 
resulting DNA product was digested with KpnI and SalI 
and inserted into those sites of pmEGFP-C1 (KmR). 
This work 3.2 
pSVP315 Encodes mEGFP-CT105PDZ. A DNA fragment encoding 
CT105 with the last 3 amino acids (PDZ domain) mutated 
to alanine was amplified from C. trachomatis L2/434 
chromosomal DNA using primers 652 and 2157. The 
resulting DNA product was digested with SalI and KpnI 
and inserted into those sites of pmEGFP-C1 (KmR). 
This work 3.2 
pALT3 Transfection vector encoding CT105-mEGFP. A DNA 
fragment containing ct105 was amplified from C. 
trachomatis L2/434 chromosomal DNA using primers 
1778 and 1779. The resulting DNA product was digested 
with SalI and AgeI and inserted into those sites of 
pmEGFP-N1 (KmR). 
This work 3.2 
pSVP307 Transfection vector encoding CT1051-100-mEGFP. A DNA 
fragment encoding the first 100 amino acid residues of 
This work 3.2 
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CT105 was amplified from C. trachomatis L2/434 
chromosomal DNA using primers 1778 and 2126. The 
resulting DNA product was digested with SalI and AgeI 
and inserted into those sites of pmEGFP-N1 (KmR). 
pSVP308 Transfection vector encoding CT1051-320-mEGFP. A DNA 
fragment encoding the first 320 amino acid residues of 
CT105 was amplified from C. trachomatis L2/434 
chromosomal DNA using primers 1778 and 2127. The 
resulting DNA product was digested with SalI and AgeI 
and inserted into those sites of pmEGFP-N1 (KmR). 
This work 3.2 
pSVP309 Transfection vector encoding CT105Δ100-320-mEGFP.  
A DNA fragment encoding the first 100 amino acid 
residues of CT105 was amplified from C. trachomatis 
L2/434 chromosomal DNA using primers 1778 and 2125.  
A DNA fragment encoding the region from the amino acid 
residue 320 to the C-terminus of CT105 was amplified 
from C. trachomatis L2/434 chromosomal DNA using 
primers 2124 and 1779. The two DNA products were 
fused by overlapping PCR using primers 1778 and 1779.  
The resulting DNA product was digested with SalI and 
AgeI and inserted into those sites of pmEGFP-N1 (KmR). 
This work 3.2 
pSVP304/pTet-
CT1051-100-2HA 
Expresses CT1051-100-2HA under the control of the 
tetracycline-inducible promoter (Ptet). A DNA fragment 
containing Ptet was amplified from pBOMB4-Tet-mCherry 
using primers 1803 and 1804. A DNA fragment encoding 
the first 100 amino acid residues of CT105 was amplified 
from C. trachomatis L2/434 chromosomal DNA using 
primers 1805 and 2122. The two DNA fragments were 
then fused by overlapping PCR using primers 1803 and 
2122. The resulting DNA product was digested with KpnI 
and NotI and inserted into those sites of pSVP247 
(AmpR). 
This work 3.2 
pSVP305/ pTet-
CT1051-320-2HA 
Expresses CT1051-320-2HA under the control of the 
tetracycline-inducible promoter (Ptet). A DNA fragment 
containing Ptet was amplified from pBOMB4-Tet-mCherry 
using primers 1803 and 1804. A DNA fragment encoding 
the first 320 amino acid residues of CT105 was amplified 
from C. trachomatis L2/434 chromosomal DNA using 
primers 1805 and 2123. The two DNA fragments were 
then fused by overlapping PCR using primers 1803 and 
2123. The resulting DNA product was digested with KpnI 
and NotI and inserted into those sites of pSVP247 
(AmpR). 
This work 3.2 
pSVP306/ pTet-
CT105 Δ100-320-
2HA 
Expresses CT105Δ100-320-2HA under the control of the 
tetracycline-inducible promoter (Ptet). A DNA fragment 
containing Ptet was amplified from pBOMB4-Tet-mCherry 
using primers 1803 and 1804.  
A DNA fragment encoding the first 100 amino acid 
residues of CT105 was amplified from C. trachomatis 
L2/434 chromosomal DNA using primers 1778 and 2125.  
A DNA fragment encoding the region from the amino acid 
residue 320 to the C-terminus of CT105 was amplified 
from C. trachomatis L2/434 chromosomal DNA using 
primers 2124 and 1779. The two DNA fragments 
encoding CT105 were fused using primers 1778 and 
1779. The resulting DNA fragment was fused with the 
fragment encoding Ptet using primers 1805 and 1552. The 
resulting DNA product was digested with KpnI and NotI 
and inserted into those sites of pSVP247 (AmpR). 
This work 3.2 
pDFTT296 Derivative of pDFTT3aadA carrying a group II intron 
targeting sequence of ctl0360 from C. trachomatis strain 
L2/434 (orthologue of ct105 in strain D/UW3).  The 5’ 
intron sequence was amplified by PCR using primers 
1860, 1861, 1862, and 1922. The resulting ~350 bp DNA 
product was digested with HindIII and BsrG1 and ligated 
into those sites of pDFTT3aadA (SpcR). 
This work 3.3 
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pSVP319 Expresses CT105::aadA-2HA under the control of the 
predicted ct105 promoter. A DNA fragment containing 
ct105::aadA and its endogenous promoter was amplified 
from C. trachomatis L2/434 ct105::aadA chromosomal 
DNA using primers 2254 and 1552. The resulting DNA 
product was digested with AgeI and NotI and inserted into 
those sites of pSVP247 (AmpR). 
This work 3.3 
pCM35 Yeast expression vector expressing GFP-CT105 under 
the control of a galactose-inducible promoter. A DNA 
fragment containing ct105 was amplified from C. 
trachomatis L2/434 chromosomal DNA using primers 799 
and 812. The resulting DNA product was digested with 
BglII and PstI, and with PstI and NotI. The two DNA 
fragments obtained were inserted into BamHI and NotI 
sites of pGFP-YES2 (AmpR). 
This work 3.3 
pSVP293 Yeast expression vector encoding CT105-EGFP under 
the control of a galactose-inducible promoter. A DNA 
fragment containing ct105 was amplified from C. 
trachomatis L2/434 chromosomal DNA using primers 
1784 and 1785.  The resulting DNA product was inserted 
into pKS84 by homologous recombination in yeast 
(AmpR). 
This work 3.3 
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Table A.2 Oligonucleotides used in this work. 
 
Number Description Sequence (5’  3’) 
Restriction 
site 
28 
Forward primer to construct 
pMBC1 
GAT TAAGTTGGGTAACGCC  
- 
60 
Reverse primer to construct 
pMBC1 
CCCAAGCTTTTACCAATGCTTAATCAGTGA GG 
HindIII 
174 
Reverse primer to construct 
pMBC2, pMBC3 
GATCGGTACCCTAAGCATAATCAGGAACAT 
CATACGGATAGATAGAGGAGCTTTGCACACC 
KpnI 
650 
Forward primer to construct 
pSG13 
GATCCTCGAGCTTCAATTTCTGGAAGTGG XhoI 
651 
Reverse primer to construct 
pSG13 
GATCGGATCCTCATGAATCGCCGCCTG 
CATCC 
BamHI 
652 
Forward primer to construct 
pSG19, pALT4, pSVP310, 
pSVP303, pSVP311, 
pSVP315 
GATCGATCGTCGACTCATTTGGTATTGGTAGT
GC 
SalI 
653 
Reverse primer to construct 
pSG19, pALT4, pSVP314, 
pSVP316, pSVP311 
GATCGGTACCCTAGATAGAGGAGCTTTGCACA
CC KpnI 
670 
Forward primer to construct 
pSG10 
GATCCTCGAGCTACGACATATCCTGTACCTC XhoI 
671 
Reverse primer to construct 
pSG10 
GATCGGATCCTTATGAACGGCTCTTCTTACG BamHI 
684 
Forward primer to construct 
pSG9 
GATCCTCGAGCTTCAGCACCAACCTCACAGG XhoI 
685 
Reverse primer to construct 
pSG9 
GATCGGATCCTTAAGACAGGGGTTTATTTAAT
TGG 
BamHI 
799 
Reverse primer to construct 
pCM35 
ATAAGAATGCGGCCGCCTAGATAGAGGAGCT
TTGCACACC 
NotI 
812 
Forward primer to construct 
pCM35 
GATCAGATCTTCATTTGGTATTGGTAGTGC 
BglII 
938 
Forward primer to construct 
pLJM1070 
GATCCTCGAGCTCTATTAGATTCTCGTTTCCC XhoI 
939 
Reverse primer to construct 
pLJM1070 
GATCGTCGACCTAACGAGCTTCCTTACGGAAA
G 
SalI 
997 
Forward primer to construct 
pCM46 
GATCAAGCTTCTAAAAGTGAGCGTTTAAAAAA
ATTAG 
HindIII 
998 
Reverse primer to construct 
pCM46 
GATCGTCGACTTACCATTCATTCGCGTCAGG SalI 
1483 
Reverse primer to construct 
pSVP277 
GATCGTCGACGTCTTAGGAGCTTTTTGCAATG
C 
SalI 
1549 
Reverse primer to construct 
pSVP263 
GATCGCGGCCGCGTGAATCGCCGCCTGCATC
CTC 
NotI 
1552 
Reverse primer to construct 
pSVP264, pMBC5, pSVP302 
and pSVP319, pSVP306 
GATCGCGGCCGCGGATAGAGGAGCTTTGCAC
ACC NotI 
1564 
Reverse primer to construct 
pSVP266 
GATCGCGGCCGCGACGAGCTTCCTTACGGAA
AGTTCC 
NotI 
1677 
Forward primer to construct 
pSVP261 
GATCGGTACCTTTCCATGAAGAATCCATCG 
KpnI 
1678 
Reverse primer to construct 
pSVP261 
GATCGCGGCCGCGCCATTCATTCGCGTCAGG
ATC 
NotI 
1679 
Forward primer to construct 
pSVP263 
GATCGGTACCGGTTAGGCATGAGTGCCTGC 
KpnI 
1680 
Forward primer to construct 
pSVP264, pMBC5 
GATCGGTACCTTCTTTATTATTGAGAAACG 
KpnI 
1681 
Forward primer to construct 
pSVP265 
GATCGGTACCTTATGAGCGAGGTTGTGAGC 
KpnI 
1682 
Reverse primer to construct 
pSVP265 
GATCGCGGCCGCGTGAACGGCTCTTCTTACG
TCCACG 
NotI 
1685 
Forward primer to construct 
pSVP266 
GATCGGTACCGCAAATTGTTAATGCAAACG 
KpnI 
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1686 
Forward primer to construct 
pSVP267 
GATCGGTACCTTCCAAAATCCTTTTTAGGG 
KpnI 
1687 
Reverse primer to construct 
pSVP267 
GATCGCGGCCGCGAGACAGGGGTTTATTTAA
TTGG 
NotI 
1693 
Forward primer to construct 
pSVP268 
GGGAATTCCATATGATGCAGCAATCGCATCAG
GC 
NdeI 
1694 Forward overlap primer to 
construct pSVP268 
G GAA CGC CAG GAT TCC GGC TAT TAA GGA 
TGA CAT GTG ATT CGC GTA GG 
- 
1695 Reverse overlap primer to 
construct pSVP268 
CC TAC GCG AAT CAC ATG TCA TCC TTA ATA 
GCC GGA ATC CTG GCG TTC C 
- 
1696 Reverse primer to construct 
pSVP268 
GATCGCGGCCGCGTCTTAGGAGCTTTTTGCAA
TGC  
NotI 
1749 
Forward primer to construct 
pSVP277 
GATCGCGGCCGCATGAGTGGTCGCCCTCGCA
CTACTAGTTTCGCTGAAAGTTGA 
NotI 
1750 
Forward overlap primer to 
construct pSVP277 
CTAGTTTCGCTGAAAGTTGAGGATGACATGTG
ATTCGCGTAGG 
 
1751 
Reverse overlap primer to 
construct pSVP277 
CCTACGCGAATCACATGTCATCCTCAACTTTC
AGCGAAACTAG 
 
1778 
Forward primer to construct 
pALT3, pSVP307, pSVP308, 
pSVP309, pSVP306 
GATCGTCGACACCATGAGCTTTGGTATTGGTA
GTGCTTG  SalI 
1779 
Reverse primer to construct 
pALT3, pSVP309, pSVP306 
GATCACCGGTGGGATAGAGGAGCTTTGCACA
CCTGC  
 
AgeI 
1780 
Forward primer to construct 
pSVP292 
GATCGGTACCACCATGAGCTTTGGTATTGGTA
GTGCTTG 
KpnI 
1783 
Reverse primer to construct 
pSVP292 
GATCGCGGCCGCTTAAGCATAATCAGGAACAT
CATACG 
NotI 
1784 
Forward primer to construct 
pSVP293 
GTTAATATACCTCTATACTTTAACGTCAAGGAG
AAAAAAC ATGTCATTTGGTATTGGTAGTGC 
- 
1785 
Reverse primer to construct 
pSVP293 
GGATGGGCACCACTCCAGTGAAAAGTTCTTCT
CCTTTACTGATAGAGGAGCTTTGCACACC 
- 
1799 
Forward primer to construct 
pMBC2 
GGAATTCCATATGGGCAGTGAGGGTAACAGC
GAA GAAGG 
NdeI 
1800 
Forward primer to construct 
pMBC3 
GGAATTCCATATGTCTGGTGCTGCTTCTGCTG
TAT GCC 
NdeI 
1801 
Reverse overlap primer to 
construct pMBC1 
CACCAGCGTTTCTGGGTGACCTGAGGCGGCG
TCT GAACCCG 
- 
1802 
Forward overlap primer to 
construct pMBC1 
CGGGTTCAGACGCCGCCTCAGGTCACCCAGA
AAC GCTGGTG 
- 
1803 
Forward primer to construct 
pSVP302, pSVP304, 
pSVP305, pSVP306 
GATCGGTACCTTAAGACCCACTTTCACATTTAA 
KpnI 
1804 
Reverse overlap primer to 
construct pSVP302, 
pSVP304, pSVP305, 
pSVP306 
CTACCAATACCAAATGACATTTCACTTTTCTCT
ATCACTGATAGGGAGTGG 
- 
1805 
Forward overlap primer to 
construct pSVP302, 
pSVP304, pSVP305, 
pSVP306 
CCACTCCCTATCAGTGATAGAGAAAAGTGAAA
TGTCATTTGGTATTGGTAG 
- 
1812 
Reverse overlap primer to 
construct pMBC5 
CCTTCTTCGCTGTTACCCTCACTGCCCATACC
TTT AACTCCCGG 
- 
1813 
Forward overlap primer to 
construct pMBC5 
CCGGGAGTTAAAGGTATGGGCAGTGAGGGTA
ACA GCGAAGAAGG 
- 
1824 
Forward primer to construct 
pSVP294 
GATCAAGCTTACCATGGGATGTATAAAATCAA
AAGGGAAAGACAGCAGA 
HindIII 
1847 
Forward overlap primer to 
construct pSVP294 
TCAAAAGGGAAAGACAGCAGAGTGAGCAAGG
GCGAGGAGCTG 
- 
1848 
Reverse overlap primer to 
construct pSVP294 
CAGCTCCTCGCCCTTGCTCACTCTGCTGTCTT
TCCCTTTTGA 
- 
1851 
Reverse primer to construct 
pmEGFP-N1 and pSVP294 
GATCGCGGCCGCTTACTTGTACAGCTCGTCCA
TGCC  
NotI 
1852 
Forward primer to construct 
pmEGFP-N1 and pmEGFP-
C1 
GATCACCGGTCGCCACCATGGTGAGCAAGGG
CGAGCTG AgeI 
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1853 
Reverse primer to construct 
pmEGFP-C1 
GATCCTCGAGACTTGTCAGCTCGTCCATGCC 
XhoI 
1858 
Forward primer to construct 
pSVP294 
GATCAAGCTTACCATGGGATG 
HindIII 
1859 
Reverse primer to construct 
pSVP294 
GATCGCGGCCGCTTACTTGTAC  
NotI 
1860 
Group II intron retargeting 
(CT105_261|262s_IBS1/2) 
AAAAAAGCTTATAATTATCCTTACATGGCGGAC
GCGTGCGCCCAGATAGGGTG 
- 
1861 
Group II intron retargeting 
(CT105_261|262s 
EBS1/delta) 
CAGATTGTACAAATGTGGTGATAACAGATAAG
TCGGACGCGGTAACTTACCTTTCTTTGT - 
1862 
Group II intron retargeting 
(CT105_261|262s EBS2)   
TGAACGCAAGTTTCTAATTTCGGTTCCATGTC
GATAGAGGAAAGTGTCT 
- 
1922 
Group II intron retargeting 
(EBS universal)  
CGAAATTAGAAACTTGCGTTCAGTAAAC 
- 
1932 
Forward primer for 16S RT-
qPCR  
GCGAAGGCGCTTTTCTAATTTAT 
- 
1933 
Reverse primer for 16S RT-
qPCR 
CCAGGGTATCTAATCCTGTTTGCT 
. 
1934 
Forward primer for ct105 RT-
qPCR  
ATGGAGCCGTTTGTGTGGTT 
- 
1935 
Reverse primer for ct105 RT-
qPCR 
CCTTCTTCGCTGTTACCCTCACT 
- 
2122 
Reverse primer for pSVP304 GATCGCGGCCGCGACTAGCAGAATATTTTTGG
TAGC 
NotI 
2123 
Reverse primer for pSVP305 GATCGCGGCCGCGACACGCACTTGCGCA 
GCAAGGC 
NotI 
2124 
Forward overlap primer to 
construct pSVP311, 
pSVP309, pSVP306 
ACCAAAAATATTCTGCTAGTGGATATCCTTCTT
GCGGATG - 
2125 
Reverse overlap primer to 
construct pSVP311, 
pSVP309, pSVP306 
CATCCGCAAGAAGGATATCCACTAGCAGAATA
TTTTTGGT - 
2126 
Reverse primer to construct 
pSVP307 
GATCACCGGTGGACTAGCAGAATATTTTTGGT
AGC 
AgeI 
2127 
Reverse primer to construct 
pSVP308 
GATCACCGGTGGACACGCACTTGCGCAGCAA
GGC 
AgeI 
2128 
Reverse primer to construct 
pSVP310 
GATCGGTACCCTAACTAGCAGAATATTTTTGG
TAGC 
KpnI 
2129 
Reverse primer to construct 
pSVP303 
GATCGGTACCCTAACACGCACTTGCGCAGCA
AGGC 
KpnI 
2155 
Forward primer to construct 
pSVP314 
GATCGATCGTCGACGGAGTAAGTCTTACATCT
ATATCC 
SalI 
2161 
Forward primer to construct 
pSVP316 
GATCGATCGTCGACGGATATCCTTCTTGCGGA
TGTGC 
SalI 
2254 
Forward primer to construct 
pSVP319 
GATCACCGGTCCTTCTTTATTATTGAGAAACG 
AgeI 
2157 
Reverse primer to construct 
pSVP315 
GATCGGTACCCTAGGCAGCGGCGCTTTGCAC
ACCTGCTTTCTGTGC 
KpnI 
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Table A.3 Saccharomyces cerevisiae strains used in this work 
 
Strains Genotype Source/Reference 
NSY01 BHY10 diploid a/α, CPY-Inv, inv-, ura- (Shohdy et al., 2005) 
SCIF00 NSY01 Pgal-gfp (pKS84) (Franco et al., 2012) 
SCIF01 NSY01 Pgal-vipA-gfp (pIF206) (Franco et al., 2012) 
SCNS00 NSY01 Pgal-vps4E233Q (Shohdy et al., 2005) 
SCSVP01 NSY01 Pgal-gfp-ct105 (pCM35) This work 
SCSVP02 NSY01 Pgal-ct105-gfp (pSVP293) This work 
 
 
 
 
